Heterocyclic derivative as well as composition and pharmaceutical application thereof

By developing PROTAC technology that combines the compound BLK with EGFR and E3 ubiquitin ligases, specific degradation of EGFR protein was achieved, solving the problem of incomplete EGFR inhibition in existing treatments and improving the efficacy of treating EGFR-related diseases.

CN119019378AInactive Publication Date: 2024-11-26TIBET HAISCO PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310545145.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-16
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing treatments for EGFR-related diseases are ineffective at inhibiting and degrading EGFR proteins, resulting in poor treatment outcomes.

Method used

A novel compound, BLK, was developed that uses a PROTAC molecule to bind to EGFR protein and E3 ubiquitin ligase, thereby achieving specific degradation of EGFR for the treatment of EGFR-related diseases.

Benefits of technology

This compound can effectively inhibit and degrade EGFR protein, improve treatment efficacy, and has higher bioavailability and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004229398470000051
    Figure BDA0004229398470000051
  • Figure BDA0004229398470000061
    Figure BDA0004229398470000061
  • Figure BDA0004229398470000064
    Figure BDA0004229398470000064
Patent Text Reader

Abstract

The invention relates to a compound shown in a general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal of the compound, an intermediate of the compound, and application of the compound in EGFR (epidermal growth factor receptor) related diseases such as cancers. B-L-K (I)
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a compound of general formula (I) or a stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, as well as intermediates and preparation methods thereof, and use thereof in EGFR-related diseases such as cancer diseases. Background Art

[0002] Epidermal growth factor receptor (EGFR) is a transmembrane protein tyrosine kinase that can act as a receptor for EGF family members to trigger the EGFR signaling pathway in human epithelial cells, thereby regulating cell proliferation, invasion, metastasis, apoptosis and angiogenesis (Nat. Rev. Cancer, 2007, 7, 169-181; Expert Opin. Ther. Targets, 2012, 16, 15-31.). Overexpression, mutation or amplification of the EGFR gene in the human body causes abnormal increase in EGFR activity, which can lead to the occurrence of many malignant tumors such as esophageal cancer, glioblastoma, anal cancer, head and neck epithelial cancer, breast cancer, lung cancer, especially non-small cell lung cancer (NSCLC) (Cells, 2019, 8, 350-361.).

[0003] PROTAC (proteolysis targeting chimera) molecules are bifunctional compounds that can simultaneously bind to targeted proteins and E3 ubiquitin ligases. Such compounds can be recognized by the proteasome of the cell, causing degradation of the targeted protein, and can effectively reduce the content of the targeted protein in the cell. By introducing ligands that can bind to different targeted proteins in PROTAC molecules, PROTAC technology can be applied to the treatment of various diseases. This technology has also received widespread attention in recent years (ACS Chem.Biol.2017,12,892-898; Drug Discovery Today Technol.2019,31,15-27.).

[0004] The development of new PROTAC drugs that bind to EGFR protein and E3 ubiquitin ligase for the treatment of diseases related to EGFR protein will be full of application prospects. Summary of the invention

[0005] The purpose of the present invention is to provide a compound with novel structure, good efficacy, high bioavailability, greater safety, and the ability to inhibit and degrade EGFR, for the treatment of EGFR-related diseases such as cancer.

[0006] The present invention provides a compound or a stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein the compound is selected from the compounds represented by general formula (I),

[0007] BLK(I);

[0008] In certain embodiments, the compound of formula (I) is selected from the group consisting of formula (Ia)

[0009] In certain embodiments, L is selected from a bond or -C 1-50 Hydrocarbyl-, wherein 0 to 20 methylene units in the hydrocarbyl are optionally further replaced by -Ak-, -Cy-;

[0010] In certain embodiments, L is selected from a bond or -C 1-20 Hydrocarbyl-, wherein 0 to 20 methylene units in the hydrocarbyl are optionally further replaced by -Ak-, -Cy-;

[0011] In certain embodiments, L is selected from a bond or -C 1-10 Hydrocarbyl-, wherein 0 to 10 (e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) methylene units are optionally further replaced by -Ak-, -Cy-;

[0012] In certain embodiments, each -Ak- is independently selected from Ak1, Ak2, Ak3, Ak4 or Ak5;

[0013] In certain embodiments, each -Ak- is independently selected from -(CH2) q -、-(CH2) q -O-, -O-(CH2) q -、-(CH2) q -NR L -、-NR L -(CH2) q -、-(CH2) q -NR L C(=O)-、-NR L (CH2) q C(=O)-、-(CH2) q -C(=O)NR L -, -C(=O)-, -C(=O)-(CH2) q -NR L -、-(C≡C) q -、-CH=CH-、-Si(R L )2-、-Si(OH)(R L )-、-Si(OH)2-、-P(=O)(OR L )-、-P(=O)(R L)-, -S-, -S(=O)-, -S(=O)2- or a bond, wherein the -CH2- is optionally further replaced by 0 to 2 (e.g., 0, 1 or 2) selected from H, halogen, OH, CN, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, halogen substituted C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, cyano substituted C 1-6 substituted by an alkyl substituent;

[0014] In certain embodiments, each -Cy- is independently selected from Cy1, Cy2, Cy3, Cy4 or Cy5;

[0015] In certain embodiments, each -Cy- is independently selected from a bond, a 4-8 membered heteromonocycle, a 4-10 membered heterocyclic ring, a 5-12 membered heterospirocycle, a 7-10 membered heterobridged ring, a 3-7 membered monocycloalkyl, a 4-10 membered cycloalkyl, a 5-12 membered spirocycloalkyl, a 7-10 membered bridged cycloalkyl, a 5-10 membered heteroaryl, or a 6-10 membered aryl, wherein the aryl, heteroaryl, cycloalkyl, heteromonocycle, heterocyclic ring, heterospirocycle, or heterobridged ring is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3, or 4) selected from H, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 The heteroaryl, heteromonocyclic, heterocyclic, heterospirocyclic or heterobridged ring contains 1 to 4 (e.g., 1, 2, 3 or 4) heteroatoms selected from O, S and N, and when the heteroatom is selected from S, it is optionally further substituted by 0, 1 or 2 =0;

[0016] In certain embodiments, Cy1, Cy2, Cy3, Cy4 or Cy5 are each independently selected from a bond, a 4-7 membered heteromonocycle, a 4-10 membered heterocyclic ring, a 5-12 membered heterospirocycle, a 7-10 membered heterobridged ring, a 3-7 membered monocycloalkyl, a 4-10 membered cycloalkyl, a 5-12 membered spirocycloalkyl, a 7-10 membered bridged cycloalkyl, a 5-10 membered heteroaryl or a 6-10 membered aryl, wherein the aryl, heteroaryl, cycloalkyl, heteromonocycle, heterocyclic ring, heterospirocycle or heterobridged ring is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3 or 4) selected from H, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4The heteroaryl, heteromonocyclic, heterocyclic, heterospirocyclic or heterobridged ring contains 1 to 4 (e.g., 1, 2, 3 or 4) heteroatoms selected from O, S and N, and when the heteroatom is selected from S, it is optionally further substituted by 0, 1 or 2 =0;

[0017] In certain embodiments, L is selected from -Cy1-Ak1-Cy2-Ak2-Cy3-Ak3-Cy4-Ak4-Cy5-Ak5-, -Cy1-Cy2-Cy3-Cy4-Ak1-Ak2-Ak3-Ak4-Ak5-, -Cy1-Ak1-Cy2-Ak2-Cy3-Ak3-Cy4-Ak4-Ak5-, -Ak1-Cy1-Ak2-Cy2-Ak3-Cy3-Ak4-Cy4-Ak5-, -Cy1-Ak1-Cy2-Ak2-Cy3-Cy4-Ak3-Ak4-Ak5-, 5-, -Cy1-Ak1-Ak2-Ak3-Ak4-Ak5-Cy2-Cy3-Cy4-, -Cy1-Cy2-Ak1-Ak2-Ak 3-Ak4-Ak5-Cy3-Cy4-, -Cy1-Cy2-Cy3-Ak1-Ak2-Ak3-Ak4-Ak5-Cy4-, -Cy1 -Cy2-Cy3-Cy4-Ak1-Ak2-Ak3-Ak4-Ak5-, -Cy1-Ak1-Cy2-Cy3-Cy4-Ak2-A k3-Ak4-Ak5-, -Cy1-Cy2-Ak1-Cy3-Cy4-Ak2-Ak3-Ak4-Ak5-, -Cy1-Cy2-Cy 3-Ak1-Cy4-Ak2-Ak3-Ak4-Ak5-, -Cy1-Ak1-Ak2-Cy2-Cy3-Cy4-Ak3-Ak4- Ak5-, -Cy1-Cy2-Ak1-Ak2-Cy3-Cy4-Ak3-Ak4-Ak5-, -Cy1-Cy2-Cy3-Ak1- Ak2-Cy4-Ak3-Ak4-Ak5-, -Cy1-Ak1-Ak2-Ak3-Cy2-Cy3-Cy4-Ak4-Ak5-, - Cy1-Cy2-Ak1-Ak2-Ak3-Cy3-Cy4-Ak4-Ak5-, -Cy1-Cy2-Cy3-Ak1-Ak2-Ak3 -Cy4-Ak4-Ak5-, -Cy1-Ak1-Ak2-Ak3-Ak4-Cy2-Cy3-Cy4-Ak5-, -Cy1-Cy2 -Ak1-Ak2-Ak3-Ak4-Cy3-Cy4-Ak5-, -Cy1-Cy2-Cy3-Ak1-Ak2-Ak3-Ak4-Cy 4-Ak5-, -Ak1-Ak2-Ak3-Ak4-Ak5-Cy1-Cy2-Cy3-Cy4-, -Ak1-Cy1-Cy2-Cy 3-Cy4-Ak2-Ak3-Ak4-Ak5-, -Ak1-Ak2-Cy1-Cy2-Cy3-Cy4-Ak3-Ak4-Ak5-,-Ak1-Ak2-Ak3-Cy1-Cy2-Cy3-Cy4-Ak4-Ak5-、-Ak1-Ak2-Ak3-Ak4-Cy1-Cy2-Cy3-Cy4-Ak5-、-Ak1-Cy1-Ak2-Ak3-Ak4-Ak5-Cy2-Cy3-Cy4-、-Ak1-Cy1-Cy2-Ak2-Ak3-Ak4-Ak5-Cy3-Cy4-、-Ak1-Cy1-Cy2-Cy3-Ak2-Ak3-Ak4-Ak5-Cy4-、-Ak1-Ak2-Cy1-Ak3-Ak4-Ak5-Cy2-Cy3-Cy4-、-Ak1-Ak2-Cy1-Cy2-Ak3-Ak4-Ak5-Cy3-Cy4-、-Ak1-Ak2-Cy1-Cy2-Cy3-Ak3-Ak4-Ak5-Cy4-、-Ak1-Ak2-Ak3-Cy1-Ak4-Ak5-Cy2-Cy3-Cy4-、-Ak1-Ak2-Ak3-Cy1-Cy2-Ak4-Ak5-Cy3-Cy4-、-Ak1-Ak2-Ak3-Cy1-Cy2-Cy3-Ak4-Ak5-Cy4-、-Ak1-Ak2-Ak3-Ak4-Cy1-Ak5-Cy2-Cy3-Cy4-、-Ak1-Ak2-Ak3-Ak4-Cy1-Cy2-Ak5-Cy3-Cy4-、-Ak1-Ak2-Ak3-Ak4-Cy1-Cy2-Cy3-Ak5-Cy4-;、

[0018] In certain embodiments, L is selected from -Cy1-, -Cy1-Ak1-, -Cy1-Ak1-Ak2-, -Cy1-Ak1-Ak2-Ak3-, -Cy1-Ak1-Ak2-Ak3-Ak4-, -Cy1-Cy2-, -Cy1-Ak1-Cy2-, -Cy1-Cy2-Ak2-, -Cy1-Ak1-Cy2-Ak2-, -Cy1-Ak1-Cy2-Ak2-Ak3-, -Ak1-Cy2-, -Cy1-Ak1-Cy2-Ak2-Ak3-Ak4-, -Cy1-Cy2-Ak2-Ak3-, -Cy1-Cy2-Ak2-Ak3-Ak4-, -Cy1-Ak1-Cy2-Ak2-Ak3-Ak4-, -Cy1-Ak1-Ak2-Cy3-, -Cy1-Ak1-Ak2-Cy3-Ak3-, -Cy1-Cy2-Cy3-, -Cy1-Ak1-Cy2-Cy3-, -Cy1-Cy2-Ak2-Cy3-, -Cy1-Cy2-Cy3-Ak3-, -Cy1-Ak1-Cy2-Cy3-Ak3-, -Cy1-Cy2-Ak2-Cy3-Ak3-, -Cy1-Ak1-Cy2-Ak2-Cy3-, -Cy1-Ak1-Cy2-Ak2-Cy3-Ak3-, -Cy1-Cy2-Cy3-Ak3-Ak4-, -Cy1-Cy2-Cy3-Ak3-Cy4-, -Cy1-Cy2-Cy3-Cy4-, -Cy1-Ak1-Cy2-Cy3-Cy4-, -Cy1-Cy2-Ak2-Cy3-Cy4-, -Cy1-Cy2-Cy3-Ak3-Cy4-, -Cy1-Cy2-Cy3-Cy4-Ak4-, -Cy1-Ak1-Cy2-Ak2-Cy3-Ak3-Cy4-, -Cy1-Ak1-Cy2-Ak2-Cy3-Cy4-, -Ak1-Ak2-Cy3-Cy4-, -Ak1-Cy2-Ak2-Cy3-, -Ak1-Cy2-Cy3-Ak3-Cy4-, -Ak1-Cy2-Cy3-Cy4-Ak4-Cy5-, -Ak1-Cy2-Ak2-, -Ak1-Ak2-Ak3-Ak4-, -Ak1-Ak2-Ak3-, -Ak1-Ak2-, -Ak1-Ak2-Ak3-Ak4-Ak5-, -Cy1-Cy2-Cy3-Ak3-Ak4-Ak5-, -Cy1-Cy2-Ak2-Cy3-Ak3-Ak4-Ak5-, -Cy1-Ak1-Cy2-Ak2-Ak3-Ak4-Ak5-, -Cy1-Cy2-Cy3-Cy4-Ak4-Ak5-, -Cy1-Ak1-Ak2-Ak3-Ak4-Ak5-, -Ak1-Cy2-Ak2-Ak3-Ak4-Ak5--Ak1-Cy2-Ak2-Ak3-Ak4-, -Ak1-Cy2-Ak2-Ak3-;;,

[0019] In certain embodiments, L is selected from -Cy1-Cy2-, -Cy1-CH2-Cy2-, Cy1, Cy2 are each independently selected from piperazine, piperidine, azetidinyl, azetyl, cyclobutyl spiroazetidinyl, azetidinyl spiroazetidinyl, cyclobutyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, cyclohexyl spiroazetidinyl, cyclohexyl spiroazetidinyl, cyclopentyl azetidinyl, azetidinyl azetidinyl, and the Cy1, Cy2 are optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3 or 4) selected from H, F, Cl, Br, I, OH, NH2, COOH, CN, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;

[0020] In certain embodiments, L is selected from a bond or a group from Table L-1 or Table L-2, the left side of the group being connected to B;

[0021] In certain embodiments, Ak1, Ak2, Ak3, Ak4, and Ak5 are each independently selected from -(CH2) q -、-(CH2) q -O-, -O-(CH2) q -、-(CH2) q -NR L -、-NR L -(CH2) q -、-(CH2) q -NR L C(=O)-、-(CH2) q -C(=O)NR L -, -C(=O)-, -C(=O)-(CH2) q -NR L -、-(C≡C) q - or a bond, wherein the -CH2- is optionally further replaced by 0 to 2 (e.g., 0, 1 or 2) selected from H, halogen, OH, CN, NH2, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, cyano substituted C 1-4 substituted by an alkyl substituent;

[0022] In certain embodiments, Ak1, Ak2, Ak3, Ak4, and Ak5 are each independently selected from -O-, -OCH2-, -CH2O-, -OCH2CH2-, -CH2CH2O-, -C≡C-, -C(CH3)2-, -CH2-, -CH2CH2-, -CH2CH2CH2-, -N(CH3)-, -NH-, -CH2N(CH3)-, -CH2NH-, -NHCH2-, -CH2CH2N(CH3)-, -CH2CH2NH-, -NHCH2CH2-, -C(=O)-, -C(=O)CH2NH-, -CH2C(=O)NH-, -C(=O)NH-, or -NHC(=O)-;

[0023] In certain embodiments, R L Each independently selected from H, C 1-6 Alkyl, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, phenyl or 5-6 membered heteroaryl;

[0024] In certain embodiments, R L Each independently selected from H or C 1-6 alkyl;

[0025] In certain embodiments, R L Each independently selected from H or C 1-4 alkyl;

[0026] In certain embodiments, R L each independently selected from H, methyl or ethyl;

[0027] In certain embodiments, Cy1, Cy2, Cy3, Cy4 or Cy5 are each independently selected from a bond, a 4-7 membered nitrogen-containing heteromonocycle, a 4-10 membered nitrogen-containing heterocyclic ring, a 5-12 membered nitrogen-containing heterospirocycle, a 7-10 membered nitrogen-containing heterobridged ring, a 3-7 membered monocycloalkyl, a 4-10 membered cycloalkyl, a 5-12 membered spirocycloalkyl, a 7-10 membered bridged cycloalkyl, a 5-10 membered heteroaryl or a 6-10 membered aryl, wherein the heteromonocycle, heterocyclic ring, heterobridged ring, heterospirocycle, cycloalkyl, aryl or heteroaryl is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 The heterocyclic, heterocyclic, heterobridged, heterospirocyclic or heteroaryl group contains 1 to 4 heteroatoms selected from O, S and N. When the heteroatom is selected from S, it is optionally further substituted by 0, 1 or 2 =0;

[0028] In certain embodiments, Cy1, Cy2, Cy3, Cy4 or Cy5 are each independently selected from a bond or a substituted or unsubstituted one of the following groups: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azetyl, azidine, piperidine, morpholine, piperazine, phenyl, cyclopropyl-cyclopropyl, cyclopropyl-cyclobutyl, cyclopropyl-cyclopentyl, cyclopropyl-cyclohexyl, cyclobutyl-cyclobutyl, cyclobutyl-cyclopentyl, cyclobutyl-cyclohexyl, cyclopentyl-cyclopentyl, cyclopentyl-cyclohexyl , cyclohexyl and cyclohexyl, cyclopropyl spirocyclopropyl, cyclopropyl spirocyclobutyl, cyclopropyl spirocyclopentyl, cyclopropyl spirocyclohexyl, cyclobutyl spirocyclobutyl, cyclobutyl spirocyclopentyl, cyclobutyl spirocyclohexyl, cyclopentyl spirocyclopentyl, cyclopentyl spirocyclohexyl, cyclohexyl spirocyclohexyl, cyclopropyl and azetidinyl, cyclopropyl and azetidinyl, cyclopropyl and azetidinyl, cyclopropyl and azetidinyl, cyclobutyl and azetidinyl, cyclobutyl and azetidinyl, cyclopentyl ... azetidinyl, cyclohexylazetidinyl, cyclohexylazetidinyl, cyclohexylazetidinyl, azetidinazetidinyl, azetidinazetidinyl, azetidinazetidinyl, azetidinazetidinyl, azetidinazetidinyl, azetidinazetidinyl, azetidinazetidinyl, azetidinazetidinyl, azetidinazetidinyl, azetidinazetidinyl, azetidinazetidinyl, azetidinazetidinyl, cyclobutylspiroazetidinyl, cyclobutylspiroazetidinyl cyclohexyl, cyclopentyl spiroazetidinyl, cyclopentyl spiroazacyclopentyl, cyclopentyl spiroazacyclohexyl, cyclohexyl spiroazetidinyl, cyclohexyl spiroazetidinyl, cyclohexyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl, azetidinyl spiroazetidinyl,

[0029] When substituted, it is optionally further substituted with 0 to 4 (e.g., 0, 1, 2, 3 or 4) selected from H, F, Cl, Br, I, OH, NH2, COOH, CN, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;

[0030] In certain embodiments, Cy1, Cy2, Cy3, Cy4 or Cy5 are each independently selected from a bond or a substituted or unsubstituted one of the following groups:

[0031] When substituted, it is optionally further substituted with 0 to 4 (e.g., 0, 1, 2, 3 or 4) substituents selected from H, F, CF3, methyl, =O, hydroxymethyl, COOH, CN or NH2;

[0032] In certain embodiments, K is selected from

[0033] In certain embodiments, K is selected from indicates that the ring is selected from an aromatic ring or a non-aromatic ring;

[0034] In certain embodiments, K is selected from

[0035]

[0036]

[0037] In certain embodiments, each Q is independently selected from a bond, -O-, -S-, -CH2-, -NR q -、-C(=O)-、-

[0038] NR q C(=O)-, -C(=O)NR q - or 3-12 membered heterocyclic group, wherein the heterocyclic group is optionally further substituted with 0 to 4 (e.g. 0, 1,

[0039] 2, 3, 4) selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-

[0040] 4-alkoxy substituent, wherein the heterocyclic group contains 1 to 4 (e.g., 1, 2, 3, 4) heteroatoms selected from O, S, and N;

[0041] In certain embodiments, each Q is independently selected from -O-, -S-, -CH2-, -NR q -, -C(=O)-, -NR q C(=O)-, -C(=O)NR q- or a 4-7 membered heterocyclic group, wherein the heterocyclic group is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3, 4) selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 (e.g., 1, 2, 3, 4) heteroatoms selected from O, S, and N;

[0042] In certain embodiments, R q Select from H or C 1-6 alkyl;

[0043] In certain embodiments, R q Select from H or C 1-4 alkyl;

[0044] In certain embodiments, R q is selected from H, methyl, ethyl;

[0045] In certain embodiments, each E is independently selected from C 3-10 Carbocyclic group, C 6-10 Aryl, 3-12 membered heterocyclyl or 5-12 membered heteroaryl, wherein the heterocyclyl or heteroaryl contains 1 to 4 (e.g. 1, 2, 3, 4) heteroatoms selected from O, S, N;

[0046] In certain embodiments, each E is independently selected from C 3-8 A carbocyclic ring, a benzene ring, a 4-7 membered heterocyclic ring, an 8-12 membered heterocyclic ring, a 7-12 membered heteroaryl group, or a 5-6 membered heteroaryl group, wherein the heterocyclic ring or heteroaryl group contains 1 to 4 (e.g., 1, 2, 3, 4) heteroatoms selected from O, S, and N;

[0047] In certain embodiments, each E is independently selected from phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, furanyl, thienyl, oxazolyl, indolinyl, isoindolyl, 1,2,3,4-tetrahydroquinolinyl or 1,2,3,4-tetrahydroisoquinolinyl;

[0048] In certain embodiments, each E is independently selected from phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, furanyl, thienyl, or oxazolyl;

[0049] In certain embodiments, each E is independently selected from phenyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl;

[0050] In certain embodiments, each E is independently selected from a benzene ring or a pyridine ring;

[0051] In certain embodiments, A is selected from C3-10 Carbocyclic group, C 6-10 Aryl, 3-10 membered heterocyclyl or 5-10 membered heteroaryl, wherein the heterocyclyl or heteroaryl contains 1 to 4 (e.g. 1, 2, 3 or 4) heteroatoms selected from O, S, N;

[0052] In certain embodiments, A, H1 or H2 are each independently selected from C 3-8 A carbocyclic ring, a benzene ring, a 4-7 membered heterocyclic ring or a 5-6 membered heteroaryl group, wherein the heterocyclic ring or heteroaryl group contains 1 to 4 (e.g., 1, 2, 3 or 4) heteroatoms selected from O, S, and N;

[0053] In certain embodiments, A, H1 or H2 are each independently selected from phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, furanyl, thienyl or oxazolyl;

[0054] In certain embodiments, A, H1 or H2 are each independently selected from phenyl or pyridinyl;

[0055] In certain embodiments, each F is independently selected from C 3-20 Carbocyclic group, C 6-20 Aryl, 3-20 membered heterocyclyl or 5-20 membered heteroaryl, wherein the heterocyclyl or heteroaryl contains 1 to 4 (e.g. 1, 2, 3, 4) heteroatoms selected from O, S, N;

[0056] In certain embodiments, each F is independently selected from a 3-7 membered monocycloalkyl, a 4-10 membered cycloalkyl, a 5-12 membered spirocycloalkyl, a 5-10 membered bridged cycloalkyl, a 4-7 membered heteromonocyclic ring, a 4-10 membered heterocyclocyclic ring, an 8-15 membered tricyclic heterocyclocyclic ring, a 12-17 membered tetracyclic heterocyclocyclic ring, a 5-12 membered heterospirocyclic ring, a 5-10 membered heterobridged ring, a C 6-14 Aryl or 5-10 membered heteroaryl, wherein the heteromonocyclic, heterocyclic, heterospirocyclic, heterobridged or heteroaryl group contains 1 to 4 (e.g., 1, 2, 3, 4) heteroatoms selected from O, S, and N;

[0057] In certain embodiments, each F is independently selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentanyl, 6,7-dihydro-5H-cyclopenta[c]pyridinyl, 2,3-dihydro-1H-indenyl, phenyl, naphthyl, anthracenyl, phenanthrenyl, azetidinyl, azopentyl, piperidinyl, morpholinyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, furanyl, thienyl, thiazolyl, benzoxazole, pyridoimidazole, benzimidazolyl, benzopyrazolyl, benzothiazolyl, benzothienyl, benzofuranyl, benzopyrrolyl, benzopyridinyl, benzopyrazinyl, benzopyrimidinyl, benzopyridazinyl, pyrrolopyrrolyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrrolopyridazinyl, pyrrolopyrazinyl, imidazopyrimidinyl, imidazopyridinyl, imidazopyrazinyl, imidazopyridazinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolopyridazinyl, pyrimidopyridinyl, pyrimidopyrazinyl, pyrimidopyridazinyl, pyrimidopyrimidinyl, pyridopyridinyl, pyridopyrazinyl, pyridopyridazinyl, pyridazinopyrazinyl, or pyrazinopyrazinyl;

[0058] In certain embodiments, each F is independently selected from

[0059] In certain embodiments, R k2 are each independently selected from a bond, -C(=O)-, -S(=O)2-, -S(=O)- or -C(R k3 )2-;

[0060] In certain embodiments, R k2 Each independently selected from -C(=O)-, -S(=O)2- or -C(R k3 )2-;

[0061] In certain embodiments, R k1 Each independently selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, wherein the alkyl, alkoxy, cycloalkyl is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Substituted by a cycloalkyl substituent;

[0062] In certain embodiments, both R k1 Together with the atoms it is attached to form C 3-6A carbocyclic ring or a 4- to 7-membered heterocyclic ring, wherein the carbocyclic ring or the heterocyclic ring is optionally further substituted by 0 to 4 rings selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;

[0063] In certain embodiments, R k3 Each independently selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl or 3-8 membered heterocyclyl, wherein the alkyl, alkoxy, cycloalkyl or heterocyclyl is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3, 4) selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 (e.g., 1, 2, 3, 4) heteroatoms selected from O, S, and N;

[0064] In certain embodiments, R k1 , R k3 Each independently selected from H, F, Cl, Br, I, OH, =O, NH2, CF3, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 Alkoxy, wherein the alkyl or alkoxy group is optionally further substituted with 0 to 4 (e.g., 0, 1, 2, 3 or 4) substituents selected from H, F, Cl, Br, I, OH, NH2;

[0065] In certain embodiments, R k1 Selected from H, F, Cl, Br, I, OH, =O, NH2, CF3, CN, COOH, CONH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, wherein the alkyl, alkoxy or cycloalkyl is optionally further substituted by 0 to 4 substituents selected from H, F, Cl, Br, I, OH, NH2;

[0066] In certain embodiments, R k3 Selected from H, F, Cl, Br, I, OH, =O, NH2, CF3, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 Alkoxy, wherein the alkyl or alkoxy is optionally further substituted by 0 to 4 substituents selected from H, F, Cl, Br, I, OH, NH2;

[0067] In certain embodiments, R k1 , R k3 Each independently selected from H, F, Cl, Br, I, OH, =O, NH2, CF3, CN, COOH, CONH2, methyl, ethyl, isopropyl, methoxy, ethoxy or isopropoxy, wherein the methyl, ethyl, isopropyl, methoxy, ethoxy or isopropoxy is optionally further substituted with 0 to 4 (e.g., 0, 1, 2, 3 or 4) substituents selected from H, F, Cl, Br, I, OH, NH2;

[0068] In certain embodiments, both R k1 Together with the atoms it is attached to form C 3-6 A carbocyclic ring or a 4- to 7-membered heterocyclic ring, wherein the carbocyclic ring or the heterocyclic ring is optionally further substituted by 0 to 4 rings selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic ring is substituted by an alkoxy substituent, and the heterocyclic ring contains 1 to 4 heteroatoms selected from O, S, and N;

[0069] In certain embodiments, both R k3 and the carbon atoms or ring skeletons directly connected to the two together form a 3-8 membered carbocyclic ring or a 3-8 membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3, 4) selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic ring is substituted by an alkoxy substituent, and the heterocyclic ring contains 1 to 4 (e.g., 1, 2, 3, 4) heteroatoms selected from O, S, and N;

[0070] In certain embodiments, both R k3 and the carbon atoms or ring skeletons directly connected to the two together form a 3-6-membered carbocyclic ring or a 3-7-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3, 4) selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic ring is substituted by an alkoxy substituent, and the heterocyclic ring contains 1 to 4 (e.g., 1, 2, 3, 4) heteroatoms selected from O, S, and N;

[0071] In certain embodiments, R k4 Each independently selected from H, OH, NH2, CN, CONH2, C 1-6 Alkyl, C 3-8Cycloalkyl or 3-8 membered heterocyclyl, wherein the alkyl, cycloalkyl or heterocyclyl is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3, 4) selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 (e.g., 1, 2, 3, 4) heteroatoms selected from O, S, and N;

[0072] In certain embodiments, R k4 Each independently selected from H, OH, NH2, CF3, CN, C 1-4 alkyl;

[0073] In certain embodiments, R k5 Each independently selected from C(CH3)2, C(=O), CH2, S(=O)2,

[0074] In certain embodiments, R k6 Each is independently selected from C(═O), CH, S(═O), S(═O)2, CH2 or N;

[0075] In certain embodiments, R k7 Each independently selected from C(CH3)2, C(═O), CH, N, CH2, O, S, N(CH3), N(CH2CH3), N(cyclopropyl) or NH;

[0076] In certain embodiments, R k7 Each independently selected from C(CH3)2, CH2, O, N(CH3), N(CH2CH3), N(cyclopropyl) or NH;

[0077] In certain embodiments, R k7 Each is independently selected from CH2, O, N(CH3) or NH;

[0078] In certain embodiments, R k8 are each independently selected from C, N or CH;

[0079] In certain embodiments, R k9 are each independently selected from a bond, C(CH3)2, C(=O), CH2, CH2CH2 or S(=O)2;

[0080] In certain embodiments, M1 is selected from a bond, -C(=O)NH-, -NHC(=O)-, -CH2-C(=O)NH-, -C(=O)CH2NH-, a 5-6 membered heteroaryl, wherein the heteroaryl is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3 or 4) selected from H, F, Cl, Br, I, OH, =O, CF3, NH2, CN, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 The heteroaryl group is substituted by an alkoxy substituent, wherein the heteroaryl group contains 1 to 4 (e.g., 1, 2, 3 or 4) heteroatoms selected from O, S and N;

[0081] In certain embodiments, M1 is selected from a bond, -C(=O)NH-, -CH2-C(=O)NH-, -C(=O)CH2NH-, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, furanyl, thienyl, thiazolyl;

[0082] In certain embodiments, M1 is selected from a bond, -CH2-C(=O)NH-, or -C(=O)CH2NH-;

[0083] In certain embodiments, M2 is selected from -NHC(=O)-C 1-6 Alkyl, -NHC(=O)-C 3-6 Cycloalkyl or 4-10 membered heterocyclyl, wherein the alkyl, cycloalkyl or heterocyclyl is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3, 4) selected from H, F, Cl, Br, I, =O, OH, NH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 (e.g., 1, 2, 3, 4) heteroatoms selected from O, S, and N;

[0084] In certain embodiments, M2 is selected from -NHC(=O)-CH3, -NHC(=O)-cyclopropyl, -NHC(=O)-cyclobutyl, azetidinyl, azetyl, benzazacyclopentyl, benzazacyclohexyl, wherein the cyclopropyl, cyclobutyl, azetidinyl, azetyl, benzazacyclopentyl or benzazacyclohexyl is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3 or 4) selected from H, F, Cl, Br, I, =O, OH, NH2, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;

[0085] In certain embodiments, M3 is selected from -NH- or -O-;

[0086] In certain embodiments, Rk10 Selected from C 1-6 Alkyl, wherein the alkyl is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3, 4) selected from H, F, Cl, Br, I, =O, OH, C 1-6 Alkyl or C 3-6 Substituted by a cycloalkyl substituent;

[0087] In certain embodiments, R k10 is selected from methyl, ethyl, isopropyl, propyl, tert-butyl, wherein the methyl, ethyl, isopropyl, propyl, tert-butyl is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3 or 4) selected from H, F, Cl, Br, I, =O, OH, C 1-4 Alkyl or C 3-6 Substituted by a cycloalkyl substituent;

[0088] In certain embodiments, G is selected from 6-10 membered aryl or 5-10 membered heteroaryl, wherein the aryl or heteroaryl is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3, 4) selected from H, F, Cl, Br, I, OH, =O, CF3, CN, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 The heteroaryl group is substituted by a cycloalkyl substituent, wherein the heteroaryl group contains 1 to 4 (e.g., 1, 2, 3, 4) heteroatoms selected from N, O, and S;

[0089] In certain embodiments, R k11 Each independently selected from H, F, Cl, Br, I, =O, OH, SH, C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Alkylthio or -OC(=O)-C 1-6 The alkyl group, alkoxy group or alkylthio group is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3, 4) groups selected from H, F, Cl, Br, I, OH, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;

[0090] In certain embodiments, in certain embodiments, R k11Each independently selected from H, F, Cl, Br, I, =O, OH, SH, methyl, ethyl, isopropyl, propyl, methoxy, ethoxy, propoxy, isopropyloxy, methylthio, ethylthio, propylthio or -OC(=O)-CH3, wherein the methyl, ethyl, isopropyl, propyl, methoxy, ethoxy, propoxy, isopropyloxy, methylthio, ethylthio, propylthio is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3 or 4) selected from H, F, Cl, Br, I, OH, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;

[0091] In certain embodiments, R k12 , R k13 Each independently selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl, wherein the alkyl or cycloalkyl is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3, 4) groups selected from H, F, Cl, Br, I, =O, OH, NH2, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;

[0092] In certain embodiments, R k12 , R k13 Each independently selected from H, methyl, ethyl, isopropyl, propyl, cyclopropyl or cyclobutyl, wherein the methyl, ethyl, isopropyl, propyl, cyclopropyl or cyclobutyl is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3 or 4) selected from H, F, Cl, Br, I, =O, OH, NH2, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;

[0093] In certain embodiments, R k14 is selected from 5-6 membered heteroaryl, wherein the heteroaryl is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3, 4) selected from H, F, Cl, Br, I, OH, =O, CF3, CN, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 The heteroaryl group is substituted by a cycloalkyl substituent, wherein the heteroaryl group contains 1 to 4 (e.g., 1, 2, 3, 4) heteroatoms selected from N, O, and S;

[0094] In certain embodiments, K is selected from one of the structural fragments shown in Table K-1;

[0095] In certain embodiments, K is selected from one of the structural fragments shown in Table K-2;

[0096] In certain embodiments, K is selected from one of the structural fragments shown in Table K-3; Table K-1

[0097]

[0098]

[0099]

[0100]

[0101]

[0102] Table K-2

[0103]

[0104]

[0105]

[0106]

[0107] Table K-3

[0108]

[0109]

[0110] In certain embodiments, K is selected from

[0111] In certain embodiments, B is selected from In certain embodiments, B is selected from In certain embodiments, B is selected from one of the following structural fragments:

[0112]

[0113]

[0114] In certain embodiments, B is selected from one of the structural fragments shown in Table B-1;

[0115] Table B-1

[0116]

[0117]

[0118]

[0119]

[0120] In certain embodiments, B is selected from In certain embodiments, B is selected from

[0121] In certain embodiments, B is selected from

[0122] In certain embodiments, L is selected from -Cy1-CH2-Cy2-, Cy1 is selected from 4-6 membered nitrogen-containing heterocyclic groups (preferably azetidinyl, azopentyl, azohexyl, piperazine), and Cy2 is selected from 4-6 membered nitrogen-containing heterocyclic groups (preferably azetidinyl, azopentyl, azohexyl, piperazine);

[0123] In certain embodiments, X1 and X2 are each independently selected from a bond, O, S, N (R x );

[0124] In certain embodiments, X1 and X2 are each independently selected from O, N(R x );

[0125] In certain embodiments, R x Selected from H, C 1-4 alkyl;

[0126] In certain embodiments, Ring B4 is selected from C 6-10 Carbocyclic, 5- to 10-membered heterocyclic, C 6-10 Aromatic ring, 5 to 10 membered heteroaromatic ring, wherein the ring B4 is optionally further substituted by 0 to 4 selected from H, F, Cl, Br, I, OH, =O, CN, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 3-6 The cycloalkyl group or the 4- to 6-membered heterocyclic ring is substituted, wherein the heterocyclic ring or the heteroaromatic ring contains 1 to 5 heteroatoms selected from O, S, and N;

[0127] In certain embodiments, ring B4 is selected from a benzene ring, preferably a para-substituted benzene ring, wherein the benzene ring is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, CN, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 3-6 substituted by a cycloalkyl group or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from O, S, and N;

[0128] In certain embodiments, Ring B4 is selected from rr is selected from 0, 1, 2 or 3, R B4 Each is independently selected from H, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, cyclopropyl, pyrrole, pyrazole;

[0129] In certain embodiments, R b9 Selected from C 6-10 Aromatic ring, 5- to 10-membered heteroaromatic ring, R b10 Selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 4 to 10 membered heterocyclic ring, said R b9 Optionally further 0 to 4 R b9a Substitute, the R b10 Optionally further 0 to 4 R b10a Substitution, the heterocyclic ring or heteroaromatic ring contains 1 to 5 heteroatoms selected from O, S, and N;

[0130] In certain embodiments, R b9 is selected from a benzene ring, a naphthalene ring, a 5- to 6-membered heteroaromatic ring, a 9- to 10-membered heteroaromatic ring, R b10 Selected from C 1-4 Alkyl, C 3-6 Cycloalkyl, 4 to 7 membered heterocycloalkyl, said R b9 Optionally further 0 to 4 R b9a Substitute, the R b10 Optionally further 0 to 4 R b10a Substitution, the heterocycloalkyl or heteroaromatic ring contains 1 to 5 heteroatoms selected from O, S, and N;

[0131] In certain embodiments, R b9 is selected from benzene ring, benzopyrrole, benzopyrazole, benzimidazole, pyridine, pyrimidine, pyrrole, pyrazole, thiazole, thiophene, oxazole, furan, R b10 is selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azetyl, azetyl, oxetanyl, oxolyl, oxetanyl, wherein R b9 Optionally further 0 to 4 R b9a Substitute, the R b10 Optionally further 0 to 4 R b10a replace;

[0132] In certain embodiments, R b9a , R b10a Each independently selected from H, F, Cl, Br, I, OH, ═O, CN, C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6Cycloalkyl, wherein the alkyl, alkoxy or cycloalkyl is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, CN, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0133] In certain embodiments, R b9a , R x Together with the atoms directly connected thereto, a 5- to 7-membered nitrogen-containing heterocyclic ring is formed, wherein the heterocyclic ring is optionally further substituted by 0 to 4 atoms selected from H, F, Cl, Br, I, OH, ═O, CN, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0134] In certain embodiments, R b9a Each independently selected from H, F, Cl, Br, I, OH, CN, CF3, methyl, methoxy;

[0135] In certain embodiments, R b10 Each independently selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, oxacyclopentyl, oxacyclohexyl, said R b10 Optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, =O, CN, methyl, methoxy;

[0136] In certain embodiments, R b11 Selected from NH2, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, NHC 3-8 carbocyclic ring, NH-4 to 10 membered heterocyclic ring, wherein the alkyl, carbocyclic ring or heterocyclic ring is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, =O, CN, C 1-4 Alkyl, C 1-4 The heterocyclic ring is substituted by an alkoxy substituent, and the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;

[0137] In certain embodiments, R b11 Selected from NH2;

[0138] In certain embodiments, q is each independently selected from 0, 1, 2, 3, 4, 5 or 6;

[0139] In certain embodiments, q is each independently selected from 0, 1, 2, 3 or 4;

[0140] In certain embodiments, q is each independently selected from 0, 1 or 2;

[0141] In certain embodiments, n1, n2, and n3 are each independently selected from 0, 1, 2, or 3;

[0142] In certain embodiments, p1 or p2 are each independently selected from 0, 1, 2, 3, 4 or 5;

[0143] In certain embodiments, p1 or p2 are each independently selected from 0, 1 or 2.

[0144] As a first embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0145] BLK(I);

[0146] L is selected from a bond or -C 1-50 Hydrocarbyl-, wherein 0 to 20 methylene units in the hydrocarbyl are optionally further replaced by -Ak-, -Cy-;

[0147] Each -Ak- is independently selected from -(CH2) q -、-(CH2) q -O-, -O-(CH2) q -、-(CH2) q -NR L -、-NR L -(CH2) q -、-(CH2) q -NR L C(=O)-、-NR L (CH2) q C(=O)-、-(CH2) q -C(=O)NR L -, -C(=O)-, -C(=O)-(CH2) q -NR L -、-(C≡C) q -、-CH=CH-、-Si(R L )2-、-Si(OH)(R L )-、-Si(OH)2-、-P(=O)(OR L )-、-P(=O)(R L )-, -S-, -S(=O)-, -S(=O)2- or a bond, wherein the -CH2- is optionally further replaced by 0 to 2 residues selected from H, halogen, OH, CN, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, halogen substituted C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, cyano substituted C 1-6substituted by an alkyl substituent;

[0148] q is each independently selected from 0, 1, 2, 3, 4, 5 or 6;

[0149] R L Each independently selected from H, C 1-6 Alkyl, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, phenyl or 5-6 membered heteroaryl;

[0150] Each -Cy- is independently selected from a bond, a 4-8 membered heteromonocycle, a 4-10 membered heterocyclic ring, a 5-12 membered heterospirocycle, a 7-10 membered heterobridged ring, a 3-7 membered monocycloalkyl, a 4-10 membered cycloalkyl, a 5-12 membered spirocycloalkyl, a 7-10 membered bridged cycloalkyl, a 5-10 membered heteroaryl, or a 6-10 membered aryl, wherein the aryl, heteroaryl, cycloalkyl, heteromonocycle, heterocyclic ring, heterospirocycle, or heterobridged ring is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 The heteroaryl, heteromonocyclic, heterocyclic, heterospirocyclic or heterobridged ring contains 1 to 4 heteroatoms selected from O, S and N. When the heteroatom is selected from S, it is optionally further substituted by 0, 1 or 2 =0;

[0151] B is selected from

[0152] X1 and X2 are each independently selected from a bond, O, S, N (R x );

[0153] R x Selected from H, C 1-4 alkyl;

[0154] Ring B4 is selected from C 6-10 Carbocyclic, 5- to 10-membered heterocyclic, C 6-10 Aromatic ring, 5 to 10 membered heteroaromatic ring, wherein the ring B4 is optionally further substituted by 0 to 4 selected from H, F, Cl, Br, I, OH, =O, CN, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 3-6 The cycloalkyl group or the 4- to 6-membered heterocyclic ring is substituted, wherein the heterocyclic ring or the heteroaromatic ring contains 1 to 5 heteroatoms selected from O, S, and N;

[0155] R b9 Selected from C 6-10 Aromatic ring, 5- to 10-membered heteroaromatic ring, Rb10 Selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 4 to 10 membered heterocyclic ring, said R b9 Optionally further 0 to 4 R b9a Substitute, the R b10 Optionally further 0 to 4 R b10a Substitution, the heterocyclic ring or heteroaromatic ring contains 1 to 5 heteroatoms selected from O, S, and N;

[0156] R b9a , R b10a Each independently selected from H, F, Cl, Br, I, OH, ═O, CN, C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 Cycloalkyl, wherein the alkyl, alkoxy or cycloalkyl is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, CN, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0157] Alternatively, R b9a , R x Together with the atoms directly connected thereto, a 5- to 7-membered nitrogen-containing heterocyclic ring is formed, wherein the heterocyclic ring is optionally further substituted by 0 to 4 atoms selected from H, F, Cl, Br, I, OH, ═O, CN, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;

[0158] R b11 Selected from NH2, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, NHC 3-8 carbocyclic ring, NH-4 to 10 membered heterocyclic ring, wherein the alkyl, carbocyclic ring or heterocyclic ring is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, =O, CN, C 1-4 Alkyl, C 1-4 The heterocyclic ring is substituted by an alkoxy substituent, and the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N;

[0159] K is selected from

[0160] Q is independently selected from a bond, -O-, -S-, -CH2-, -NR q -, -C(=O)-, -NR q C(=O)-, -C(=O)NR q- or a 3-12 membered heterocyclic group, wherein the heterocyclic group is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S, and N;

[0161] R q Select from H or C 1-6 alkyl;

[0162] A is selected from C 3-10 Carbocyclic group, C 6-10 Aryl, 3-10 membered heterocyclic group or 5-10 membered heteroaryl, wherein the heterocyclic group or heteroaryl group contains 1 to 4 heteroatoms selected from O, S and N;

[0163] F are each independently selected from C 3-20 Carbocyclic group, C 6-20 Aryl, 3-20 membered heterocyclic group or 5-20 membered heteroaryl, wherein the heterocyclic group or heteroaryl group contains 1 to 4 heteroatoms selected from O, S and N;

[0164] R k2 are each independently selected from a bond, -C(=O)-, -S(=O)2-, -S(=O)- or -C(R k3 )2-;

[0165] R k1 Each independently selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, wherein the alkyl, alkoxy, cycloalkyl is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Substituted by a cycloalkyl substituent;

[0166] Alternatively, two R k1 Together with the atoms it is attached to form C 3-6 A carbocyclic ring or a 4- to 7-membered heterocyclic ring, wherein the carbocyclic ring or the heterocyclic ring is optionally further substituted by 0 to 4 rings selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;

[0167] R k3Each independently selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl or 3-8 membered heterocyclic group, wherein the alkyl, alkoxy, cycloalkyl or heterocyclic group is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S, and N;

[0168] Or two R k3 and the carbon atoms or ring skeletons directly connected to the two together form a 3-8 membered carbocyclic ring or a 3-8 membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally further substituted by 0 to 4 selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic ring is substituted by an alkoxy substituent, and the heterocyclic ring contains 1 to 4 heteroatoms selected from O, S, and N;

[0169] R k4 Each independently selected from H, OH, NH2, CN, CONH2, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-8 membered heterocyclic group, wherein the alkyl, cycloalkyl or heterocyclic group is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S, and N;

[0170] M1 is selected from a bond, -CH2-C(=O)NH- or -C(=O)CH2NH-;

[0171] M2 is selected from -NHC(=O)-C 1-6 Alkyl, -NHC(=O)-C 3-6 Cycloalkyl or 4-10 membered heterocyclic group, wherein the alkyl, cycloalkyl or heterocyclic group is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, =O, OH, NH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S, and N;

[0172] M3 is selected from -NH- or -O-;

[0173] Rk10 Selected from C 1-6 Alkyl, wherein the alkyl is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, =O, OH, C 1-6 Alkyl or C 3-6 Substituted by a cycloalkyl substituent;

[0174] R k11 Each independently selected from H, F, Cl, Br, I, =O, OH, SH, C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Alkylthio or -OC(=O)-C 1-6 The alkyl group, alkoxy group or alkylthio group may be further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;

[0175] R k12 , R k13 Each independently selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl, wherein the alkyl or cycloalkyl is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, =O, OH, NH2, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;

[0176] R k14 is selected from 5-6 membered heteroaryl, wherein the heteroaryl is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, =O, CF3, CN, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 The heteroaryl group is substituted by a substituent of a cycloalkyl group, wherein the heteroaryl group contains 1 to 4 heteroatoms selected from N, O, and S;

[0177] G is selected from 6-10 membered aryl or 5-10 membered heteroaryl, wherein the aryl or heteroaryl is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, =O, CF3, CN, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 The heteroaryl group is substituted by a substituent of a cycloalkyl group, wherein the heteroaryl group contains 1 to 4 heteroatoms selected from N, O, and S;

[0178] n1, n2, n3 are each independently selected from 0, 1, 2 or 3;

[0179] p1 and p2 are each independently selected from 0, 1, 2, 3, 4 or 5.

[0180] As a second embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0181] L is selected from -Cy1-Ak1-Cy2-Ak2-Cy3-Ak3-Cy4-Ak4-Cy5-Ak5-, -Cy1-Cy2-Cy3-Cy4-Ak1-Ak2-Ak3-Ak4-Ak5-, -Cy1-Ak1-Cy2-Ak2-Cy3-Ak3-Cy4-Ak4-Ak5-, -Ak1-Cy1-Ak2-Cy2-Ak3-Cy3-Ak4-Cy4-Ak5-, -Cy1-Ak1-Cy2-Ak2-Cy3-Cy4-Ak3-Ak4-Ak5-, -Cy1-Ak1-Cy2-Ak2-Ak3-Cy3-Cy4-Ak4-Ak5-, -Cy1-Ak1-Ak2-Ak3-Ak4-Ak5-Cy2-Cy3-Cy4-, -Cy1-Cy2-Ak1-Ak2-Ak3-Ak4-Ak5-Cy3-Cy4-, -Cy1-Cy2-Cy3-Ak1-Ak2-Ak3-Ak4-Ak5-Cy4-, -Cy1-Cy2-Cy3-Cy4-Ak1-Ak2-Ak3-Ak4-Ak5-, -Cy1-Ak1-Cy2-Cy3-Cy4-Ak2-Ak3-Ak4-Ak5-, -Cy1-Cy2-Ak1-Cy3-Cy4-Ak2-Ak3-Ak4-Ak5-, -Cy1-Cy2-Cy3-Ak1-Cy4-Ak2-Ak3-Ak4-Ak5-, -Cy1-Ak1-Ak2-Cy2-Cy3-Cy4-Ak3-Ak4-Ak5-, -Cy1-Cy2-Ak1-Ak2-Cy3-Cy4-Ak3-Ak4-Ak5-, -Cy1-Cy2-Cy3-Ak1-Ak2-Cy4-Ak3-Ak4-Ak5-, -Cy1-Ak1-Ak2-Ak3-Cy2-Cy3-Cy4-Ak4-Ak5-, -Cy1-Cy2-Ak1-Ak2-Ak3-Cy3-Cy4-Ak4-Ak5-, -Cy1-Cy2-Cy3-Ak1-Ak2-Ak3-Cy4-Ak4-Ak5-, -Cy1-Ak1-Ak2-Ak3-Ak4-Cy2-Cy3-Cy4-Ak5-, -Cy1-Cy2-Ak1-Ak2-Ak3-Ak4-Cy3-Cy4-Ak5-, -Cy1-Cy2-Cy3-Ak1-Ak2-Ak3-Ak4-Cy4-Ak5-, -Ak1-Ak2-Ak3-Ak4-Ak5-Cy1-Cy2-Cy3-Cy4-, -Ak1-Cy1-Cy2-Cy3-Cy4-Ak2-Ak3-Ak4-Ak5-, -Ak1-Ak2-Cy1-Cy2-Cy3-Cy4-Ak3-Ak4-Ak5-, -Ak1-Ak2-Ak3-Cy1-Cy2-Cy3-Cy4-Ak4-Ak5--Ak1-Ak2-Ak3-Ak4-Cy1-Cy2-Cy3-Cy4-Ak5-, -Ak1-Cy1-Ak2-Ak3-Ak4-Ak 5-Cy2-Cy3-Cy4-, -Ak1-Cy1-Cy2-Ak2-Ak3-Ak4-Ak5-Cy3-Cy4-, -Ak1-Cy1- Cy2-Cy3-Ak2-Ak3-Ak4-Ak5-Cy4-, -Ak1-Ak2-Cy1-Ak3-Ak4-Ak5-Cy2-Cy3- Cy4-, -Ak1-Ak2-Cy1-Cy2-Ak3-Ak4-Ak5-Cy3-Cy4-, -Ak1-Ak2-Cy1-Cy2-Cy 3-Ak3-Ak4-Ak5-Cy4-, -Ak1-Ak2-Ak3-Cy1-Ak4-Ak5-Cy2-Cy3-Cy4-, -Ak1- Ak2-Ak3-Cy1-Cy2-Ak4-Ak5-Cy3-Cy4-, -Ak1-Ak2-Ak3-Cy1-Cy2-Cy3-Ak4- Ak5-Cy4-, -Ak1-Ak2-Ak3-Ak4-Cy1-Ak5-Cy2-Cy3-Cy4-, -Ak1-Ak2-Ak3-Ak 4-Cy1-Cy2-Ak5-Cy3-Cy4-, -Ak1-Ak2-Ak3-Ak4-Cy1-Cy2-Cy3-Ak5-Cy4-;,

[0182] Ak1, Ak2, Ak3, Ak4, Ak5 are each independently selected from -(CH2) q -、-(CH2) q -O-, -O-(CH2) q -、-(CH2) q -NR L -、-NR L -(CH2) q -、-(CH2)q-NR L C(=O)-、-(CH2) q -C(=O)NR L -, -C(=O)-, -C(=O)-(CH2) q -NR L -、-(C≡C) q - or a bond, wherein the -CH2- is optionally further replaced by 0 to 2 (e.g., 0, 1 or 2) selected from H, halogen, OH, CN, NH2, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, cyano substituted C 1-4 substituted by an alkyl substituent;

[0183] Cy1, Cy2, Cy3, Cy4 or Cy5 are each independently selected from a bond, a 4-7 membered heteromonocycle, a 4-10 membered heterocyclic ring, a 5-12 membered heterospirocycle, a 7-10 membered heterobridged ring, a 3-7 membered monocycloalkyl, a 4-10 membered cyclic ring, a 5-12 membered spirocycloalkyl, a 7-10 membered bridged cycloalkyl, a 5-10 membered heteroaryl or a 6-10 membered aryl, wherein the aryl, heteroaryl, cycloalkyl, heteromonocycle, heterocyclic ring, heterospirocycle or heterobridged ring is optionally further substituted by 0 to 4 (e.g., 0, 1, 2, 3 or 4) selected from H, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 The heteroaryl, heteromonocyclic, heterocyclic, heterospirocyclic or heterobridged ring contains 1 to 4 (e.g., 1, 2, 3 or 4) heteroatoms selected from O, S and N, and when the heteroatom is selected from S, it is optionally further substituted by 0, 1 or 2 =0;

[0184] q is each independently selected from 0, 1, 2, 3 or 4;

[0185] R L Each independently selected from H or C 1-6 alkyl;

[0186] The remaining groups are defined the same as in the first embodiment of the present invention.

[0187] As a third embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0188] Cy1, Cy2, Cy3, Cy4 or Cy5 are each independently selected from a bond, a 4-7 membered nitrogen-containing heteromonocycle, a 4-10 membered nitrogen-containing heterocyclic ring, a 5-12 membered nitrogen-containing heterospirocycle, a 7-10 membered nitrogen-containing heterobridged ring, a 3-7 membered monocycloalkyl, a 4-10 membered cycloalkyl, a 5-12 membered spirocycloalkyl, a 7-10 membered bridged cycloalkyl, a 5-10 membered heteroaryl or a 6-10 membered aryl, wherein the heteromonocycle, heterocyclic ring, heterobridged ring, heterospirocycle, cycloalkyl, aryl or heteroaryl is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 The heterocyclic, heterocyclic, heterobridged, heterospirocyclic or heteroaryl group contains 1 to 4 heteroatoms selected from O, S and N. When the heteroatom is selected from S, it is optionally further substituted by 0, 1 or 2 =0;

[0189] R L Each independently selected from H or C 1-4 alkyl;

[0190] R b9 is selected from a benzene ring, a naphthalene ring, a 5- to 6-membered heteroaromatic ring, a 9- to 10-membered heteroaromatic ring, R b10 Selected from C 1-4 Alkyl, C 3-6 Cycloalkyl, 4 to 7 membered heterocycloalkyl, said R b9 Optionally further 0 to 4 R b9a Substitute, the R b10 Optionally further 0 to 4 R b10a Substitution, the heterocycloalkyl or heteroaromatic ring contains 1 to 5 heteroatoms selected from O, S, and N;

[0191] K is selected from

[0192]

[0193] indicates that the ring is selected from an aromatic ring or a non-aromatic ring;

[0194] Q is independently selected from -O-, -S-, -CH2-, -NR q -, -C(=O)-, -NR q C(=O)-, -C(=O)NR q - or a 4-7 membered heterocyclic group, wherein the heterocyclic group is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S, and N;

[0195] R q Select from H or C 1-4 alkyl;

[0196] R k1 , R k3 Each independently selected from H, F, Cl, Br, I, OH, =O, NH2, CF3, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 Alkoxy, wherein the alkyl or alkoxy is optionally further substituted by 0 to 4 substituents selected from H, F, Cl, Br, I, OH, NH2;

[0197] Or two R k3and the carbon atoms or ring skeletons directly connected to the two together form a 3-6-membered carbocyclic ring or a 3-7-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally further substituted by 0 to 4 atoms selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic ring is substituted by an alkoxy substituent, and the heterocyclic ring contains 1 to 4 heteroatoms selected from O, S, and N;

[0198] R k4 Each independently selected from H, OH, NH2, CF3, CN, C 1-4 alkyl;

[0199] R k5 Each independently selected from C(CH3)2, C(=O), CH2, S(=O)2,

[0200] R k6 Each is independently selected from C(═O), CH, S(═O), S(═O)2, CH2 or N;

[0201] R k7 Each independently selected from C(CH3)2, C(═O), CH, N, CH2, O, S, N(CH3), N(CH2CH3), N(cyclopropyl) or NH;

[0202] R k8 are each independently selected from C, N or CH;

[0203] R k9 are each independently selected from a bond, C(CH3)2, C(=O), CH2, CH2CH2 or S(=O)2;

[0204] A, H1 or H2 are each independently selected from C 3-8 A carbocyclic ring, a benzene ring, a 4-7 membered heterocyclic ring or a 5-6 membered heteroaryl group, wherein the heterocyclic ring or heteroaryl group contains 1 to 4 heteroatoms selected from O, S, and N;

[0205] E are each independently selected from C 3-8 A carbocyclic ring, a benzene ring, a 4-7 membered heterocyclic ring, an 8-12 membered heterocyclyl, a 7-12 membered heteroaryl or a 5-6 membered heteroaryl, wherein the heterocyclic ring or heteroaryl contains 1 to 4 heteroatoms selected from O, S and N;

[0206] F is independently selected from 3-7 membered monocyclic alkyl, 4-10 membered cycloalkyl, 5-12 membered spirocyclic alkyl, 5-10 membered bridged cycloalkyl, 4-7 membered heteromonocyclic, 4-10 membered heterocyclocyclic, 8-15 membered tricyclic heterocyclocyclic, 12-17 membered tetracyclic heterocyclocyclic, 5-12 membered heterospirocyclic, 5-10 membered heterobridged ring, C 6-14 Aryl or 5-10 membered heteroaryl, wherein the heteromonocyclic, heterocyclic, heterospirocyclic, heterobridged or heteroaryl group contains 1 to 4 heteroatoms selected from O, S and N;

[0207] The definitions of the remaining groups are the same as those in any one of the first and second embodiments of the present invention.

[0208] As a fourth embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0209] R L is selected from H, methyl or ethyl;

[0210] q is each independently selected from 0, 1 or 2;

[0211] Cy1, Cy2, Cy3, Cy4 or Cy5 are each independently selected from a bond or one of the following groups which are substituted or unsubstituted: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azetyl, azidine, piperidine, morpholine, piperazine, phenyl, cyclopropyl-cyclopropyl, cyclopropyl-cyclobutyl, cyclopropyl-cyclopentyl, cyclopropyl-cyclohexyl, cyclobutyl-cyclobutyl, cyclobutyl-cyclopentyl, cyclobutyl-cyclohexyl, cyclopentyl-cyclopentyl , cyclopentyl and cyclohexyl, cyclohexyl and cyclohexyl, cyclopropyl spirocyclopropyl, cyclopropyl spirocyclobutyl, cyclopropyl spirocyclopentyl, cyclopropyl spirocyclohexyl, cyclobutyl spirocyclobutyl, cyclobutyl spirocyclopentyl, cyclobutyl spirocyclohexyl, cyclopentyl spirocyclopentyl, cyclopentyl spirocyclohexyl, cyclohexyl spirocyclohexyl, cyclopropyl and azetidinyl, cyclopropyl and azetidinyl, cyclopropyl and azetidinyl, cyclopropyl and azetidinyl, cyclobutyl and azetidinyl, cyclobutyl and azetidinyl, cyclobutyl and azetidinyl, cyclobutyl and azetidinyl Hexyl, cyclopentylazacyclolidinyl, cyclopentylazacyclopentyl, cyclopentylazahexyl, cyclohexylazacyclolidinyl, cyclohexylazacyclopentyl, cyclohexylazacyclohexyl, azetidinazacyclolidinyl, azetidinazacyclopentyl, azetidinazacyclohexyl, azetidinazacyclohexyl, azetidinazacyclolidinyl, azetidinazacyclopentyl, azetidinazacyclohexyl, azetidinazacyclohexyl, azetidinazacyclolidinyl, azetidinazacyclopentyl, azetidinazacyclohexyl, azetidinazacyclohexyl, cyclobutylspiroazacyclo butyl, cyclobutyl spiroazacyclopentyl, cyclobutyl spiroazacyclohexyl, cyclopentyl spiroazetidinyl, cyclopentyl spiroazacyclopentyl, cyclopentyl spiroazacyclohexyl, cyclohexyl spiroazetidinyl, cyclohexyl spiroazacyclopentyl, cyclohexyl spiroazetidinyl, cyclohexyl spiroazetidinyl, azetidinyl spiroazacyclopentyl, azetidinyl spiroazacyclohexyl, azetidinyl spiroazacyclopentyl, azetidinyl spiroazacyclohexyl, azetidinyl spiroazacyclopentyl, azetidinyl spiroazacyclohexyl, azetidinyl spiroazacyclopentyl, azetidinyl spiroazacyclohexyl, azetidinyl spiroazacyclopentyl, azetidinyl spiroazacyclohexyl, When substituted, it is optionally further substituted with 0 to 4 moieties selected from H, F, Cl, Br, I, OH, NH2, COOH, CN, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent;

[0212] R b9 is selected from benzene ring, benzopyrrole, benzopyrazole, benzimidazole, pyridine, pyrimidine, pyrrole, pyrazole, thiazole, thiophene, oxazole, furan, R b10 is selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azetyl, azetyl, oxetanyl, oxolyl, oxetanyl, wherein R b9 Optionally further 0 to 4 R b9aSubstitute, the R b10 Optionally further 0 to 4 R b10a replace;

[0213] Ring B4 is selected from a benzene ring, wherein the benzene ring is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, ═O, CN, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 3-6 substituted by a cycloalkyl group or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from O, S, and N;

[0214] K is selected from

[0215]

[0216]

[0217] E is each independently selected from phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, furanyl, thienyl or oxazolyl;

[0218] A is each independently selected from phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, furanyl, thienyl or oxazolyl;

[0219] F is independently selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentanyl, 6,7-dihydro-5H-cyclopenta[c]pyridinyl, 2,3-dihydro-1H-indenyl, phenyl, naphthyl, anthracenyl, phenanthrenyl, azetidinyl, azopentyl, piperidinyl, morpholinyl, pyridyl, pyridonyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazine, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, furanyl, thienyl, thiazolyl, benzoxazole, pyridoimidazole, benzimidazolyl, benzopyrazolyl, benzothiazolyl, benzothienyl, benzo furanyl, benzopyrrolyl, benzopyridinyl, benzopyrazinyl, benzopyrimidinyl, benzopyridazinyl, pyrrolopyrrolyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrrolopyridazinyl, pyrrolopyrazinyl, imidazopyrimidinyl, imidazopyridinyl, imidazopyrazinyl, imidazopyridazinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolopyridazinyl, pyrimidopyridinyl, pyrimidopyrazinyl, pyrimidopyridazinyl, pyrimidopyrimidinyl, pyridopyridinyl, pyridopyrazinyl, pyridopyridazinyl, pyridazinopyrazinyl, or pyrazinopyrazinyl;

[0220] F are each independently selected from

[0221] R k7 Each independently selected from C(CH3)2, CH2, O, N(CH3), N(CH2CH3), N(cyclopropyl) or NH;

[0222] p1 or p2 are each independently selected from 0, 1 or 2;

[0223] The definitions of the remaining groups are the same as those in any one of the first, second and third embodiments of the present invention.

[0224] As a fifth embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0225] Cy1, Cy2, Cy3, Cy4 or Cy5 are each independently selected from a bond or a substituted or unsubstituted one of the following groups:

[0226] When substituted, it is optionally further substituted with 0 to 4 substituents selected from H, F, CF3, methyl, =O, hydroxymethyl, COOH, CN or NH2;

[0227] X1 and X2 are each independently selected from O, N(R x );

[0228] K is selected from one of the structural fragments shown in Table K-1;

[0229] The remaining groups are defined the same as in any one of the first, second, third or fourth embodiments of the present invention.

[0230] As a sixth embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0231] L is selected from -Cy1-, -Cy1-Cy2-, -Cy1-Ak1-Cy2-, -Cy1-Cy2-Ak2-, -Cy1-Ak1-Cy2-Ak2-, -Cy1-Ak1-Cy2-Ak2-Ak3-, -Ak1-Cy2-, -Cy1-Ak1-Cy2-Ak2-Ak3-Ak4-, -Cy1-Cy2-Ak2-Ak3-, -Cy1-Cy2-Ak2-Ak3-Ak4-, -Cy1-Ak1-Cy2-Ak2-Ak3-Ak4-, -Cy1-Ak1-Ak2-Cy3-, -Cy1-Ak1-Ak2-Cy3-Ak3-, -Cy1-Cy2-Cy3-, -Cy1-Ak1-Cy2-Cy3-, -Cy1-Cy2-Ak2-Cy3-, -Cy1-Cy2-Cy3-Ak3-, -Cy1-Ak1-Cy2-Cy3-Ak3-, -Cy1-Cy2-Ak2-Cy3-Ak3-, -Cy1-Ak1-Cy2-Ak2-Cy3-, -Cy1-Ak1-Cy2-Ak2-Cy3-Ak3-, -Cy1-Cy2-Cy3-Ak3-Ak4-, -Cy1-Cy2-Cy3-Ak3-Cy4-, -Cy1-Cy2-Cy3-Cy4-, -Cy1-Ak1-Cy2-Cy3-Cy4-, -Cy1-Cy2-Ak2-Cy3-Cy4-, -Cy1-Cy2-Cy3-Ak3-Cy4-, -Cy1-Cy2-Cy3-Cy4-Ak4-, -Cy1-Ak1-Cy2-Ak2-Cy3-Ak3-Cy4-, -Cy1-Ak1-Cy2-Ak2-Cy3-Cy4-, -Ak1-Ak2-Cy3-Cy4-, -Ak1-Cy2-Ak2-Cy3-, -Ak1-Cy2-Cy3-Ak3-Cy4-, -Ak1-Cy2-Cy3-Cy4-Ak4-Cy5-, -Ak1-Cy2-Ak2-, -Ak1-Ak2-Ak3-Ak4-, -Ak1-Ak2-Ak3-, -Ak1-Ak2-, -Ak1-Ak2-Ak3-Ak4-Ak5-, -Cy1-Cy2-Cy3-Ak3-Ak4-Ak5-, -Cy1-Cy2-Ak2-Cy3-Ak3-Ak4-Ak5-, -Cy1-Ak1-Cy2-Ak2-Ak3-Ak4-Ak5-, -Cy1-Cy2-Cy3-Cy4-Ak4-Ak5-, -Cy1-Ak1-Ak2-Ak3-Ak4-Ak5-, -Ak1-Cy2-Ak2-Ak3-Ak4-Ak5-, -Ak1-Cy2-Ak2-Ak3-Ak4-, -Ak1-Cy2-Ak2-Ak3-;

[0232] Ak1, Ak2, Ak3, Ak4, and Ak5 are each independently selected from -O-, -OCH2-, -CH2O-, -OCH2CH2-, -CH2CH2O-, -C≡C-, -C(CH3)2-, -CH2-, -CH2CH2-, -CH2CH2CH2-, -N(CH3)-, -NH-, -CH2N(CH3)-, -CH2NH-, -NHCH2-, -CH2CH2N(CH3)-, -CH2CH2NH-, -NHCH2CH2-, -C(=O)-, -C(=O)CH2NH-, -CH2C(=O)NH-, -C(=O)NH-, or -NHC(=O)-;

[0233] The remaining groups are defined the same as in any one of the first, second, third, fourth or fifth embodiments of the present invention. As a seventh embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0234] L is selected from a bond or one of the groups shown in Table L-1 or L-2, wherein the left side of the group is connected to B;

[0235] The remaining groups are defined the same as in any one of the first, second, third, fourth, fifth or sixth embodiments of the present invention.

[0236] As an eighth embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0237] B is selected from one of the following structural fragments:

[0238]

[0239]

[0240] R B4 Each is independently selected from H, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, cyclopropyl, pyrrole, pyrazole;

[0241] rr is selected from 0, 1, 2 or 3;

[0242] R b9a Each independently selected from H, F, Cl, Br, I, OH, CN, CF3, methyl, methoxy;

[0243] R b10 Each independently selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, oxacyclopentyl, oxacyclohexyl, said R b10Optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, =O, CN, methyl, methoxy;

[0244] K is selected from one of the structural fragments shown in Table K-2;

[0245] The remaining groups are defined the same as in any one of the first, second, third, fourth, fifth, sixth or seventh embodiments of the present invention.

[0246] As a ninth embodiment of the present invention, the compound represented by the above general formula (I) or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,

[0247] B is selected from one of the structural fragments in Table B-1;

[0248] K is selected from one of the structural fragments shown in Table K-3;

[0249] The remaining groups are defined the same as in any one of the first, second, third, fourth, fifth, sixth, seventh or eighth embodiments of the present invention.

[0250] The present invention relates to the following compound or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein the compound is selected from one of the structures in Table E-1.

[0251] Table E-1

[0252]

[0253]

[0254]

[0255]

[0256]

[0257]

[0258]

[0259]

[0260]

[0261]

[0262]

[0263]

[0264]

[0265]

[0266]

[0267]

[0268]

[0269]

[0270]

[0271]

[0272] Table L-1L Group

[0273]

[0274]

[0275]

[0276]

[0277]

[0278]

[0279]

[0280]

[0281]

[0282]

[0283]

[0284] Table L-2L Group

[0285]

[0286] The present invention relates to a pharmaceutical composition, comprising the above-mentioned compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, and a pharmaceutically acceptable carrier.

[0287] The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of the above-mentioned compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, and a pharmaceutically acceptable carrier.

[0288] In some embodiments, the pharmaceutical composition of the present invention may be in the form of a unit preparation (the amount of the main drug in the unit preparation is also referred to as "preparation strength").

[0289] "Effective amount" or "therapeutically effective amount" as described herein refers to administering a sufficient amount of a compound disclosed herein that will alleviate one or more symptoms of the disease or condition being treated (e.g., inhibiting or degrading EGFR-related diseases such as cancer) to some extent. In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms or causes of the disease, or any other desired changes in the biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound disclosed herein required to provide a clinically significant reduction in disease symptoms.Examples of therapeutically effective amounts include, but are not limited to, 1-1500 mg, 1-1200 mg, 1-1000 mg, 1-900 mg, 1-800 mg, 1-700 mg, 1-600 mg, 2-600 mg, 3-600 mg, 4-600 mg, 5-600 mg, 6-600 mg, 10-600 mg, 20-600 mg, 25-600 mg, 30-600 mg, 40-600 mg, 50-600 mg, 60-600 mg, 70-600 mg, 75-600 mg, 80-600 mg, 90-600 mg, 100-600 mg, 200-600 mg, 1-500 mg, 2-500mg, 3-500mg, 4-500mg, 5-500mg, 6-500mg, 10-500mg, 20-500mg, 25-500mg, 30-500mg, 40-500mg, 50-500mg, 60-500mg, 70-500mg, 75-500mg , 80-500mg, 90-500mg, 100-500mg, 125-500mg, 150-500mg, 200-500mg, 250-500mg, 300-500mg, 400-500mg, 5-400mg, 10-400mg, 20-400mg, 25-40 0mg, 30-400mg, 40-400mg, 50-400mg, 60-400mg, 70-400mg, 75-400mg, 80-400mg, 90-400mg, 100-400mg, 125-400mg, 150-400mg, 200-400mg, 250- 400mg, 300-400mg, 1-300mg, 2-300mg, 5-300mg, 10-300mg, 20-300mg, 25-300mg, 30-300mg, 40-300mg, 50-300mg, 60-300mg, 70-300mg, 75-300mg , 80-300mg, 90-300mg, 100-300mg, 125-300mg, 150-300mg, 200-300mg, 250-300mg, 1-200mg, 2-200mg, 5-200mg, 10-200mg, 20-200mg, 25-200mg, 30-200mg, 40-200mg, 50-200mg, 60-200mg, 70-200mg, 75-200mg, 80-200mg, 90-200mg, 100-200mg, 125-200mg, 150-200mg, 80-1000mg, 80-800mg.

[0290] In some embodiments, the pharmaceutical composition includes but is not limited to 1-1500 mg, 1-1000 mg, 20-800 mg, 40-800 mg, 40-400 mg, 25-200 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg,

[0291] 40mg, 45mg, 50mg, 55mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, 100mg,

[0292] 110mg, 120mg, 125mg, 130mg, 140mg, 150mg, 160mg, 170mg, 180mg, 190mg,

[0293] 200mg, 210mg, 220mg, 230mg, 240mg, 250mg, 300mg, 320mg, 400mg, 480mg,

[0294] 500 mg, 600 mg, 800 mg, 1000 mg of the compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal.

[0295] A method for treating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, the therapeutically effective amount preferably being 1-1500 mg, and the disease preferably being kidney disease.

[0296] A method for treating a disease in a mammal, the method comprising administering to a subject a daily dose of 1-1500 mg / day of a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein the daily dose may be a single dose or divided doses. In some embodiments, the daily dose includes but is not limited to 10-1500 mg / day, 10-1200 mg / day, 10-1000 mg / day, 10-800 mg / day, 25-800 mg / day, 50-8 In some embodiments, daily doses include but are not limited to 10 mg / day, 20 mg / day, 25 mg / day, 50 mg / day, 100 mg / day, 125 mg / day, 150 mg / day, 200 mg / day, 400 mg / day, 500 mg / day, 1000 mg / day, 2000 mg / day, 2000 mg / day, 400 mg / day, 500 mg / day, 1000 mg / day, 2000 mg / day, 400 mg / day, 500 mg / day, 1000 mg / day, 2000 mg / day, 400 mg / day, 500 mg / day, 1000 mg / day, 2000 mg / day, 4000 mg / day, 500 mg / day, 1000 mg / day, 2000 mg / day, 4000 mg / day, 500 mg / day, 1000 mg / day, 2000 mg / day, 4000 mg / day, 5000 mg / day, 10 ...2500 mg / day, 5000 mg / day, 10000 mg / day, 2000 mg / day, 4000 mg / day, 5000 mg / day, 5000 mg / day, 10000 mg / day, 2000 mg / day, 2500 mg / day, 5000 mg / day,

[0297] day, 600 mg / day, 800 mg / day, 1000 mg / day, 1200 mg / day, 1400 mg / day.

[0298] The present invention relates to the use of the above-mentioned compound of the present invention or its stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, or the above-mentioned pharmaceutical composition in the preparation of a drug for treating diseases related to EGFR activity or expression.

[0299] The present invention relates to the use of the above-mentioned compound of the present invention or its stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, or the above-mentioned pharmaceutical composition in the preparation of drugs for treating and inhibiting or degrading EGFR-related diseases.

[0300] The present invention relates to the use of the above-mentioned compound of the present invention or its stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, or the above-mentioned pharmaceutical composition, characterized in that the disease is selected from cancer.

[0301] The present invention relates to a kit, which may include a composition in a single-dose or multi-dose form, and the kit contains a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, and the amount of the compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal is the same as its amount in the above-mentioned pharmaceutical composition.

[0302] The amount of the compound of the invention or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof is in each case calculated as the free base.

[0303] Unless stated to the contrary, the terms used in the specification and claims have the following meanings.

[0304] The carbon, hydrogen, oxygen, sulfur, nitrogen or F, Cl, Br, I involved in the groups and compounds of the present invention include their isotopes, and the carbon, hydrogen, oxygen, sulfur or nitrogen involved in the groups and compounds of the present invention are optionally further replaced by one or more of their corresponding isotopes, wherein the carbon isotopes include 12 C. 13 C and 14 C, hydrogen isotopes include protium (H), deuterium (D, also called heavy hydrogen), tritium (T, also called super tritium), oxygen isotopes include 16 O. 17 O and 18 O, sulfur isotopes include32 S. 33 S. 34 S and 36 S, isotopes of nitrogen include 14 N and 15 N, fluorine isotopes include 17 F and 19 F, isotopes of chlorine include 35 Cl and 37 Isotopes of Cl and bromine include 79 Br and 81 Br.

[0305] "Halogen" refers to F, Cl, Br or I.

[0306] "Halogen substituted" refers to substitution with F, Cl, Br or I, including but not limited to substitution with 1 to 10 substituents selected from F, Cl, Br or I, substitution with 1 to 6 substituents selected from F, Cl, Br or I, and substitution with 1 to 4 substituents selected from F, Cl, Br or I. "Halogen substituted" is abbreviated as "halo".

[0307] "Alkyl" refers to a substituted or unsubstituted straight or branched chain saturated aliphatic hydrocarbon group, including but not limited to alkyl groups of 1 to 20 carbon atoms, alkyl groups of 1 to 8 carbon atoms, alkyl groups of 1 to 6 carbon atoms, and alkyl groups of 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and various branched chain isomers thereof; the alkyl groups appearing in this article are defined in accordance with this definition. Alkyl groups can be monovalent, divalent, trivalent, or tetravalent.

[0308] "Hydrocarbon group" refers to a substituted or unsubstituted, straight or branched, saturated or unsaturated group consisting of carbon and hydrogen atoms. The hydrocarbon group can be monovalent, divalent, trivalent or tetravalent.

[0309] "Heteroalkyl" refers to a substituted or unsubstituted alkyl group in which one or more (including but not limited to 2, 3, 4, 5 or 6) carbon atoms are replaced by heteroatoms (including but not limited to N, O or S). Non-limiting examples include -X(CH2)vX(CH2)vX(CH2)vH (v is an integer from 1 to 5, each X is independently selected from a bond or a heteroatom, the heteroatom includes but is not limited to N, O or S, and at least one X is selected from a heteroatom, and the N or S in the heteroatom can be oxidized to various oxidation states). The heteroalkyl group can be monovalent, divalent, trivalent or tetravalent.

[0310] "Alkylene" refers to substituted or unsubstituted straight-chain or branched divalent saturated hydrocarbon groups, including -(CH2) v-(v is an integer from 1 to 10), examples of alkylene include but are not limited to methylene, ethylene, propylene and butylene.

[0311] "Heteroalkylene" refers to a substituted or unsubstituted alkylene in which one or more (including but not limited to 2, 3, 4, 5 or 6) carbon atoms are replaced by heteroatoms (including but not limited to N, O or S). Non-limiting examples include -X(CH2)vX(CH2)vX(CH2)v-, v is an integer from 1 to 5, each X is independently selected from a bond, N, O or S, and at least one X is selected from N, O or S.

[0312] "Cycloalkyl" refers to a substituted or unsubstituted saturated carbocyclic hydrocarbon radical, typically having 3 to 10 carbon atoms, non-limiting examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Cycloalkyl groups appearing herein are defined as above. Cycloalkyl groups may be monovalent, divalent, trivalent or tetravalent.

[0313] "Heterocycloalkyl" refers to a substituted or unsubstituted saturated cyclic hydrocarbon containing heteroatoms, including but not limited to 3 to 10 atoms, 3 to 8 atoms, including 1 to 3 heteroatoms selected from N, O or S, and the selectively substituted N and S in the ring of heterocycloalkyl can be oxidized to various oxidation states. Heterocycloalkyl can be connected to a heteroatom or a carbon atom, and heterocycloalkyl can be connected to an aromatic ring or a non-aromatic ring. Heterocycloalkyl can be connected to a bridge ring or a spiro ring, and non-limiting examples include oxirane, aziridine, oxadiazine, azetidinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, dioxolane, dioxane, pyrrolidinyl, piperidinyl, imidazolidinyl, oxazolidinyl, oxazolidinyl, morpholinyl, hexahydropyrimidinyl, piperazinyl. Heterocycloalkyl can be monovalent, divalent, trivalent or tetravalent.

[0314] "Alkenyl" refers to a substituted or unsubstituted straight chain or branched unsaturated hydrocarbon group having at least one, typically one, two or three carbon-carbon double bonds, with a backbone of 2 to 10, 2 to 6 or 2 to 4 carbon atoms, examples of alkenyl groups include but are not limited to vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 2- Methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octenyl, 3-octenyl, 1-nonenyl, 3-nonenyl, 1-decenyl, 4-decenyl, 1,3-butadiene, 1,3-pentadiene, 1,4-pentadiene and 1,4-hexadiene, etc.; the alkenyl groups appearing in this article have the same definition as this definition. The alkenyl group can be monovalent, divalent, trivalent or tetravalent.

[0315] "Alkynyl" refers to a substituted or unsubstituted straight or branched monovalent unsaturated hydrocarbon radical having at least one, typically one, two or three carbon-carbon triple bonds, including but not limited to 2 to 10 carbon atoms, 2 to 6 carbon atoms, 2 to 4 carbon atoms in the backbone chain. Examples of alkynyl radicals include but are not limited to ethynyl, propargyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1- -methyl-1-butynyl, 2-methyl-1-butynyl, 2-methyl-3-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-1-pentynyl, 2-methyl-1-pentynyl, 1-heptynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 1-octynyl, 3-octynyl, 1-nonynyl, 3-nonynyl, 1-decynyl, 4-decynyl and the like; the alkynyl group may be monovalent, divalent, trivalent or tetravalent.

[0316] "Alkoxy" refers to substituted or unsubstituted -O-alkyl. Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy, cyclopropyloxy, and cyclobutyloxy.

[0317] "Carbocyclyl" or "carbocycle" refers to a substituted or unsubstituted saturated or unsaturated aromatic or non-aromatic ring, which can be a 3-8-membered monocyclic ring, a 4-12-membered bicyclic ring, or a 10-15-membered tricyclic ring system, and the carbocyclyl can be attached to the aromatic or non-aromatic ring, which can be a monocyclic ring, a bridged ring, or a spirocyclic ring. Non-limiting examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexenyl, benzene ring, naphthalene ring, "Carbocyclyl" or "carbocycle" can be monovalent, divalent, trivalent or tetravalent.

[0318] "Heterocyclyl" or "heterocycle" refers to a substituted or unsubstituted saturated or unsaturated aromatic or non-aromatic ring, which can be a 3-8 membered monocyclic ring, a 4-12 membered bicyclic ring or a 10-15 membered tricyclic ring system, and contains 1 or more (including but not limited to 2, 3, 4 or 5) heteroatoms selected from N, O or S. The N and S selectively substituted in the heterocyclyl ring can be oxidized to various oxidation states. The heterocyclic group may be connected to a heteroatom or a carbon atom, may be connected to an aromatic ring or a non-aromatic ring, may be connected to a bridged ring or a spiro ring, and non-limiting examples include oxirane, aziridine, oxetanyl, azetidinyl, 1,3-dioxolanyl, 1,4-dioxolanyl, 1,3-dioxhexacyclyl, azepanyl, pyridyl, furanyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, morpholinyl, thiomorpholinyl, 1,3-dithianyl, dihydrofuranyl, dihydropyranyl, dithiolanyl, tetrahydrofuranyl, py ... furanyl, tetrahydropyrrolyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydropyranyl, benzimidazolyl, benzopyridinyl, pyrrolopyridinyl, benzodihydrofuranyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, pyrazinyl, indazolyl, benzothiophenyl, benzofuranyl, benzopyrrolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzopyridinyl, benzopyrimidinyl, benzopyrazinyl, piperazinyl, azabicyclo[3.2.1]octyl, azabicyclo[5.2.0]nonanyl, oxatricyclo[5.3.1.1]dodecyl, azaadamantyl, oxaspiro[3.3]heptanyl,

[0319] "Heterocyclyl" or "heterocycle" may be monovalent, divalent, trivalent or tetravalent.

[0320] "Spiro" or "spirocyclyl" refers to a polycyclic group in which substituted or unsubstituted monocyclic rings share one atom (called spiro atom), and the number of ring atoms in the spiro system includes but is not limited to 5 to 20, 6 to 14, 6 to 12, 6 to 10, wherein one or more rings may contain 0 or more (including but not limited to 1, 2, 3 or 4) double bonds, and optionally may contain 0 to 5 selected from N, O or S (=O) n of heteroatoms.

[0321]

[0322] "Spirocycle" or "spirocyclyl" can be monovalent, divalent, trivalent or tetravalent.

[0323] "Parallel ring" or "parallel ring group" refers to a polycyclic group in which each ring in the system shares a pair of adjacent atoms with other rings in the system, wherein one or more rings may contain 0 or more (including but not limited to 1, 2, 3 or 4) double bonds and may be substituted or unsubstituted, and each ring in the parallel ring system may contain 0 to 5 heteroatoms or groups containing heteroatoms (including but not limited to selected from N, S(=O) n or O, n is 0, 1 or 2). The number of ring atoms in the ring system includes, but is not limited to, 5 to 20, 5 to 14, 5 to 12, 5 to 10. Non-limiting examples include:

[0324] "Bicyclic" or "bicyclic group" can be monovalent, divalent, trivalent or tetravalent.

[0325] "Bridged ring" or "bridged ring group" refers to a substituted or unsubstituted polycyclic group containing any two atoms that are not directly connected, which may contain 0 or more double bonds, and any ring in the ring system may contain 0 to 5 groups selected from heteroatoms or heteroatom-containing groups (including but not limited to N, S(=O)n or O, where n is 0, 1, 2). The number of ring atoms includes but is not limited to 5 to 20, 5 to 14, 5 to 12 or 5 to 10. Non-limiting examples include

[0326] Cubane, adamantane. "Bridged ring" or "bridged ring group" can be monovalent, divalent, trivalent or tetravalent.

[0327] "Carbospirocycle", "spirocarbocyclyl", "spirocarbocyclyl" or "carbospirocyclyl" refers to a "spirocycle" whose ring system consists of only carbon atoms. "Carbospirocycle", "spirocarbocyclyl", "spirocarbocyclyl" or "carbospirocyclyl" appearing in this article has the same definition as spirocycle.

[0328] "Carbocyclic ring", "cyclic carbocyclyl", "cyclic carbocyclyl" or "carbocyclic ring" refers to a "cyclic ring" whose ring system consists of only carbon atoms. "Carbocyclic ring", "cyclic carbocyclyl", "cyclic carbocyclyl" or "carbocyclic ring" appearing in this article have the same definition as cyclic ring.

[0329] "Carbobridge ring", "bridged ring carbocyclic group", "bridged carbocyclic group" or "carbon bridged cyclic group" refers to a "bridged ring" whose ring system consists of only carbon atoms. "Carbobridge ring", "bridged ring carbocyclic group", "bridged carbocyclic group" or "carbon bridged cyclic group" appearing in this article have the same definition as the bridged ring.

[0330] "Heteromonocycle", "monocyclic heterocyclyl" or "heteromonocyclic group" refers to a "heterocyclic group" or "heterocycle" of a monocyclic ring system. The heterocyclic group, "monocyclic heterocyclyl" or "heteromonocyclic group" appearing in this document has the same definition as heterocycle.

[0331] "Heterocyclic ring", "heterocyclic ring group", "cyclic heterocyclic group" or "heterocyclic group" refer to a "cyclic ring" containing a heteroatom. The heterocyclic ring, "heterocyclic ring group", "cyclic heterocyclic group" or "heterocyclic group" appearing in this document have the same definition as cyclic ring.

[0332] "Heterospirocycle", "heterospirocyclyl", "spiro heterocyclyl" or "heterospirocyclyl" refers to a "spirocycle" containing a heteroatom. Heterospirocycle, "heterospirocyclyl", "spiro heterocyclyl" or "heterospirocyclyl" appearing herein have the same definition as spirocycle.

[0333] "Heterobridged ring", "heterobridged ring group", "bridged heterocyclic group" or "heterobridged ring group" refers to a "bridged ring" containing a heteroatom. The heterobridged ring, "heterobridged ring group", "bridged heterocyclic group" or "heterobridged ring group" appearing herein have the same definition as the bridged ring.

[0334] "Aryl" or "aromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group having a single ring or a fused ring, wherein the number of ring atoms in the aromatic ring includes, but is not limited to, 6 to 18, 6 to 12, or 6 to 10 carbon atoms. The aryl ring may be fused to a saturated or unsaturated carbocyclic or heterocyclic ring, wherein the ring connected to the parent structure is the aryl ring, non-limiting examples of which include benzene ring, naphthalene ring, "Aryl" or "aromatic ring" can be monovalent, divalent, trivalent or tetravalent. When divalent, trivalent or tetravalent, the point of attachment is on the aryl ring.

[0335] "Heteroaryl" or "heteroaromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group containing 1 to 5 heteroatoms or groups containing heteroatoms (including but not limited to N, O or S(=O)n, n is 0, 1, 2), and the number of ring atoms in the heteroaromatic ring includes but is not limited to 5 to 15, 5 to 10 or 5 to 6. Non-limiting examples of heteroaryl include but are not limited to pyridyl, furanyl, thienyl, pyridyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, benzopyrazole, benzimidazole, benzopyridine, pyrrolopyridine, etc. The heteroaryl ring can be fused to a saturated or unsaturated carbocyclic ring or heterocyclic ring, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples include The heteroaryl groups appearing in this article have the same definition as this definition. The heteroaryl group can be monovalent, divalent, trivalent or tetravalent. When divalent, trivalent or tetravalent, the attachment site is located on the heteroaryl ring.

[0336] "5-membered ring and 5-membered heteroaromatic ring" refers to a 5-membered fused heteroaromatic ring, at least one of the two rings contains one or more heteroatoms (including but not limited to O, S or N), and the whole group is aromatic. Non-limiting examples include pyrrolopyrrole ring, pyrazolopyrrole ring, pyrazolopyrazole ring, pyrrolofuran ring, pyrazolofuran ring, pyrrolothiophene ring, and pyrazolothiophene ring.

[0337] "5- and 6-membered heteroaromatic ring" refers to a 5- and 6-membered fused heteroaromatic ring, where at least one of the two fused rings contains one or more heteroatoms (including but not limited to O, S or N), and the entire group is aromatic. Non-limiting examples include benzo 5-membered heteroaromatic, 6-membered heteroaromatic ring and 5-membered heteroaromatic ring.

[0338] "Substituted" or "substituted" means substituted by one or more (including but not limited to 2, 3, 4 or 5) substituents, including but not limited to H, F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxyl, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclic, bridged, spiro, cycloalkyl, hydroxyalkyl, =O, carbonyl, aldehyde, carboxylic acid, formate, -(CH2) m -C(=O)-R a 、-O-(CH2) m -C(=O)-R a 、-(CH2) m -C(=O)-NR b R c 、-(CH2) m S(=O) n R a 、-(CH2) m -Alkenyl-R a , ORd or -(CH2) m -alkynyl-R a (wherein m and n are 0, 1 or 2), arylthio, thiocarbonyl, silane or -NR b R c etc., where R b With R c are independently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, R b With R c A five- or six-membered cycloalkyl or heterocyclic group may be formed.

[0339] “Containing 1 to X heteroatoms selected from O, S, and N” means containing 1, 2, 3, ..., X heteroatoms selected from O, S, and N.

[0340] "0 to X substituents selected from..." means substituted by 0, 1, 2, 3...X substituents selected from...", X is selected from any integer between 1 and 10. For example, "0 to 4 substituents selected from..." means substituted by 0, 1, 2, 3 or 4 substituents selected from..." For example, "0 to 5 substituents selected from..." means substituted by 0, 1, 2, 3, 4 or 5 substituents selected from..." For example, "the heterobridged ring is optionally further substituted by 0 to 4 substituents selected from H or F" means that the heterobridged ring is optionally further substituted by 0, 1, 2, 3 or 4 substituents selected from H or F.

[0341] The XY-membered ring (X is selected from an integer less than Y and greater than or equal to 3, and Y is selected from any integer between 4 and 12) includes X+1, X+2, X+3, X+4...Y-membered rings. The ring includes a heterocyclic ring, a carbocyclic ring, an aromatic ring, an aryl group, a heteroaryl group, a cycloalkyl group, a heteromonocyclic ring, a heterocyclic ring, a heterospirocyclic ring or a heterobridged ring. For example, "a 4-7-membered heteromonocyclic ring" refers to a 4-membered, 5-membered, 6-membered or 7-membered heteromonocyclic ring, and "a 5-10-membered heterocyclic ring" refers to a 5-membered, 6-membered, 7-membered, 8-membered, 9-membered or 10-membered heterocyclic ring.

[0342] "Optional" or "optionally" means that the event or circumstance described later may but need not occur, and the description includes situations where the event or circumstance occurs or does not occur. For example, "alkyl optionally substituted with F" means that alkyl may but need not be substituted with F, and the description includes situations where alkyl is substituted with F and situations where alkyl is not substituted with F.

[0343] "Pharmaceutical composition" refers to a mixture of one or more compounds of the present invention, or stereoisomers, tautomers, deuterated forms, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals thereof and other chemical components, wherein "other chemical components" refers to pharmaceutically acceptable carriers, excipients and / or one or more other therapeutic agents.

[0344] "Preparation specifications" refers to the weight of the main drug contained in each vial, tablet or other unit preparation.

[0345] "Prodrug" refers to a compound of the present invention that can be converted into a biologically active compound through in vivo metabolism. The prodrug of the present invention is prepared by modifying the amino or carboxyl group in the compound of the present invention, and the modification can be removed by conventional operations or in vivo to obtain the parent compound. When the prodrug of the present invention is administered to a mammalian subject, the prodrug is cleaved to form a free amino or carboxyl group.

[0346] "Stereoisomers" refer to isomers resulting from different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers and conformational isomers.

[0347] "Tautomers" refer to functional group isomers produced by the rapid movement of an atom in a molecule between two positions, such as keto-enol isomerism and amide-imino alcohol isomerism.

[0348] “IC 50 ” is the concentration of a drug or inhibitor required to inhibit a specified biological process (or a component of the process such as an enzyme, receptor, cell, etc.) by half. DETAILED DESCRIPTION

[0349] In order to accomplish the purpose of the present invention, the compounds used in the reactions described herein are prepared according to organic synthesis techniques known to those skilled in the art, starting from commercially available chemicals and / or compounds described in the chemical literature. "Commercially available chemicals" are obtained from standard commercial sources, including Shanghai Aladdin Biochemical Technology Co., Ltd., Shanghai McLean Biochemical Technology Co., Ltd., Sigma-Aldrich, Alfa Aesar (China) Chemical Co., Ltd., TCI (Shanghai) Chemical Industry Development Co., Ltd., Anage Chemical, Shanghai Titan Technology Co., Ltd., Kelon Chemical, Bailingwei Technology Co., Ltd., etc.

[0350] The following embodiments illustrate the technical solutions of the present invention in detail, but the protection scope of the present invention includes but is not limited to them.

[0351] The compounds used in the reactions described herein are prepared according to organic synthesis techniques known to those skilled in the art, starting from commercially available chemicals and / or compounds described in the chemical literature. "Commercially available chemicals" are obtained from regular commercial sources, and suppliers include: Titan Technology, Anaiji Chemical, Shanghai Demo, Chengdu Kelon Chemical, Shaoyuan Chemical Technology, Nanjing Yaoshi, WuXi AppTec, and Bailingwei Technology.

[0352] The structures of the compounds were determined by nuclear magnetic resonance (NMR) or / and mass spectrometry (MS). NMR shifts (δ) were measured in 10 -6 The unit of (ppm) is given. NMR measurements were performed using a (Bruker Avance III 400 and Bruker Avance 300) nuclear magnetic spectrometer, the measurement solvents were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD), and the internal standard was tetramethylsilane (TMS);

[0353] MS was measured using (Agilent 6120B (ESI) and Agilent 6120B (APCI));

[0354] HPLC determination was performed using an Agilent 1260DAD high pressure liquid chromatograph (Zorbax SB-C18 100×4.6 mm, 3.5 μM);

[0355] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The silica gel plate used in thin layer chromatography (TLC) uses a specification of 0.15mm-0.20mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm-0.5mm;

[0356] Column chromatography generally uses Yantai Huanghai Silica Gel 200-300 mesh silica gel as the carrier.

[0357] SEM: THP: Boc: tert-butoxycarbonyl; Ms: TBS: MTBE: methyl tert-butyl ether; Bn: DIPEA: N,N-diisopropylethylamine; DMA: N,N-dimethylacetamide; DMSO: dimethyl sulfoxide; DCM: dichloromethane; Cbz: NMP: N-methylpyrrolidone; PE: petroleum ether; DMF: N,N-dimethylformamide;

[0358] Pd2(dba)3: CAS 51364-51-3; Pd(dppf)Cl2·DCM: CAS 95464-05-4;

[0359] Xphos: CAS 564483-18-7;

[0360] Example 16: Preparation of Compound 16

[0361]

[0362] Step 1: Preparation of 16G

[0363] 16F (5.00 g, 20.23 mmol), ethylene glycol (8.79 g, 141.61 mmol), p-toluenesulfonic acid monohydrate (0.096 g, 0.50 mmol) and toluene (60 mL) were added to a reaction flask and reacted at 140°C for about 6 h. The reaction solution was concentrated to dryness under reduced pressure, ethyl acetate (100 mL) was added to the residue, washed with saturated sodium bicarbonate aqueous solution (100 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain a crude product of 16G (6.00 g).

[0364] LCMS m / z=292.1[M+H] +

[0365] Step 2: Preparation of 16H

[0366] The crude product of 16G (5.00 g, 20.59 mmol), palladium carbon (1.5 g) and methanol (30 mL) were added to a reaction bottle and reacted at room temperature for 3 h under a hydrogen atmosphere. The reaction solution was filtered through diatomaceous earth and the filtrate was concentrated under reduced pressure to give a crude product of compound 16H (3.6 g).

[0367] LCMS m / z=158.2[M+H] +

[0368] Step 3: Preparation of 16I

[0369] The crude product of 16H (3.24 g, 20.61 mmol), p-fluoronitrobenzene (3.20 g, 22.67 mmol), and potassium carbonate (5.69 g, 41.14 mmol) were added to dimethyl sulfoxide (80 mL) and reacted at 80°C overnight. The reaction solution was poured into 200 mL of water and filtered, and the filter cake was washed with water (100 mL). After the filter cake was dried, it was dissolved in DCM / MeOH (100 mL, v / v=10 / 1), separated, and the organic phase was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure to obtain 16I (4.9 g, yield: 85%).

[0370] Step 4: Preparation of 16J

[0371] 16I (1.00 g, 3.59 mmol) was dissolved in THF (6 mL), and concentrated hydrochloric acid (1.31 g, 36.00 mmol, 12 M) was diluted with water (6 mL) and added dropwise to the reaction solution, and stirred at 50°C for 1 h. The reaction solution was cooled to room temperature, adjusted to alkalinity with sodium hydroxide aqueous solution, extracted with ethyl acetate three times, the organic phases were combined, washed once with saturated brine, and the organic phase was purified by silica gel column chromatography (mobile phase: petroleum ether / ethyl acetate (V / V) = 1 / 1) after concentration with anhydrous sodium sulfate to obtain 16J (648 mg, yield: 77%).

[0372] LCMS m / z=235.1[M+H] +

[0373] Step 5: Preparation of 16K

[0374] 16J (0.43 g, 1.84 mmol) and tert-butyl piperazine-1-carboxylate (0.36 g, 1.93 mmol) were dissolved in DCM (30 mL), and acetic acid (0.22 g, 3.68 mmol) and sodium triacetoxyborohydride (0.78 g, 3.68 mmol) were added, and the mixture was reacted at room temperature for 2 h. After the reaction, 50 mL of saturated sodium bicarbonate aqueous solution was added, and then 100 mL of dichloromethane was added for extraction, and the organic phase was collected, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (mobile phase: petroleum ether / ethyl acetate (V / V) = 1 / 1) to obtain 16K (0.62 g, yield: 83%).

[0375] LCMS m / z=405.2[M+H] +

[0376] Step 6: Preparation of 16L

[0377] 16K (0.62 g, 1.53 mmol), zinc powder (1.00 g, 15.30 mmol), and ammonium chloride (0.82 g, 15.30 mmol) were dissolved in tetrahydrofuran (30 mL) and water (5 mL) and stirred at room temperature for 1 h. 2 mL of ammonia water was added to the reaction solution, and the mixture was extracted with dichloromethane three times. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound 16L (0.57 g).

[0378] LCMS m / z=375.2[M+H] +

[0379] Step 7: Preparation of 16M

[0380] 16B (0.48 g, 1.52 mmol) and 16L (0.57 g, 1.52 mmol) were dissolved in 1,4-dioxane (15 mL), and DIPEA (0.39 g, 3.04 mmol) was added, and the mixture was reacted at 105°C for 2 h. The mixture was cooled to room temperature, concentrated, and purified by flash column chromatography (mobile phase: dichloromethane / methanol (V / V) = 100 / 1-15 / 1) to obtain 16M (365 mg, yield: 36%).

[0381] LCMS m / z=656.2[M+H] +

[0382] Step 8: Preparation of 16N

[0383] Compound 16M (0.27 g, 0.40 mmol) and 16E (0.15 g, 0.44 mmol) were dissolved in 1,4-dioxane (18 mL) and water (3 mL), and Pd(dppf)Cl2.DCM (0.033 g, 0.04 mmol) and potassium carbonate (0.11 g, 0.80 mmol) were added, and nitrogen was replaced 3 times, and the reaction was carried out at 70°C for 5 h. The reaction solution was cooled to room temperature, and 200 mL of ethyl acetate was added to dilute the reaction solution, and the reaction solution was washed with water 3 times. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and flash column chromatography (mobile phase: petroleum ether / ethyl acetate (V / V) = 1 / 2) was used to obtain compound 16N (278 mg, yield: 93%).

[0384] LCMS m / z=745.3[M+H] +

[0385] Step 9: Preparation of 16O

[0386] 16N (0.20 g, 0.27 mmol), 4-aminotetrahydropyran (0.27 g, 2.70 mmol) dissolved in DMF (8 mL), potassium carbonate (0.112 g, 0.81 mmol) were added to a sealed tube, replaced with nitrogen three times, and sealed at 100°C for 16 h. Cooled to room temperature, the reaction solution was diluted with 100 mL of ethyl acetate, washed with water three times, and washed with saturated brine once. The organic phase was concentrated with anhydrous sodium sulfate and then flash column chromatography (mobile phase: dichloromethane / methanol (V / V) = 15 / 1) was obtained to obtain 16O (0.2 g, purity 50%, yield: 45%).

[0387] LCMS m / z=810.4[M+H] +

[0388] Step 10: Preparation of 16P

[0389] 16O (0.20 g, 50% purity, 0.12 mmol) was dissolved in DCM (5 mL), trifluoroacetic acid (5 mL) was added at room temperature, and stirred for 2 h. The reaction solution was concentrated under reduced pressure, and the residue was purified by reverse phase column (acetonitrile: water (0.1% TFA) = 75:25) and then adjusted to alkalinity with saturated sodium bicarbonate aqueous solution, extracted with dichloromethane 3 times, and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 16P (0.14 g, purity 50%, yield: 95%).

[0390] LCMS m / z=610.3[M+H] +

[0391] Step 11: Compound 16

[0392] 16P (0.14 g, 50% purity, 0.11 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (0.046 g, 0.17 mmol) and DIPEA (0.028 g, 0.22 mmol) were dissolved in DMSO (15 mL) and reacted at 90°C for 3 h. The reaction solution was cooled to room temperature, diluted with 100 mL of ethyl acetate, washed with water 3 times, washed with saturated sodium chloride once, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and flash column chromatography (mobile phase: dichloromethane / methanol (V / V) = 12 / 1) was performed to obtain a crude product, which was then purified by TLC (developing solvent: dichloromethane / methanol (V / V) = 15 / 1), and the purified product was further prepared by medium pressure (acetonitrile: water (0.1% TFA)) to obtain compound 16 (9 mg, yield: 9%).

[0393] LCMS m / z=866.8[M+H] +

[0394] 1 H NMR(400MHz, CD3OD / CDCl3(v / v=1:1))δ7.69(d,1H),7.67–7.60(m,2H),7.53(d,1H),7.3 5–7.22(m,4H),7.14(dd,1H),7.01(d,2H),6.45(d,1H),5.05–4.93(m,1H),4.27–4.13(m ,1H),4.03–3.89(m,2H),3.69–3.60(m,2H),3.60–3.41(m,6H),2.87–2.69(m,5H),2.68– 2.56(m,4H),2.36(d,2H),2.17–2.02(m,3H),2.01–1.89(m,2H),1.81–1.69(m,1H),1.54–

[0395] 1.38(m,4H).

[0396] Example 30: Preparation of Compound 30

[0397]

[0398] Step 1: Preparation of 30A

[0399] 16N (0.50 g, 0.67 mmol) and isopropylamine (0.79 g, 13.43 mmol) were added to NMP (5 mL), and the mixture was reacted at 120°C for 1 h in a microwave oven. The mixture was cooled to room temperature, and ethyl acetate (20 mL) and water (20 mL) were added and stirred for a few minutes, and then the mixture was allowed to stand for stratification. The organic layer was washed with a saturated sodium chloride aqueous solution (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (eluent: methanol-dichloromethane = 0% to 9%). The obtained product (0.45 g) was added with dichloromethane (3 mL) and trifluoroacetic acid (3 mL), and the mixture was reacted at room temperature for 3 h, and then concentrated under reduced pressure. The residue was dissolved in dichloromethane (30 mL), and a 0.5 N sodium hydroxide aqueous solution (10 mL) was added under ice-cooling. The mixture was stirred and then separated. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 30A (0.31 g, yield: 82%).

[0400] Step 2: Preparation of compound 30

[0401] 30A (0.31 g, 0.55 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (0.15 g, 0.55 mmol) and DIPEA (0.11 g, 0.85 mmol) were dissolved in DMSO (10 mL) and reacted at 90° C. for 3 h. The mixture was cooled to room temperature, ethyl acetate (50 mL) was added, washed with water three times, washed once with saturated sodium chloride, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography: eluent: methanol-dichloromethane = 0% to 9%. The product was further purified by preparative HPLC (instrument: waters2767 preparative liquid phase; chromatographic column: XBridge@Prep C18 (30 mm×150 mm); mobile phase composition: mobile phase A: acetonitrile, mobile phase B: water (containing 0.1% trifluoroacetic acid)). The prepared product was treated with saturated sodium bicarbonate aqueous solution to give compound 30 (50 mg, yield: 11%).

[0402] LCMS m / z=824.3[M+H] +

[0403] 1H NMR(400MHz, CD3OD / CDCl3(v / v=1:1))δ7.75–7.64(m,3H),7.52(d,1H),7.37–7.19( m,4H),7.14(dd,1H),7.10-6.95(m,2H),6.45(d,1H),5.05–4.90(m,1H),4.38–4.26 (m,1H),3.71–3.54(m,2H),3.52–3.41(m,4H),2.91–2.53(m,9H),2.36(d,2H),2.17 –2.09(m,1H),2.02–1.89(m,2H),1.81–1.67(m,1H),1.51–1.39(m,2H),1.22(d,6H).

[0404] Example 31: Preparation of Compound 31

[0406]

[0407] Step 1: Preparation of 31A

[0408] 16N (0.50 g, 0.67 mmol), cyclopropylamine (0.76 g, 13.43 mmol) and NMP (5 mL) were added to a reaction bottle, and the mixture was reacted at 120°C for 1 h in a microwave oven. The mixture was cooled to room temperature, and ethyl acetate (20 mL) and water (20 mL) were added, stirred for a few minutes, and then allowed to stand for stratification. The organic layer was washed with saturated aqueous sodium chloride solution (10 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (eluent: methanol-dichloromethane = 0% to 9%). Dichloromethane (3 mL) and trifluoroacetic acid (3 mL) were added to the resulting product (0.47 g), and the mixture was reacted at room temperature for 3 h. The mixture was concentrated under reduced pressure, and dichloromethane (30 mL) was added. Under ice-cooling, 0.5 N aqueous sodium hydroxide solution (10 mL) was added, and the mixture was separated after stirring. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 31A (0.33 g, yield: 87%).

[0409] Step 2: Preparation of compound 31

[0410] 31A (0.33 g, 0.58 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (0.16 g, 0.58 mmol) and DIPEA (0.12 g, 0.87 mmol) were dissolved in DMSO (10 mL) and reacted at 90° C. for 3 h. The reaction solution was cooled to room temperature, ethyl acetate (50 mL) was added, washed with water three times, washed once with saturated sodium chloride, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (eluent: methanol-dichloromethane = 0% to 9%). The obtained product was further purified by preparative HPLC (instrument: waters2767 preparative liquid phase; chromatographic column: XBridge@Prep C18 (30 mm×150 mm); mobile phase composition: mobile phase A: acetonitrile, mobile phase B: water (containing 0.1% trifluoroacetic acid)). The prepared product was treated with saturated sodium bicarbonate aqueous solution to give compound 31 (110 mg, yield: 23%).

[0411] LCMS m / z=822.2[M+H] +

[0412] 1 H NMR(400MHz,DMSO-d6)δ11.26(s,1H),11.17(s,1H),11.07(s,1H),7.77(d,2H),7. 66(d,1H),7.50–7.15(m,8H),6.93(d,2H),6.43(s,1H),6.32(s,1H),5.10-5.01(m, 1H),3.60(d,2H),3.45(s,4H),3.02–2.49(m,10H),2.22(d,2H),2.07–1.95(m,1H), 1.81(d,2H),1.66(s,1H),1.32-1.21(m,2H),0.83-0.77(m,2H),0.62–0.51(m,2H).

[0413] Example 32: Preparation of Compound 32

[0414]

[0415] Step 1: Preparation of 32A

[0416] 16M (0.9 g, 1.37 mmol) and 2-fluorophenylboronic acid (0.21 g, 1.51 mmol) were dissolved in 1,4-dioxane (15 mL) and water (5 mL), and Pd(dppf)Cl2.DCM (0.17 g, 0.21 mmol) and potassium carbonate (0.58 g, 2.74 mmol) were added, and the mixture was reacted at 60°C for 4 h under nitrogen atmosphere. The mixture was cooled to room temperature, ethyl acetate (50 mL) was added, and the mixture was washed twice with saturated sodium chloride aqueous solution. The organic layer was dried over anhydrous sodium sulfate, and the residue was concentrated under reduced pressure and purified by column chromatography (eluent: DCM / CH3OH=95 / 5 (V / V)) to obtain compound 32A (0.8 g, yield: 94%).

[0417] Step 2: Preparation of 32B

[0418] Compound 32A (0.50 g, 0.80 mmol) and 4-aminotetrahydropyran (1.62 g, 16 mmol) were dissolved in NMP (3 mL), added to a microwave tube, and reacted at 100°C for 1 h. The reaction solution was cooled to room temperature, and water (6 mL) was added under stirring. Solids precipitated under stirring, filtered, and the filter cake was washed with water and concentrated to dryness under reduced pressure. It was purified by silica gel column chromatography (eluent: DCM / CH3OH=99 / 1-90 / 10 (V / V)) to obtain compound 32B (0.35 g, yield: 64%).

[0419] Step 3: Preparation of 32C

[0420] 32B (0.35 g, 0.51 mmol) was dissolved in DCM (5 mL), trifluoroacetic acid (3 mL) was added at room temperature, and the reaction was carried out for 2 h. The reaction solution was concentrated under reduced pressure, dichloromethane (20 mL) was added, and 0.5 N aqueous sodium hydroxide solution was used to adjust the pH to 9-10. After separation, the aqueous phase was extracted with dichloromethane (10 mL), and the organic layers were combined and dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 32C (0.30 g).

[0421] Step 4: Preparation of compound 32

[0422] 32C (0.30 g, 0.51 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (0.15 g, 0.54 mmol) and DIPEA (0.13 g, 1.00 mmol) were dissolved in DMSO (5 mL) and reacted at 95°C for 3 h. After cooling to room temperature, methanol (2.5 mL) and water (15 ml) were added, stirred for 30 minutes, filtered, the filter cake was washed with water, and the filter cake was concentrated to dryness under reduced pressure. The obtained product was purified by preparative HPLC (instrument: waters 2767 preparative liquid phase; chromatographic column: XBridge@Prep C18 (30 mm×150 mm); mobile phase composition: mobile phase A: acetonitrile, mobile phase B: water (containing 0.1% trifluoroacetic acid)), and the prepared product was treated with saturated sodium bicarbonate aqueous solution to obtain compound 32 (0.11 g, yield: 26%).

[0423] LCMS m / z=423.80[(M+2H) / 2] +

[0424] 1 H NMR(400MHz, CD3OD / CDCl3(v / v=1:1))δ10.74(s,1H),7.70(d,1H),7.64–7.55(m,2H),7.55–7.42(m,2H),7.37–7.27(m,2H),7.26–7. 18(m,1H),7.15(dd,1H),7.00(d,2H),5.24(d,1H),5.06–4.90(m,1H),4.27–4.13(m,1H),4.06–3.92(m,2H),3.69–3.41(m,8H),2.87–

[0425] 2.68(m,5H),2.68–2.56(m,4H),2.35(d,2H),2.17–2.09(m,1H),2.09–1.88(m,4H),1.83–

[0426] 1.66(m,1H),1.66–1.51(m,2H),1.50–1.37(m,2H).

[0427] Example 33: Preparation of Compound 33

[0428]

[0429] Step 1: Preparation of 33A

[0430] 16M (1.1 g, 1.68 mmol) and 3-fluorophenylboronic acid (0.26 g, 1.85 mmol) were dissolved in 1,4-dioxane (15 mL) and water (5 mL), and Pd(dppf)Cl2.DCM (0.21 g, 0.25 mmol) and potassium carbonate (0.46 g, 3.36 mmol) were added, and the mixture was reacted at 60°C for 4 h under nitrogen atmosphere. The mixture was cooled to room temperature, ethyl acetate (50 mL) was added, and the mixture was washed twice with saturated sodium chloride aqueous solution. The organic layer was dried over anhydrous sodium sulfate, and the residue was concentrated under reduced pressure and purified by column chromatography (eluent: DCM / CH3OH=95 / 5 (V / V)) to obtain 33A (0.71 g, yield: 68%).

[0431] Step 2: Preparation of 33B

[0432] 33A (0.25 g, 0.40 mmol) and 4-aminotetrahydropyran (1.62 g, 16 mmol) were dissolved in NMP (3 mL) and added to a microwave tube, and the mixture was reacted at 100°C for 1 h. The mixture was cooled to room temperature, and water (6 mL) was added under stirring, and the mixture was filtered. The filter cake was washed with water and concentrated to dryness under reduced pressure, and purified by silica gel column chromatography (eluent: DCM / CH3OH=99 / 1-90 / 10 (V / V)) to obtain 33B (0.23 g, yield: 83%).

[0433] Step 3: Preparation of 33C

[0434] 33B (0.23 g, 0.33 mmol) was dissolved in DCM (5 mL), trifluoroacetic acid (3 mL) was added at room temperature, and the reaction was allowed to react for 2 h. The reaction solution was concentrated under reduced pressure, and dichloromethane (20 mL) was added. 0.5 N sodium hydroxide solution was used to adjust the pH to 9-10. After separation, the aqueous phase was extracted with dichloromethane (10 mL). The organic layers were combined and dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 33C (0.19 g).

[0435] Step 4: Preparation of compound 33

[0436] 33C (0.19 g, 0.32 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (0.097 g, 0.35 mmol) and DIPEA (0.083 g, 0.64 mmol) were dissolved in DMSO (5 mL) and reacted at 95°C for 3 h. After cooling to room temperature, methanol (2.5 mL) and water (15 ml) were added, stirred for 30 minutes, filtered, the filter cake was washed with water, and the filter cake was concentrated to dryness under reduced pressure. The obtained product was purified by preparative HPLC (instrument: waters 2767 preparative liquid phase; chromatographic column: XBridge@Prep C18 (30 mm×150 mm); mobile phase composition: mobile phase A: acetonitrile, mobile phase B: water (containing 0.1% trifluoroacetic acid)), and the prepared product was treated with saturated sodium bicarbonate aqueous solution to obtain compound 33 (45 mg, yield: 17%).

[0437] LCMS m / z=845.4[M+H] +

[0438] 1 H NMR(400MHz, CD3OD / CDCl3(v / v=1:1))δ10.74(s,1H),7.70(d,1H),7.59-7.55(m,2H),7. 52–7.41(m,2H),7.38-7.31(m,2H),7.19–7.08(m,2H),7.01(d,2H),5.63(d,1H),5.06-4. 97(m,1H),4.26–4.12(m,1H),4.01(d,2H),3.70–3.43(m,8H),2.87–2.57(m,9H),2.36(d ,2H),2.18–2.04(m,3H),1.96(d,2H),1.75(s,1H),1.64-1.55(m,2H),1.49-1.39(m,2H).

[0439] Example 34: Preparation of Compound 34

[0440]

[0441] Step 1: Preparation of 34A

[0442] 16M (1.1 g, 1.37 mmol) and 4-fluorophenylboronic acid (0.26 g, 1.86 mmol) were dissolved in 1,4-dioxane (15 mL) and water (5 mL), and Pd(dppf)Cl2.DCM (0.21 g, 0.26 mmol) and potassium carbonate (0.71 g, 3.36 mmol) were added, and the mixture was reacted at 60°C for 4 h under nitrogen atmosphere. The mixture was cooled to room temperature, ethyl acetate (50 mL) was added, and the mixture was washed twice with saturated sodium chloride aqueous solution. The organic layer was dried over anhydrous sodium sulfate, and the residue was concentrated under reduced pressure and purified by column chromatography (eluent: DCM / CH3OH=95 / 5 (V / V)) to obtain 34A (0.9 g, yield: 86%).

[0443] Step 2: Preparation of 34B

[0444] 34A (0.50 g, 0.80 mmol) and 4-aminotetrahydropyran (1.62 g, 16 mmol) were dissolved in NMP (3 mL), added to a microwave tube, and reacted at 100°C for 1 h. After cooling to room temperature, water (6 mL) was added with stirring, filtered, the filter cake was washed with water, concentrated under reduced pressure, and purified by silica gel column chromatography (eluent: DCM / CH3OH=99 / 1-90 / 10 (V / V)) to obtain 34B (0.40 g, yield: 73%).

[0445] Step 3: Preparation of 34C

[0446] 34B (0.40 g, 0.58 mmol) was dissolved in DCM (5 mL), trifluoroacetic acid (3 mL) was added at room temperature, and the reaction was continued for 2 h. The reaction solution was concentrated under reduced pressure, dichloromethane (20 mL) was added, and 0.5 N sodium hydroxide solution was used to adjust the pH to 9-10. After separation, the aqueous phase was extracted with dichloromethane (10 mL), and the organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 34C (0.34 g, yield: 99%).

[0447] Step 4: Preparation of compound 34

[0448] 34C (0.34 g, 0.58 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (0.18 g, 0.65 mmol) and DIPEA (0.15 g, 1.16 mmol) were dissolved in DMSO (5 mL) and reacted at 95°C for 3 h. After cooling to room temperature, methanol (2.5 mL) and water (15 ml) were added, stirred for 30 minutes, filtered, the filter cake was washed with water, and the filter cake was concentrated to dryness under reduced pressure. The obtained product was purified by preparative HPLC (instrument: waters 2767 preparative liquid phase; chromatographic column: XBridge@Prep C18 (30 mm×150 mm); mobile phase composition: mobile phase A: acetonitrile, mobile phase B: water (containing 0.1% trifluoroacetic acid)), and the prepared product was treated with saturated sodium bicarbonate aqueous solution to obtain compound 34 (0.14 g, yield: 29%).

[0449] LCMS m / z=423.80[(M+2H) / 2] +

[0450] 1 H NMR(400MHz, CD3OD / CDCl3(v / v=1:1))δ10.71(s,1H),7.70(d,m,1H),7.64-7.61(m ,2H),7.59-7.57(m,2H),7.33(d,1H),7.23–7.13(m,3H),7.00(d,2H),5.54(d,1H), 5.04–4.94(m,1H),4.25–4.13(m,1H),4.05-3.95(m,2H),3.68-3.43(m,8H),2.84– 2.61(m,9H),2.35(d,2H),2.18–1.93(m,5H),1.78-1.68(m,1H),1.63–1.40(m,4H).

[0451] Example 35: Preparation of Compound 35

[0452]

[0453] 32C (0.09 g, 0.15 mmol), 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindole-1,3-dione (0.053 g, 0.18 mmol) and DIPEA (0.058 g, 0.45 mmol) were dissolved in DMSO (5 mL) and reacted at 90°C for 12 h. The reaction solution was cooled to room temperature, water was added, and a yellow solid precipitated. The diatomaceous earth was filtered, and the filter cake was washed with water three times. The filter cake was redissolved in dichloromethane / methanol (V / V=10 / 1), anhydrous sodium sulfate was added, concentrated, and flash column chromatography (mobile phase: dichloromethane / methanol (V / V=15 / 1)) was performed to obtain compound 35 (93 mg, yield: 71%).

[0454] LCMS m / z=863.90[M+H] +

[0455] Example 36: Preparation of Compound 36

[0456]

[0457] Step 1: Preparation of 36B

[0458] Oxalyl chloride (2.55 g, 20.09 mmol) was dissolved in dichloromethane (150 mL), and the temperature was lowered to -78 ° C under nitrogen protection. Dimethyl sulfoxide (4.18 g, 53.50 mmol) was slowly added dropwise. After the addition was completed, the mixture was reacted at -78 ° C for 1 h. A dichloromethane solution of compound 36A (2.50 g, 10.70 mmol) was added, and the mixture was reacted at -78 ° C for 0.5 h. Triethylamine (5.40 g, 53.38 mmol) was added, and the temperature was slowly raised to room temperature and reacted for 1.5 h. Saturated aqueous ammonium chloride was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, concentrated, and then subjected to rapid column chromatography (mobile phase: petroleum ether / ethyl acetate (V / V=4 / 1)) to obtain 36B (2.28 g, yield: 92%).

[0459] Step 2: Preparation of 36C

[0460] Compound 36B (2.10 g, 9.09 mmol), benzyl-1-piperazine carbonate (2.00 g, 9.09 mmol) and dichloromethane (100 mL) were added to a reaction flask, and glacial acetic acid (1.09 g, 18.18 mmol) and sodium triacetoxyborohydride (3.85 g, 18.18 mmol) were added under stirring. The mixture was stirred at room temperature for 2 hours, and 1N sodium hydroxide aqueous solution was added to adjust the alkalinity. The mixture was extracted with dichloromethane three times, and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (mobile phase: ethyl acetate / petroleum ether (V / V) = 10 / 1-1 / 1) to obtain 36C (2.30 g, yield: 58%).

[0461] LCMS m / z=436.1[M+H] +

[0462] Step 3: Preparation of 36D hydrochloride

[0463] Compound 36C (1.00 g, 2.30 mmol) was dissolved in dichloromethane (10 mL), and hydrogen chloride was added dropwise to obtain a 1,4-dioxane solution (20 mL, 4 M). After the addition was completed, the mixture was stirred at room temperature for 1 hour. The reaction solution was directly concentrated under reduced pressure to remove hydrochloric acid and 1,4-dioxane to obtain the hydrochloride of 36D (1.00 g).

[0464] LCMS m / z=336.4[M+H] +

[0465] Step 4: Preparation of 36E

[0466] Compound 36D (1.00 g, 2.25 mmol) and 1-fluoro-4-nitrobenzene (0.32 g, 2.25 mmol) were dissolved in dimethyl sulfoxide (20 mL), potassium carbonate (1.55 g, 11.25 mmol) was added, and the temperature was raised to 80°C for 2 h. The reaction solution was cooled to room temperature, diluted with 300 mL of ethyl acetate, washed with water 3 times, and washed with saturated brine once. The organic phase was purified by anhydrous sodium sulfate, concentrated, and then pulped (petroleum ether / ethyl acetate (V / V) = 2 / 1) to obtain 36E (0.73 g, yield: 71%)

[0467] LCMS m / z=457.6[M+H] +

[0468] Step 5: Preparation of 36F

[0469] Compound 36E (0.40 g, 0.88 mmol) was dissolved in tetrahydrofuran (18 mL), and zinc powder (0.58 g, 8.80 mmol) was added. Then, an aqueous solution (3 mL) of ammonium chloride (0.47 g, 8.80 mmol) was added dropwise. After the addition, the mixture was stirred at room temperature for 20 min. 2 mL of ammonia water was added to the reaction solution, and the mixture was extracted with dichloromethane three times. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 36F (0.375 g), which was used directly in the next step.

[0470] LCMS m / z=427.4[M+H]+

[0471] Step 6: Preparation of 36G

[0472] Compound 36F (0.375 g, 0.88 mmol) and compound 16B (0.28 g, 0.88 mmol) were dissolved in 1,4-dioxane (15 mL), and N,N-diisopropylethylamine (0.227 g, 1.76 mmol) was added. After the addition, the temperature was raised to 105°C and stirred for 2 h. The reaction solution was cooled to room temperature, concentrated, and subjected to rapid column chromatography (mobile phase: dichloromethane / methanol (V / V) = 15 / 1) to obtain 36G (0.57 g, yield: 91%).

[0473] LCMS m / z=708.5[M+H]+

[0474] Step 7: Preparation of 36H

[0475] Compound 36G (0.57 g, 0.81 mmol) and 2-fluorophenylboronic acid (0.113 g, 0.81 mmol) were dissolved in 1,4-dioxane (30 mL) and water (5 mL), and Pd(dppf)Cl2.DCM (0.099 g, 0.12 mmol) and potassium carbonate (0.224 g, 1.62 mmol) were added. The nitrogen atmosphere was replaced three times and the reaction was carried out at 60°C for 3 h. The reaction solution was cooled to room temperature, diluted with 300 mL of ethyl acetate, washed once with water and once with saturated sodium chloride, and the organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. 36H (0.47 g, yield: 85%) was obtained by flash column chromatography (mobile phase: dichloromethane / methanol (V / V) = 20 / 1).

[0476] LCMS m / z=676.6[M+H] +

[0477] Step 8: Preparation of 36I

[0478] Compound 36H (0.47 g, 0.70 mmol) and 4-aminotetrahydropyran (1.42 g, 14.04 mmol) were dissolved in N-methylpyrrolidone (5 mL), heated to 120°C and subjected to microwave reaction for 1 h. The reaction solution was cooled to room temperature and directly poured into water to precipitate a yellow solid, which was filtered and washed with water three times. The filter cake was collected and redissolved in dichloromethane / methanol (V / V=10 / 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by flash column chromatography (flowability: dichloromethane / methanol (V / V)=15 / 1) to obtain 36I (0.4 g, yield: 77%).

[0479] LCMS m / z=741.3[M+H] +

[0480] Step 9: Preparation of 36J

[0481] Compound 36I (0.4 g, 0.54 mmol) was dissolved in isopropanol (10 mL), palladium carbon (0.23 g) was added, hydrogen was replaced 3 times, and the temperature was raised to 50°C for 3 h. The reaction solution was cooled to room temperature, and palladium carbon was directly filtered through diatomaceous earth. The filter cake was washed with dichloromethane / methanol (V / V=10 / 1), and the organic phases were combined and concentrated under reduced pressure to obtain 36J (0.28 g, yield: 85%).

[0482] LCMS m / z=607.2[M+H] +

[0483] Step 10: Preparation of compound 36

[0484] 36J (0.14 g, 0.23 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (0.076 g, 0.28 mmol) and DIPEA (0.089 g, 0.69 mmol) were dissolved in DMSO (5 mL) and reacted at 90°C for 12 h. The reaction solution was cooled to room temperature, water was added, and a yellow solid precipitated. The diatomaceous earth was filtered, and the filter cake was washed with water three times. The filter cake was redissolved in dichloromethane / methanol (V / V=10 / 1), anhydrous sodium sulfate was added, and the mixture was concentrated and flash column chromatography (mobile phase: dichloromethane / methanol (V / V=15 / 1)) was performed to obtain compound 36 (95 mg, yield: 47%).

[0485] LCMS m / z=432.2[(M+2H) / 2] +

[0486] Example 37: Preparation of Compound 37

[0487]

[0488] 36J (0.14 g, 0.23 mmol), 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindole-1,3-dione (0.081 g, 0.28 mmol) and DIPEA (0.089 g, 0.69 mmol) were dissolved in DMSO (5 mL) and reacted at 90°C for 12 h. The reaction solution was cooled to room temperature, water was added, and a yellow solid precipitated. The diatomaceous earth was filtered, and the filter cake was washed with water three times. The filter cake was redissolved in dichloromethane / methanol (V / V=10 / 1), anhydrous sodium sulfate was added, and the mixture was concentrated and flash column chromatography (mobile phase: dichloromethane / methanol (V / V=15 / 1)) was performed to obtain compound 37 (110 mg, yield: 50%).

[0489] LCMS m / z=441.1[(M+2H) / 2] +

[0490] Example 38: Preparation of Compound 38

[0491]

[0492] Step 1: Preparation of 38A

[0493] Compound 1-fluoro-4-nitrobenzene (1.6 g, 11.34 mmol) and N-Boc-piperazine (2.33 g, 12.50 mmol) were mixed and dissolved in DMSO (10 mL), and DIPEA (2.20 g, 17.02 mmol) was added, and the temperature was raised to 100°C and stirred for 5 h. After cooling to room temperature, 20 mL of water was added, and the mixture was stirred for 10 min, filtered, and the filter cake was washed once with 10 mL of water, and the filter cake was dried under reduced pressure to obtain compound 38A (3.3 g, yield: 95%).

[0494] Step 2: Preparation of 38B

[0495] Compound 38A (1.6 g, 5.20 mmol) was dissolved in a mixed solvent of THF (16 mL) and water (4 mL), and zinc powder (3.40 g, 51.98 mmol) and ammonium chloride (2.78 g, 51.95 mmol) were added. After addition, the mixture was reacted at room temperature for 2 h. 10 mL of ammonia water was added to the reaction solution, and 20 mL of dichloromethane was added for extraction. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound 38B (1.2 g, yield: 83%).

[0496] Step 3: Preparation of 38C

[0497] Compound 38B (1.3 g, 4.09 mmol) and 16B (1.13 g, 4.09 mmol) were dissolved in 1,4-dioxane (15 mL), and DIPEA (1.06 g, 8.18 mmol) was added, and the mixture was stirred at 100°C for 1 h. After cooling to room temperature, 20 mL of dichloromethane and 20 mL of water were added for extraction, and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 5-1 / 1) to obtain compound 38C (1.1 g, yield: 48%).

[0498] LCMS m / z=559.0[M+H] +

[0499] Step 4: Preparation of 38D

[0500] Compound 38C (1.1 g, 1.97 mmol), 2-fluorophenylboronic acid (0.30 g, 2.17 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (0.24 g, 0.30 mmol) and potassium carbonate (0.54 g, 3.94 mmol) were added to a 100 mL single-mouth bottle in sequence, 1,4-dioxane (15 mL) and water (5 mL) were added, nitrogen was replaced three times, the temperature was raised to 60°C and stirred for 3 h. After cooling to room temperature, 20 mL of dichloromethane and 20 mL of water were added for extraction, the organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 5-1 / 1) to obtain compound 38D (1 g, yield: 96%).

[0501] LCMS m / z=527.2[M+H] +

[0502] Step 5: Preparation of 38E

[0503] Compound 38D (1 g, 1.90 mmol) and 4-aminotetrahydropyran (3.84 g, 37.96 mmol) were added to a microwave tube in sequence, and NMP (5 mL) was added, and the mixture was stirred at 120°C for 1 h. After cooling to room temperature, 10 mL of water was added, and a large amount of solid was precipitated, which was filtered. The filter cake was dissolved in 20 mL of dichloromethane, and 10 mL of saturated brine was added, and the liquids were separated. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 5-1 / 1) to obtain compound 38E (0.72 g, yield: 64%).

[0504] Step 6: Preparation of 38F

[0505] Compound 38E (0.72 g, 1.22 mmol) was dissolved in DCM (3 mL), TFA (3 mL) was added at room temperature, and the mixture was stirred overnight at room temperature. The mixture was concentrated under reduced pressure, 30 mL of dichloromethane was added to the residue, and the pH was adjusted to > 8 with 1N aqueous sodium hydroxide solution. After separation, the organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and used directly in the next step.

[0506] Step 7: Preparation of 38G

[0507] Compound 4-hydroxymethylpiperidine (350 mg, 3.04 mmol) was dissolved in DMSO (10 mL), and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (920 mg, 3.34 mmol) and diisopropylethylamine (0.79 g, 6.11 mmol) were added in sequence, and the mixture was heated to 80°C and stirred for 1 h. After cooling to room temperature, water (50 mL) was added to quench the reaction, and dichloromethane (50 mL×3) was added. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol / dichloromethane (v / v) = 0 / 100-3 / 100) to obtain compound 38G (0.82 g, yield: 73%).

[0508] LCMS m / z=372.1[M+H] +

[0509] Step 8: Preparation of compound 38H

[0510] 38G (0.8 g, 2.15 mmol) was dissolved in dichloromethane (20 mL), and Dess-Martin periodinane (1.37 g, 3.22 mmol) was added in batches at 0°C, and the mixture was heated to room temperature for 1 hour. Saturated sodium thiosulfate aqueous solution (50 mL) was added to quench the mixture, and the mixture was extracted with dichloromethane (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol / dichloromethane (v / v) = 0 / 100-2 / 100) to obtain compound 38H (0.6 g, yield 76%).

[0511] Step 9: Preparation of compound 38

[0512] Compound 38F (0.1 g, 0.20 mmol) and 38H (0.081 g, 0.22 mmol) were dissolved in a mixed solvent of chloroform (10 mL) and acetonitrile (2 mL), 0.1 g of anhydrous sodium sulfate was added, the temperature was raised to 50°C and stirred for 10 min, sodium triacetoxyborohydride (0.13 g, 0.61 mmol) was added at this temperature, and after the addition, the mixture was stirred for 20 min and cooled to room temperature. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane / methanol (V / V) = 100 / 1-25 / 1) to obtain compound 38 (90 mg, yield: 53%).

[0513] LCMS m / z=845.3[M+H] +

[0514] Example 39: Preparation of Compound 39

[0515]

[0516] Step 1: Preparation of compound 39A

[0517] Compound 38F (0.15 g, 0.31 mmol) and tert-butyl 4-fluoro-4-formylpiperidine-1-carboxylate (36B) (0.20 g, 0.86 mmol) were dissolved in chloroform (10 mL), 0.1 g of anhydrous sodium sulfate was added, the temperature was raised to 50°C and stirred for 10 min, sodium triacetoxyborohydride (0.20 g, 0.94 mmol) was added at this temperature, and after the addition, the mixture was stirred for 20 min and cooled to room temperature. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane / methanol (V / V) = 100 / 1-30 / 1) to obtain compound 39A (0.16 g, yield: 73%).

[0518] LCMS m / z=708.1[M+H] +

[0519] Step 2: Preparation of compound 39B

[0520] Compound 39A (0.16 g, 0.23 mmol) was dissolved in DCM (2 mL), and TFA (2 mL) was added at room temperature. After the addition was complete, the mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure, and 20 mL of dichloromethane and 10 mL of saturated sodium bicarbonate aqueous solution were added to the residue. The mixture was stirred for 2 min and then separated. The organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and used directly in the next step.

[0521] Step 3: Preparation of compound 39

[0522] Compound 39B (0.16 g, 0.26 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (0.086 g, 0.31 mmol) were dissolved in DMSO (5 mL), and DIPEA (0.17 g, 1.3 mmol) was added, and the mixture was heated to 110°C and stirred for 5 h. The mixture was cooled to room temperature, 10 mL of water was added, and the mixture was stirred for 2 min, and filtered. The filter cake was dissolved in 20 mL of dichloromethane, and 10 mL of saturated sodium chloride aqueous solution was added, and the liquids were separated. The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol (V / V) = 100 / 1-25 / 1) to obtain compound 39 (70 mg, yield: 31%).

[0523] LCMS m / z=863.3[M+H] +

[0524] Example 40: Preparation of Compound 40

[0525]

[0526] Step 1: Preparation of compound 40A

[0527] Compound 3-azetidinemethanol (270 mg, 3.04 mmol) was dissolved in DMSO (19 mL), and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (840 mg, 3.04 mmol) and diisopropylethylamine (0.79 g, 6.08 mmol) were added in sequence, and the mixture was heated to 80°C and stirred for 1 h. After cooling to room temperature, water (50 mL) was added to quench the reaction, and dichloromethane (50 mL×3) was added. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol / dichloromethane (v / v) = 0 / 100-3 / 100) to obtain compound 40A (0.8 g, yield: 77%).

[0528] LCMS m / z=344.1[M+H] +

[0529] Step 2: Preparation of compound 40B

[0530] 40A (0.8 g, 2.33 mmol) was dissolved in dichloromethane (50 mL), and Dess-Martin periodinane (1.48 g, 3.5 mmol) was added in batches at 0°C, and the mixture was heated to room temperature for 1 hour. Saturated sodium thiosulfate aqueous solution (50 mL) was added to quench the mixture, and the mixture was extracted with dichloromethane (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol / dichloromethane (v / v) = 0 / 100-2 / 100) to obtain compound 40B (0.6 g, yield 75%).

[0531] Step 3: Preparation of compound 40

[0532] Compound 38F (0.075 g, 0.22 mmol) and 40B (0.1 g, 0.20 mmol) were dissolved in a mixed solvent of chloroform (10 mL) and acetonitrile (2 mL), 0.1 g of anhydrous sodium sulfate was added, the temperature was raised to 50°C and stirred for 10 min, sodium triacetoxyborohydride (0.13 g, 0.61 mmol) was added at this temperature, and after the addition, the mixture was stirred for 20 min and cooled to room temperature. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane / methanol (V / V) = 100 / 1-25 / 1) to obtain compound 40 (80 mg, yield: 49%).

[0533] LCMS m / z=817.3[M+H] +

[0534] Example 41: Preparation of Compound 41

[0535]

[0536] Step 1: Preparation of compound 41A

[0537] N-Boc-piperazine (0.7 g, 3.76 mmol) and 4-nitrobenzaldehyde (0.63 g, 4.14 mmol) were added to acetonitrile (20 mL) in sequence. After addition, the mixture was stirred at room temperature for 10 min. Sodium triacetoxyborohydride (1.59 g, 7.52 mmol) was added and stirred for 30 min. TLC monitored the reaction to be complete. 40 mL of water was added and stirred for 20 min. A large amount of solid precipitated. 20 mL of water was added and stirred for 2 min. The mixture was filtered and the filter cake was washed with 20 mL of water and dried under reduced pressure to obtain compound 41A (0.7 g, yield: 58%).

[0538] Step 2: Preparation of compound 41B

[0539] Compound 41A (0.7 g, 2.18 mmol) was dissolved in a mixed solvent of ethanol (30 mL) and water (10 mL), iron powder (1.22 g, 21.8 mmol) and ammonium chloride (1.17 g, 21.8 mmol) were added in sequence, and the mixture was heated to 80°C and stirred for 1 h. The mixture was cooled to room temperature, filtered, and the filter cake was washed with 30 mL of ethyl acetate. The filtrate was combined, 30 mL of saturated brine was added, and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound 41B (0.55 g, yield: 86%).

[0540] LCMS m / z=292.1[M+H] +

[0541] Step 3: Preparation of compound 41C

[0542] Compound 41B (0.27 g, 0.94 mmol) and 16B (0.30 g, 0.94 mmol) were dissolved in 1,4-dioxane (10 mL), and DIPEA (0.24 g, 1.86 mmol) was added, and the mixture was stirred at 100°C for 1 h. After cooling to room temperature, 20 mL of dichloromethane and 20 mL of water were added for extraction, and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 5-1 / 1) to obtain compound 41C (0.33, yield: 61%).

[0543] LCMS m / z=573.0[M+H] +

[0544] Step 4: Preparation of compound 41D

[0545] Compound 41C (0.33 g, 0.58 mmol), 2-fluorophenylboronic acid (0.089 g, 0.64 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (0.071 g, 0.087 mmol) and potassium carbonate (0.16 g, 1.16 mmol) were added to a 100 mL single-mouth bottle in sequence, 1,4-dioxane (10 mL) and water (3 mL) were added, nitrogen was replaced three times, the temperature was raised to 60°C and stirred for 3 h. After cooling to room temperature, 20 mL of dichloromethane and 20 mL of water were added for extraction, the organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 5-1 / 1) to obtain compound 41D (0.29 g, yield: 92%).

[0546] LCMS m / z=541.5[M+H] +

[0547] Step 5: Preparation of Compound 41E

[0548] Compound 41D (0.29 g, 0.54 mmol) and 4-aminotetrahydropyran (1.09 g, 10.78 mmol) were added to a microwave tube in sequence, and NMP (5 mL) was added, and the mixture was stirred at 120°C for 1 h. After cooling to room temperature, 10 mL of water was added, and a large amount of solid was precipitated, which was filtered. The filter cake was dissolved in 20 mL of dichloromethane, and 10 mL of saturated brine was added, and the liquid was separated. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 5-1 / 1) to obtain compound 41E (0.22 g, yield: 67%).

[0549] Step 6: Preparation of Compound 41F

[0550] Compound 41E (0.22 g, 1.22 mmol) was dissolved in DCM (3 mL), TFA (3 mL) was added at room temperature, and the mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure, 30 mL of dichloromethane was added to the residue, and the pH was adjusted to > 8 with 1N aqueous sodium hydroxide solution. After separation, the organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and used directly in the next step.

[0551] LCMS m / z=506.3[M+H] +

[0552] Step 3: Preparation of compound 41

[0553] Compound 41F (0.24 g, 0.47 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (0.13 g, 0.47 mmol) were dissolved in DMSO (5 mL), and DIPEA (0.30 g, 2.35 mmol) was added, and the temperature was raised to 110°C and stirred for 5 h. After cooling to room temperature, 10 mL of water was added, and the mixture was stirred for 2 min, and filtered. The filter cake was dissolved in 20 mL of dichloromethane, and 10 mL of saturated sodium chloride aqueous solution was added, and the liquids were separated. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol (V / V) = 100 / 1-25 / 1) to obtain compound 41 (120 mg, yield: 33%).

[0554] LCMS m / z=762.2[M+H] +

[0555] Example 42: Preparation of Compound 42

[0556]

[0557] Step 1: Preparation of 42A

[0558] p-Fluoronitrobenzene (1.4 g, 9.92 mmol), N-BOC-piperazine (1.85 g, 9.92 mmol), potassium carbonate (2.74 g, 19.87 mmol) and DMF (20 mL) were added to a reaction bottle, heated in an oil bath at 50 °C for 3 hours, cooled to room temperature, added with water (20 mL), stirred for crystallization for 30 minutes, filtered, washed with water and petroleum ether, and concentrated under reduced pressure to obtain compound 42A (2.2 g, yield: 72%).

[0559] Step 2: Preparation of 42B

[0560] Compound 42A (1 g, 3.26 mmol), zinc powder (2.13 g, 32.56 mmol), ammonium chloride (1.75 g, 32.68 mmol), THF (15 mL) and water (5 mL) were added to the reaction flask, and the reaction was stirred at room temperature for 1 hour. Dichloromethane (20 mL) and saturated aqueous sodium bicarbonate solution (20 mL) were added and stirred for 5 minutes. Appropriate amount of diatomaceous earth was applied and the mixture was filtered. The filter cake was washed with dichloromethane, the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 42B (0.82 g, yield: 91%).

[0561] Step 3: Preparation of 42C

[0562] Compound 42B (0.26 g, 0.94 mmol), compound 16B (0.30 g, 0.94 mmol), DIPEA (0.24 g, 1.88 mmol) and 1,4-dioxane (10 mL) were added to the reaction flask, heated in an oil bath at 100 °C for 3 hours, cooled to room temperature, added with an appropriate amount of silica gel, concentrated under reduced pressure, and purified by column chromatography with eluent: petroleum ether / ethyl acetate (V / V) = 100 / 0-50 / 50 to obtain compound 42C (0.4 g, yield: 76%).

[0563] LCMS m / z=559.4[M+H] +

[0564] Step 4: Preparation of 42D

[0565] Compound 42C (0.4 g, 0.72 mmol), 2-fluorophenylboronic acid (0.11 g, 0.76 mmol), Pd(dppf)Cl2.DCM (0.088 g, 0.11 mmol), potassium carbonate (0.20 g, 1.45 mmol) and 1,4-dioxane (10 mL) were added to the reaction flask, and water (3 mL) was added. The mixture was ventilated with nitrogen three times and stirred in an oil bath at 55 °C for 5 hours. The reaction of the raw materials was completed according to TLC. The mixture was cooled to room temperature, and ethyl acetate (50 mL) was added. The mixture was washed twice with saturated sodium chloride aqueous solution. The organic layer was dried over anhydrous sodium sulfate, filtered, concentrated after adding an appropriate amount of silica gel, and purified by column chromatography. The eluent was petroleum ether / ethyl acetate (V / V) = 100 / 0-50 / 50 to obtain compound 42D (0.32 g, yield: 84.3%).

[0566] LCMS m / z=527.2[M+H] +

[0567] Step 5: Preparation of 42E

[0568] Compound 42D (0.32 g, 0.61 mmol), 4-aminotetrahydropyran (1.24 g, 12.24 mmol) and NMP (6 mL) were added to a reaction flask, and the mixture was reacted at 120°C in a microwave oven for 2 hours. The mixture was cooled to room temperature, and ethyl acetate (20 mL) and water (20 mL) were added, stirred and separated. The organic layer was dried over anhydrous sodium sulfate and filtered, and an appropriate amount of silica gel was added and concentrated. The mixture was purified by column chromatography with an eluent of dichloromethane / methanol (V / V) = 100 / 0-95 / 5 to give compound 42E (0.30 g, yield: 83.1%).

[0569] LCMS m / z=592.2[M+H] +

[0570] Step 6: Preparation of 42F

[0571] Compound 42E (0.30 g, 0.51 mmol) and dichloromethane (3 mL) were added to the reaction flask, and trifluoroacetic acid (2 mL) was added dropwise with stirring. The reaction was stirred at room temperature for 2 hours, and the mixture was concentrated under reduced pressure. Dichloromethane (20 mL) was added, and the pH was adjusted to 9-10 with 0.5N sodium hydroxide solution, and then the layers were separated by stirring. The aqueous layer was extracted twice with dichloromethane. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 42F (0.25 g).

[0572] Step 7: Preparation of 42G

[0573] 4-Methylphthalic anhydride (CAS: 19438-61-0, 10 g, 61.65 mmol), 3-aminopiperidine-2,6-dione hydrochloride (8.37 g, 73.98 mmol), sodium acetate (7.59 g, 92.47 mmol) and acetic acid (100 mL) were added to the reaction flask, and the reaction was stirred in an oil bath at 95 ° C for 16 hours. After cooling to room temperature, water (100 mL) was added, stirred and slurried for 1 hour, filtered, the filter cake was washed with water, and after drying, MTBE (200 mL) was added to the solid, stirred and slurried for 1 hour, filtered, the filter cake was washed with MTBE, and concentrated under reduced pressure to dryness to obtain compound 42G (16 g, yield: 95%).

[0574] LCMS m / z=273.1[M+H] +

[0575] Step 8: Preparation of 42H

[0576] Compound 42G (7 g, 25.71 mmol), NBS (5.03 g, 28.28 mmol), dibenzoyl peroxide (1.25 g, 5.14 mmol) and acetonitrile (100 mL) were added to the reaction flask, and the mixture was stirred in an oil bath at 90 °C for about 5 hours. The mixture was cooled to room temperature, and an appropriate amount of silica gel was added for concentration. The mixture was purified by column chromatography with an eluent of petroleum ether / ethyl acetate (V / V) = 100 / 0-60 / 40-40 / 60 to give compound 42H (7.4 g, yield: 81.9%).

[0577] Step 9: Preparation of compound 42

[0578] Compound 42F (180 mg, 0.37 mmol), compound 42H (129.93 mg, 0.37 mmol), DIPEA (95.64 mg, 0.74 mmol) and DMF (3 mL) were added to the reaction flask, and the reaction was stirred in an oil bath at 60°C for 3 hours. The mixture was cooled to room temperature, ethyl acetate (30 mL) was added, and the mixture was washed twice with saturated aqueous sodium chloride solution. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated by adding an appropriate amount of silica gel sand. The mixture was purified by column chromatography, eluent: dichloromethane / methanol (V / V) = 100 / 0-95 / 5, and compound 42 (0.068 g, yield: 24%) was obtained.

[0579] LCMS m / z=762.3[M+H] +

[0580] Example 43: Preparation of Compound 43

[0581]

[0582] Step 1: Preparation of 43A

[0583] p-Fluoronitrobenzene (0.7 g, 4.96 mmol), tert-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate (1.12 g, 4.96 mmol), potassium carbonate (1.37 g, 9.92 mmol) and DMF (10 mL) were added to the reaction flask, heated in an oil bath at 50 °C for 3 hours, cooled to room temperature, added with water (10 mL), stirred for crystallization for 30 minutes, filtered, washed with water and petroleum ether, and concentrated under reduced pressure to give compound 43A (1.45 g, yield: 84.1%).

[0584] LCMS m / z=348.2[M+H] +

[0585] Step 2: Preparation of 43B

[0586] Compound 43A (1 g, 2.88 mmol), zinc powder (1.88 g, 28.74 mmol), ammonium chloride (1.54 g, 28.80 mmol), THF (15 mL) and water (5 mL) were added to the reaction flask, and the reaction was stirred at room temperature for 1 hour. Dichloromethane (20 mL) and saturated aqueous sodium bicarbonate solution (20 mL) were added and stirred for 5 minutes. Appropriate amount of celite was applied and the mixture was filtered. The filter cake was washed with dichloromethane, the organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 43B (0.85 g).

[0587] Step 3: Preparation of 43C

[0588] Compound 43B (0.3 g, 0.95 mmol), compound 16B (0.30 g, 0.95 mmol), DIPEA (0.25 g, 1.9 mmol) and 1,4-dioxane (10 mL) were added, and the reaction was heated in an oil bath at 100°C for about 3 hours. The mixture was cooled to room temperature, and an appropriate amount of silica gel was added, and the mixture was concentrated under reduced pressure to dryness. The mixture was purified by silica gel column chromatography with the eluent being petroleum ether / ethyl acetate (V / V) = 100 / 0-50 / 50 to obtain compound 43C (0.3 g, yield: 53%).

[0589] LCMS m / z=599.5[M+H] +

[0590] Step 4: Preparation of 43D

[0591] Compound 43C (0.2 g, 0.33 mmol), 2-fluorophenylboronic acid (0.048 g, 0.35 mmol), Pd(dppf)Cl2.DCM (0.040 g, 0.050 mmol), potassium carbonate (0.091 g, 0.66 mmol) and 1,4-dioxane (10 mL) were added to the reaction flask, and water (3 mL) was added. The mixture was ventilated with nitrogen three times, and stirred in an oil bath at 50 °C for 5 hours. The mixture was cooled to room temperature, ethyl acetate (50 mL) was added, and the mixture was washed twice with saturated sodium chloride aqueous solution. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated with an appropriate amount of silica gel. The mixture was purified by silica gel column chromatography with an eluent of petroleum ether / ethyl acetate (V / V) = 100 / 0-40 / 60 to give compound 43D (0.17 g, yield: 91%).

[0592] Step 5: Preparation of 43E

[0593] Compound 43D (0.17 g, 0.30 mmol), 4-aminotetrahydropyran (0.61 g, 6 mmol) and NMP (6 mL) were added to the reaction flask, and the mixture was reacted at 120 °C for 2 hours in a microwave oven. The mixture was cooled to room temperature, and ethyl acetate (20 mL) and water (20 mL) were added, stirred and separated, and the organic layer was dried over anhydrous sodium sulfate and filtered. An appropriate amount of silica gel was added, and the mixture was concentrated under reduced pressure and purified by silica gel column chromatography. The eluent was dichloromethane / methanol (V / V) = 100 / 0-95 / 5 to obtain compound 43E (0.18 g, yield: 95%).

[0594] Step 6: Preparation of 43F

[0595] Compound 43E (0.18 g, 0.28 mmol) and dichloromethane (3 mL) were added to the reaction flask, and trifluoroacetic acid (1.4 mL) was added dropwise with stirring. The reaction was stirred at room temperature for 2 hours, and the mixture was concentrated under reduced pressure. Dichloromethane (20 mL) was added, and the pH was adjusted to 9-10 with 0.5N aqueous sodium hydroxide solution, and the layers were separated. The aqueous layer was extracted twice with dichloromethane (20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 43F (0.14 g, yield: 94%).

[0596] Step 7: Preparation of compound 43

[0597] Compound 43F (0.14 g, 0.26 mmol), compound 42H (0.091 g, 0.26 mmol), DIPEA (0.067 g, 0.52 mmol) and DMF (3 mL) were added to the reaction flask, heated in an oil bath at 60°C for 3 hours, cooled to room temperature, added with ethyl acetate (30 mL), washed twice with saturated sodium chloride aqueous solution, the organic layer was dried over anhydrous sodium sulfate, filtered, added with an appropriate amount of silica gel, concentrated under reduced pressure, and purified by silica gel column chromatography, eluent: dichloromethane / methanol (V / V) = 100 / 0-95 / 5, to obtain compound 43 (0.049 g, yield: 24%)

[0598] LCMS m / z=802.3[M+H] +

[0599] Example 44: Preparation of Compound 44

[0600]

[0601] 43F (0.31 g, 0.58 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (0.19 g, 0.70 mmol) and DIPEA (0.22 g, 1.74 mmol) were dissolved in DMSO (10 mL) and reacted at 90°C for 12 h. The reaction solution was cooled to room temperature, water was added, and a yellow solid precipitated. The filter cake was filtered with diatomaceous earth, and the filter cake was washed with water three times. The filter cake was redissolved in dichloromethane / methanol (V / V=10 / 1), dried over anhydrous sodium sulfate, concentrated, and flash column chromatography (mobile phase: dichloromethane / methanol (V / V=15 / 1)) was performed to obtain compound 44 (12 mg, yield: 2%).

[0602] LCMS m / z=788.90[M+H] +

[0603] Example 45: Preparation of Compound 45

[0604]

[0605] Step 1: Preparation of compound 45A

[0606] 2,6-diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (0.5 g, 2.52 mmol) and 4-fluoronitrobenzene (0.36 g, 2.52 mmol) were mixed and dissolved in DMSO (5 mL), and DIPEA (0.65 g, 5.07 mmol) was added, and the mixture was heated to 120°C and stirred for 3 h. After cooling to room temperature, 10 mL of water was added, and the mixture was stirred for 10 min, filtered, and the filter cake was washed once with 10 mL of water, and the filter cake was dried under reduced pressure to obtain compound 45A (0.7 g, yield: 87%).

[0607] Step 2: Preparation of compound 45B

[0608] Compound 45A (0.7 g, 2.18 mmol) was dissolved in a mixed solvent of ethanol (10 mL), tetrahydrofuran (10 mL) and water (7 mL), iron powder (1.22 g, 21.9 mmol) and ammonium chloride (1.17 g, 21.9 mmol) were added in sequence, and the mixture was heated to 80°C and stirred for 1 h. The mixture was cooled to room temperature, filtered, and the filter cake was washed with 30 mL of ethyl acetate. The filtrate was combined, 30 mL of saturated brine was added, and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound 45B (0.65 g, yield: 99%).

[0609] Step 3: Preparation of compound 45C

[0610] Compound 45B (0.25 g, 0.85 mmol) and 16B (0.27 g, 0.85 mmol) were dissolved in 1,4-dioxane (10 mL), and DIPEA (0.22 g, 1.70 mmol) was added, and the mixture was stirred at 100°C for 1 h. After cooling to room temperature, 20 mL of dichloromethane and 20 mL of water were added for extraction, and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 5-1 / 1) to obtain compound 45C (0.41 g, yield: 82%).

[0611] Step 4: Preparation of compound 45D

[0612] Compound 45C (0.41 g, 0.72 mmol), 2-fluorophenylboronic acid (0.11 g, 0.79 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (0.088 g, 0.011 mmol) and potassium carbonate (0.20 g, 1.44 mmol) were added to a 100 mL single-mouth bottle in sequence, 1,4-dioxane (10 mL) and water (3 mL) were added, nitrogen was replaced three times, the temperature was raised to 60°C and stirred for 3 h. After cooling to room temperature, 20 mL of dichloromethane and 20 mL of water were added for extraction, the organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 5-1 / 1) to obtain the target compound 45D (0.34 g, yield: 87%).

[0613] LCMS m / z=539.2[M+H] +

[0614] Step 5: Preparation of compound 45E

[0615] Compound 45D (0.34 g, 0.63 mmol) and 4-aminotetrahydropyran (1.28 g, 12.63 mmol) were added to a microwave tube in sequence, and NMP (5 mL) was added, and the mixture was stirred at 120°C for 1 h. After cooling to room temperature, 10 mL of water was added, and a large amount of solid was precipitated, which was filtered. The filter cake was dissolved in 20 mL of dichloromethane, and 10 mL of saturated brine was added, and the liquid was separated. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether (V / V) = 0 / 100-35 / 65-dichloromethane / methanol (V / V) = 97 / 3) to obtain compound 45E (0.3 g, yield: 79%).

[0616] LCMS m / z=604.8[M+H] +

[0617] Step 6: Preparation of compound 45F

[0618] Compound 45E (0.3 g, 0.50 mmol) was dissolved in DCM (3 mL), TFA (3 mL) was added at room temperature, and the mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure, 30 mL of dichloromethane was added to the residue, and the pH was adjusted to > 8 with 1N aqueous sodium hydroxide solution. After separation, the organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and used directly in the next step.

[0619] Step 7: Preparation of compound 45

[0620] Compound 45F (0.16 g, 0.32 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (0.088 g, 0.32 mmol) were dissolved in DMSO (5 mL), and DIPEA (0.12 g, 0.97 mmol) was added, and the mixture was heated to 110°C and stirred for 5 h. The mixture was cooled to room temperature, and 10 mL of water was added, and the mixture was stirred for 2 min, and filtered. The filter cake was dissolved in 20 mL of dichloromethane, and 10 mL of saturated sodium chloride aqueous solution was added, and the liquids were separated. The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol (V / V) = 100 / 1-25 / 1) to obtain compound 45 (100 mg, yield: 41%).

[0621] LCMS m / z=760.2[M+H] +

[0622] Example 46: Preparation of Compound 46

[0623]

[0624] Step 1: Preparation of 46A

[0625] Compound 32A (0.2 g, 0.32 mmol), cyclopropylamine (0.37 g, 6.4 mmol) and NMP (3 mL) were added to the reaction flask, and the mixture was reacted at 100 °C in a microwave for 1 hour. The mixture was cooled to room temperature, and ethyl acetate (20 mL) and water (20 mL) were added. The mixture was stirred and separated into layers. The organic layer was washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and an appropriate amount of silica gel was added to concentrate under reduced pressure. The mixture was purified by silica gel column chromatography, eluent: dichloromethane / methanol (V / V) = 100 / 0-95 / 5 to give compound 46A (0.19 g, yield: 92.1%).

[0626] LCMS m / z=645.4[M+H] +

[0627] Step 2: Preparation of 46B

[0628] Compound 46A (0.19 g, 0.29 mmol) and dichloromethane (3 mL) were added to the reaction flask, and trifluoroacetic acid (2 mL) was added dropwise with stirring. The reaction was stirred at room temperature for about 2 hours, and the mixture was concentrated under reduced pressure. Dichloromethane (20 mL) was added, and the pH was adjusted to 9-10 with 0.5 N sodium hydroxide solution. The layers were separated, and the aqueous layer was extracted twice with dichloromethane (20 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give compound 46B (0.12 g, yield: 76%).

[0629] Step 3: Preparation of compound 46

[0630] Compound 46B (0.12 g, 0.22 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (0.067 g, 0.24 mmol), DIPEA (0.057 g, 0.44 mmol) and DMSO (6 mL) were added to the reaction flask, stirred in an oil bath at 95 ° C for 6 hours, cooled to room temperature, added with ethyl acetate (30 mL), washed twice with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure and purified by silica gel column chromatography, eluent: dichloromethane / methanol (V / V) = 100 / 0-95 / 5, the product was purified by preparative HPLC (instrument: Waters 2767 preparative liquid phase; chromatographic column: XBridge@Prep C18 (30 mm × 150 mm); mobile phase composition: mobile phase A: acetonitrile, mobile phase B: water (containing 0.1% trifluoroacetic acid)) was purified, and the prepared product was treated with saturated sodium bicarbonate aqueous solution to obtain compound 46 (6 mg, yield: 3.4%)

[0631] LCMS m / z=801.3[M+H] +

[0632] Example 47: Preparation of Compound 47

[0633]

[0634] Step 1: Preparation of 47A

[0635] Compound 32A (0.20 g, 0.32 mmol) and oxetane-3-amine (0.467 g, 6.4 mmol) were dissolved in N-methylpyrrolidone (5 mL), heated to 120°C and subjected to microwave reaction for 1 h. The reaction solution was cooled to room temperature and directly poured into water to precipitate a yellow solid, which was filtered and the filter cake was washed with water 3 times. The filter cake was collected and redissolved in dichloromethane / methanol (V / V=10 / 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by flash column chromatography (flowability: dichloromethane / methanol (V / V)=15 / 1) to obtain 47A (0.12 g, yield: 56%).

[0636] LCMS m / z=661.4[M+H] +

[0637] Step 2: Preparation of 47B

[0638] 47A (0.14 g, 0.21 mmol) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (5 mL) was added dropwise at room temperature. After the addition was complete, the mixture was reacted at room temperature for 1 h. The reaction solution was directly concentrated under reduced pressure to remove trifluoroacetic acid, and then 100 mL of dichloromethane / methanol (V / V=10 / 1) was added for redissolution. The aqueous sodium hydroxide solution was adjusted to alkalinity, and the mixture was separated and extracted. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound 47B (0.1 g, yield: 84%).

[0639] LCMS m / z=561.1[M+H] +

[0640] Step 3: Preparation of compound 47

[0641] 47B (0.1 g, 0.18 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (0.06 g, 0.22 mmol) and DIPEA (0.07 g, 0.54 mmol) were dissolved in DMSO (5 mL) and reacted at 90°C for 12 h. The reaction solution was cooled to room temperature, water was added, and a yellow solid precipitated. The solid was filtered with diatomaceous earth, and the filter cake was washed with water three times. The filter cake was redissolved in dichloromethane / methanol (V / V=10 / 1), dried over anhydrous sodium sulfate, concentrated, and flash column chromatography (mobile phase: dichloromethane / methanol (V / V=15 / 1)) was performed to obtain compound 47 (16 mg, yield: 10%).

[0642] LCMS m / z=817.3[M+H] +

[0643] Example 48: Preparation of Compound 48

[0644]

[0645] Step 1: Preparation of 48A

[0646] Compound 16M (520 mg, 0.79 mmol), 2,4-difluorophenylboronic acid (130.99 mg, 0.83 mmol), Pd(dppf)Cl2.DCM (96.77 mg, 0.12 mmol), potassium carbonate (218.37 mg, 1.58 mmol), 1,4-dioxane (9 mL) and water (3 mL) were added to the reaction flask. After nitrogen ventilation three times, the reaction was heated in an oil bath at 40-45 ° C under nitrogen protection for 7 hours, cooled to room temperature, ethyl acetate (40 mL) was added, and the mixture was washed with saturated sodium chloride aqueous solution. The organic layer was dried over anhydrous sodium sulfate, filtered, and an appropriate amount of silica gel was added. After concentration under reduced pressure, it was purified by silica gel column chromatography, eluent: dichloromethane / methanol (V / V) = 100 / 0-95 / 5 to obtain compound 48A (0.42 g, yield: 83%).

[0647] LCMS m / z=642.7[M+H] +

[0648] Step 2: Preparation of 48B

[0649] Compound 48A (0.42 g, 0.65 mmol), 4-aminotetrahydropyran (1.31 g, 13 mmol) and NMP (10 mL) were added to the reaction flask, and the mixture was reacted at 120 °C for 2 hours in a microwave oven. The mixture was cooled to room temperature, and ethyl acetate (30 mL) and water (30 mL) were added, stirred and separated. The organic layer was dried over anhydrous sodium sulfate and filtered. An appropriate amount of silica gel was added, and the mixture was concentrated under reduced pressure and purified by silica gel column chromatography. The eluent was dichloromethane / methanol (V / V) = 100 / 0-95 / 5 to obtain compound 48B (0.44 g, yield: 96%).

[0650] LCMS m / z=707.3[M+H] +

[0651] Step 3: Preparation of 48C

[0652] Compound 48B (0.44 g, 0.62 mmol) and dichloromethane (5 mL) were added to the reaction flask, and trifluoroacetic acid (3 mL) was added under stirring. The reaction was stirred at room temperature for 2 hours, and the mixture was concentrated under reduced pressure. Dichloromethane (20 mL) was added, and the pH was adjusted to 10-11 with 1N sodium hydroxide solution. The layers were stirred and separated, and the aqueous layer was extracted four times with dichloromethane. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 48C (0.38 g).

[0653] Step 4: Preparation of compound 48

[0654] Compound 48C (0.19 g, 0.31 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (0.094 g, 0.34 mmol), DIPEA (0.080 g, 0.62 mmol) and DMSO (6 mL) were added to the reaction flask, and the mixture was stirred in an oil bath at 95 °C for 6 hours. The mixture was cooled to room temperature, ethyl acetate (30 mL) was added, and the mixture was washed twice with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and an appropriate amount of silica gel was added, concentrated under reduced pressure, and purified by silica gel column chromatography, eluent: dichloromethane / methanol (V / V) = 100 / 0-95 / 5 to obtain compound 48 (0.14 g, yield: 52%).

[0655] LCMS m / z=432.60[(M+2H) / 2] +

[0656] Example 49: Preparation of Compound 49

[0657]

[0658] Step 1: Preparation of compound 49

[0659] 48C (0.19 g, 0.31 mmol), 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoro-2,3-dihydro-1H-isoindole-1,3-dione (0.10 g, 0.34 mmol) and DIPEA (0.080 g, 0.62 mmol) were dissolved in DMSO (5 mL), stirred in an oil bath at 95° C. for 6 hours, cooled to room temperature, added with ethyl acetate (30 mL), washed twice with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, filtered, added with an appropriate amount of silica gel, concentrated under reduced pressure, and purified by silica gel column chromatography, eluent: dichloromethane / methanol (V / V) = 100 / 0-95 / 5 to obtain compound 49 (0.12 g, yield: 44%).

[0660] LCMS m / z=441.50[(M+2) / 2] +

[0661] Example 50: Preparation of Compound 50

[0662]

[0663] Step 1: Preparation of 50A

[0664] Compound 36G (0.38 g, 0.54 mmol) and (2,4-difluorophenyl)boronic acid (0.085 g, 0.54 mmol) were dissolved in 1,4-dioxane (30 mL) and water (5 mL), and Pd(dppf)Cl2.DCM (0.066 g, 0.081 mmol) and potassium carbonate (0.15 g, 1.08 mmol) were added. The atmosphere was replaced with nitrogen three times and the reaction was carried out at 50°C for 6 h. The reaction solution was cooled to room temperature, diluted with 100 mL of ethyl acetate, washed once with water, and washed once with a saturated sodium chloride aqueous solution. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. 50A (0.157 g, yield: 41%) was obtained by flash column chromatography (mobile phase: dichloromethane / methanol (V / V) = 20 / 1).

[0665] Step 2: Preparation of 50B

[0666] Compound 50A (0.157 g, 0.23 mmol) and 4-aminotetrahydropyran (0.47 g, 4.60 mmol) were dissolved in N-methylpyrrolidone (5 mL), heated to 120°C and subjected to microwave reaction for 1 h. The reaction solution was cooled to room temperature and directly poured into water to precipitate a yellow solid, which was filtered and the filter cake was washed with water 3 times. The filter cake was collected and redissolved in dichloromethane / methanol (V / V=10 / 1), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by flash column chromatography (flowability: dichloromethane / methanol (V / V)=15 / 1) to obtain 50B (0.165 g, yield: 94%).

[0667] LCMS m / z=759.2[M+H] +

[0668] Step 3: Preparation of 50C

[0669] Compound 50B (0.165 g, 0.22 mmol) was dissolved in isopropanol (10 mL), palladium carbon (0.093 g) was added, hydrogen was replaced 3 times, and the temperature was raised to 50°C for 3 h. The reaction solution was cooled to room temperature, and the palladium carbon was directly filtered through diatomaceous earth. The filter cake was washed with dichloromethane / methanol (V / V=10 / 1), and the organic phases were combined and concentrated under reduced pressure to obtain 50C (0.04 g, yield: 29%).

[0670] LCMS m / z=625.8[M+H] +

[0671] Step 4: Preparation of Compound 50

[0672] 50C (0.04 g, 0.064 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (0.021 g, 0.077 mmol) and DIPEA (0.024 g, 0.19 mmol) were dissolved in DMSO (5 mL) and reacted at 90°C for 12 h. The reaction solution was cooled to room temperature, water was added, and a yellow solid precipitated. The diatomaceous earth was filtered, and the filter cake was washed with water three times. The filter cake was redissolved in dichloromethane / methanol (V / V=10 / 1), anhydrous sodium sulfate was added, and the mixture was concentrated and flash column chromatography (mobile phase: dichloromethane / methanol (V / V=15 / 1)) was performed to obtain compound 50 (15 mg, yield: 26%).

[0673] LCMS m / z=441.50[(M+2H) / 2] +

[0674] Example 51: Preparation of Compound 51

[0675]

[0676] Step 1: Preparation of Compound 51A

[0677] Compound 38A (1.5 g, 4.88 mmol) was dissolved in DCM (S0,5 mL), and 10 mL of 4N HCl / 1,4-dioxane solution was added at room temperature and stirred for 2 h. 20 mL of ethyl acetate was added, filtered, 50 mL of dichloromethane was added to the filter cake, and pH>8 was adjusted with 2N sodium hydroxide aqueous solution. After separation, the aqueous phase was extracted with DCM (20 mL x2), the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was directly used in the next step.

[0678] Step 2: Preparation of compound 51B

[0679] Compound 51A (0.3 g, 1.44 mmol) was dissolved in chloroform (10 mL), tert-butyl 4-fluoro-4-formylpiperidine-1-carboxylate (36B) (0.68 g, 2.93 mmol) and 0.2 g of anhydrous sodium sulfate were added, the mixture was heated to 45°C and stirred for 10 min, sodium triacetoxyborohydride (1.03 g, 4.88 mmol) was added, and the mixture was stirred for 30 min at this temperature. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 5-2 / 1) to obtain a crude product, 5 mL of ethyl acetate was added, and 15 mL of petroleum ether was added after stirring for 10 min. The mixture was stirred for 10 min and filtered. The filter cake was dried under reduced pressure to obtain 51B (0.46 g, yield: 76%).

[0680] LCMS m / z=367.2[M-55] +

[0681] Step 3: Preparation of Compound 51C

[0682] Compound 51B (0.46 g, 1.09 mmol) was dissolved in a mixed solvent of ethanol (10 mL), tetrahydrofuran (6 mL) and water (4 mL), iron powder (0.61 g, 10.92 mmol) and ammonium chloride (0.58 g, 10.85 mmol) were added in sequence, and the mixture was heated to 75°C and stirred for 1.5 h. The mixture was cooled to room temperature, filtered through diatomaceous earth, and the filter cake was washed with 30 mL of dichloromethane. The filtrate was combined, and the filtrate was washed with 20 mL of saturated brine. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain compound 51C (0.42 g, yield: 98%).

[0683] LCMS m / z=393.5[M+H] +

[0684] Step 4: Preparation of Compound 51D

[0685] Compound 51C (0.40 g, 1.02 mmol) and 16B (0.32 g, 1.02 mmol) were dissolved in 1,4-dioxane (10 mL), and DIPEA (0.26 g, 2.05 mmol) was added, and the mixture was stirred at 100°C for 1 h. After cooling to room temperature, 20 mL of dichloromethane and 20 mL of water were added for extraction, and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 5-1 / 1) to obtain compound 51D (0.45 g, yield: 65%).

[0686] Step 5: Preparation of Compound 51E

[0687] Compound 51D (0.45 g, 0.67 mmol), 2,4-difluorophenylboronic acid (0.12 g, 0.74 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (0.082 g, 0.010 mmol) and potassium carbonate (0.18 g, 1.33 mmol) were added to a 100 mL single-mouth bottle in sequence, 1,4-dioxane (10 mL) and water (3 mL) were added, nitrogen was replaced three times, the temperature was raised to 40°C and stirred overnight. After cooling to room temperature, 20 mL of dichloromethane and 20 mL of water were added for extraction, the organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure, and the residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 5-1 / 1) to obtain compound 51E (0.4 g, yield: 90%).

[0688] LCMS m / z=660.1[M+H] +

[0689] Step 6: Preparation of Compound 51F

[0690] Compound 51E (0.4 g, 0.61 mmol) and 4-aminotetrahydropyran (1.23 g, 12.2 mmol) were added to a microwave tube in sequence, and NMP (5 mL) was added, and the mixture was stirred at 120°C for 1 h. After cooling to room temperature, 10 mL of water was added, and a large amount of solid was precipitated, which was filtered. The filter cake was dissolved in 20 mL of dichloromethane, and 10 mL of saturated brine was added, and the liquids were separated. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol (V / V) = 100 / 0-100 / 3) to obtain compound 51F (0.32 g, yield: 72%).

[0691] Step 7: Preparation of Compound 51G

[0692] Compound 51F (0.32 g, 0.44 mmol) was dissolved in DCM (3 mL), TFA (3 mL) was added at room temperature, and the mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure, 30 mL of dichloromethane was added to the residue, and the pH was adjusted to > 8 with 1N aqueous sodium hydroxide solution. After separation, the organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and used directly in the next step.

[0693] Step 7: Preparation of Compound 51

[0694] Compound 51G (0.25 g, 0.40 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione (0.11 g, 0.40 mmol) were dissolved in DMSO (5 mL), and DIPEA (0.26 g, 2.01 mmol) was added, and the mixture was heated to 110°C and stirred for 5 h. The mixture was cooled to room temperature, and 10 mL of water was added, and the mixture was stirred for 2 min, and filtered. The filter cake was dissolved in 20 mL of dichloromethane, and 10 mL of saturated sodium chloride aqueous solution was added, and the layers were separated. The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane / methanol (V / V) = 100 / 1-25 / 1) to obtain compound 51 (140 mg, yield: 40%).

[0695] LCMS m / z=881.3[M+H] +

[0696] Biological test cases

[0697] Test Example 1: Proliferation inhibition activity against NCI-H1975 (EGFR-L858R-T790M) and A431 (EGFR-WT) cells

[0698] NCI-H1975 (EGFR-L858R-T790M) and A431 (EGFR-WT) cells were purchased from ATCC, and the culture medium was RPMI1640 + 10% FBS and DMEM + 10% FBS, respectively, and cultured in a 37°C, 5% CO2 incubator. On the first day, NCI-H1975 (EGFR-L858R-T790M) and A431 (EGFR-WT) cells in the exponential growth phase were collected, and live cells were counted using an automatic cell analyzer (countstar). The cell suspension was adjusted with culture medium and plated on a 96-well cell culture plate, with 1000 NCI-H1975 (EGFR-L858R-T790M) cells per well and 3000 A431 cells per well. On the second day, the culture medium was removed, and 90 μL of fresh culture medium and 10 μL of different concentrations of compounds were added to each well, with a final DMSO concentration of 0.1% per well. The cells were cultured in an incubator at 37°C and 5% CO2 for 72 hours. After drug treatment for 72 hours, 50 μL of CTG solution (promega, G7572) pre-melted and equilibrated to room temperature was added to each well, mixed with a microplate shaker for 2 minutes, and placed at room temperature for 10 minutes before measuring the fluorescence signal value with an ELISA reader (PHERAstar FSX).

[0699] The cell viability was calculated using the formula V sample / V vehicle control x100% calculation. Where V sample is the reading of the drug-treated group, V vehicle control The origen9.2 software was used to draw the S-shaped dose-survival rate curve and calculate the IC 50 value.

[0700] Table 1 Results of the proliferation inhibition activity of the test compounds on NCI-H1975 (EGFR-L858R-T790M) cells

[0701] Compound No. <![CDATA[IC 50 (μM)]]> Compound 16 A

[0702] Note: In Table 1, A<0.2μM, 0.2μM≤B<0.5μM, 0.5μM≤C<1μM

[0703] Table 2 Results of the proliferation inhibition activity of the test compounds on A431 (EGFR-WT) cells

[0704] Compound No. <![CDATA[IC 50 (μM)]]> Compound 16 C Compound 32 C

[0705] Note: In Table 2, A<1μM, 1μM≤B<10μM, 10μM≤C

[0706] Conclusion: The compounds of the present invention, such as the compounds in the examples, have good proliferation inhibitory activity against NCI-H1975 (EGFR-L858R-T790M) cells; they have poor proliferation inhibitory activity against A431 (EGFR-WT) cells and have good selectivity.

[0707] Test Example 2: Proliferation inhibition activity on NCI-H1975 EGFR-L858R-T790M-C797S cells

[0708] Cells NCI-H1975 EGFR-L858R-T790M-C797S were cultured in a 37°C, 5% CO2 incubator, and the culture medium was RPMI1640+10% FBS+100μg / mL hygromycin. Cells in the exponential growth phase were collected, and the cell suspension was adjusted to an appropriate concentration with a culture medium without hygromycin and plated on a 96-well plate with a plating density of 1500 cells / well and a volume of 90μL. 10μL of compounds of different concentrations were added, and a solvent control group of cells plus DMSO was set up, and the concentration of DMSO was 0.1%. The cell culture plate was placed in a 37°C, 5% CO2 incubator and cultured for 72 hours. After the culture, according to the instructions of the CellTiter-Glo kit (Promega, G7572), 50 μL of CTG solution pre-melted and equilibrated to room temperature was added to each well, mixed with a microplate shaker for 2 minutes, and placed at room temperature for 10 minutes before measuring the fluorescence signal value with an ELISA reader (Envision2104). The cell survival rate (Surviving cells%) data were processed using formula (1), and GraphPad Prism 5.0 software was used to draw the S-shaped dose-survival rate curve using a nonlinear regression model and calculate the IC 50 Value. Where V sample is the reading of the drug-treated group, V vehicle control is the reading for the control group.

[0709] Surviving cells %=V sample / V vehicle control x100% (Formula 1)

[0710] Conclusion: The compounds of the present invention have good proliferation inhibitory activity on NCI-H1975 EGFR-L858R-T790M-C797S cells.

[0711] Test Example 3: Pharmacokinetic Test in Mice

[0712] Experimental purpose: This study administered the test substance to ICR mice by single-dose intravenous and oral gavage, determined the concentration of the test substance in mouse plasma, and evaluated the pharmacokinetic characteristics and bioavailability of the test substance in mice.

[0713] Experimental animals: Male ICR mice, 20-25 g, purchased from Chengdu Dashuo Experimental Animal Co., Ltd. (SCXK (Sichuan) 2020-030.

[0714] Experimental method: On the day of the experiment, ICR mice were randomly divided into groups according to body weight. They were fasted but not watered 1 day before administration, and food was resumed 4 hours after administration.

[0715]

[0716] * Doses are given as free base;

[0717] (DMSO: dimethyl sulfoxide; DMA: dimethylacetamide; Solutol: polyethylene glycol-15-hydroxystearate; PEG400: polyethylene glycol 400; SBE-β-CD: sulfobutyl-β-cyclodextrin; Saline: physiological saline;)

[0718] Sampling: Blood was collected from the eye socket under isoflurane anesthesia before and after administration and placed in an EDTAK2 centrifuge tube. The tube was centrifuged at 5000 rpm and 4°C for 10 min to collect plasma.

[0719] Time points for plasma collection in G1 group: 0, 5 min, 15 min, 30 min, 1, 2, 4, 7, and 24 h;

[0720] Time points for plasma collection in G2 group: 0, 5 min, 15 min, 30 min, 1, 2, 4, 7, and 24 h;

[0721] All samples were stored below -60°C before analysis and testing. The samples were quantitatively analyzed by LC-MS / MS.

[0722] Table 3 Oral absorption results of test compounds in mice (administration method ig (10 mg / kg))

[0723] Compound No. Is it absorbed orally? Compound 16 yes Compound 32 yes

[0724] * Note: Compounds were administered ig (orally).

[0725] Conclusion: The compounds synthesized by the technology of the present invention, such as the example compounds, have good oral absorption properties in mice.

Claims

1. A compound or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein: The compound is selected from the compounds represented by general formula (I), BLK(I); L is selected from a bond or -C 1-50 Hydrocarbyl-, wherein 0 to 20 methylene units in the hydrocarbyl are optionally further replaced by -Ak-, -Cy-; Each -Ak- is independently selected from -(CH2) q -、-(CH2) q -O-, -O-(CH2) q -、-(CH2) q -NR L -、-NR L -(CH2) q -、-(CH2) q -NR L C(=O)-、-NR L (CH2) q C(=O)-、-(CH2) q -C(=O)NR L -, -C(=O)-, -C(=O)-(CH2) q -NR L -、-(C≡C) q -、-CH=CH-、-Si(R L )2-、-Si(OH)(R L )-、-Si(OH)2-、-P(=O)(OR L )-、-P(=O)(R L )-, -S-, -S(=O)-, -S(=O)2- or a bond, wherein the -CH2- is optionally further replaced by 0 to 2 residues selected from H, halogen, OH, CN, NH2, C 1-6 Alkyl, C 1-6 Alkoxy, halogen substituted C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, cyano substituted C 1-6 substituted by an alkyl substituent; q is each independently selected from 0, 1, 2, 3, 4, 5 or 6; R L Each independently selected from H, C 1-6 Alkyl, 3-7 membered heterocyclyl, 3-7 membered cycloalkyl, phenyl or 5-6 membered heteroaryl; Each -Cy- is independently selected from a bond, a 4-8 membered heteromonocycle, a 4-10 membered heterocyclic ring, a 5-12 membered heterospirocycle, a 7-10 membered heterobridged ring, a 3-7 membered monocycloalkyl, a 4-10 membered cycloalkyl, a 5-12 membered spirocycloalkyl, a 7-10 membered bridged cycloalkyl, a 5-10 membered heteroaryl, or a 6-10 membered aryl, wherein the aryl, heteroaryl, cycloalkyl, heteromonocycle, heterocyclic ring, heterospirocycle, or heterobridged ring is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 The heteroaryl, heteromonocyclic, heterocyclic, heterospirocyclic or heterobridged ring contains 1 to 4 heteroatoms selected from O, S and N. When the heteroatom is selected from S, it is optionally further substituted by 0, 1 or 2 =0; B is selected from X1 and X2 are each independently selected from a bond, O, S, N (R x ); R x Selected from H, C 1-4 alkyl; Ring B4 is selected from C 6-10 Carbocyclic, 5- to 10-membered heterocyclic, C 6-10 Aromatic ring, 5 to 10 membered heteroaromatic ring, wherein the ring B4 is optionally further substituted by 0 to 4 selected from H, F, Cl, Br, I, OH, =O, CN, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 3-6 The cycloalkyl group or the 4- to 6-membered heterocyclic ring is substituted, wherein the heterocyclic ring or the heteroaromatic ring contains 1 to 5 heteroatoms selected from O, S, and N; R b9 Selected from C 6-10 Aromatic ring, 5- to 10-membered heteroaromatic ring, R b10 Selected from C 1-6 Alkyl, C 3-10 Carbocyclic ring, 4 to 10 membered heterocyclic ring, said R b9 Optionally further 0 to 4 R b9a Substitute, the R b10 Optionally further 0 to 4 R b10a Substitution, the heterocyclic ring or heteroaromatic ring contains 1 to 5 heteroatoms selected from O, S, and N; R b9a , R b10a Each independently selected from H, F, Cl, Br, I, OH, ═O, CN, C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 Cycloalkyl, wherein the alkyl, alkoxy or cycloalkyl is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, CN, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent; Alternatively, R b9a , R x Together with the atoms directly connected thereto, a 5- to 7-membered nitrogen-containing heterocyclic ring is formed, wherein the heterocyclic ring is optionally further substituted by 0 to 4 atoms selected from H, F, Cl, Br, I, OH, ═O, CN, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent; R b11 Selected from NH2, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, NHC 3-8 carbocyclic ring, NH-4 to 10 membered heterocyclic ring, wherein the alkyl, carbocyclic ring or heterocyclic ring is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, =O, CN, C 1-4 Alkyl, C 1-4 The heterocyclic ring is substituted by an alkoxy substituent, and the heterocyclic ring contains 1 to 3 heteroatoms selected from O, S, and N; K is selected from Q is independently selected from a bond, -O-, -S-, -CH2-, -NR q -, -C(=O)-, -NR q C(=O)-, -C(=O)NR q - or a 3-12 membered heterocyclic group, wherein the heterocyclic group is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S, and N; R q Select from H or C 1-6 alkyl; A is selected from C 3-10 Carbocyclic group, C 6-10 Aryl, 3-10 membered heterocyclic group or 5-10 membered heteroaryl, wherein the heterocyclic group or heteroaryl group contains 1 to 4 heteroatoms selected from O, S and N; F are each independently selected from C 3-20 Carbocyclic group, C 6-20 Aryl, 3-20 membered heterocyclic group or 5-20 membered heteroaryl, wherein the heterocyclic group or heteroaryl group contains 1 to 4 heteroatoms selected from O, S and N; R k2 are each independently selected from a bond, -C(=O)-, -S(=O)2-, -S(=O)- or -C(R k3 )2-; R k1 Each independently selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, wherein the alkyl, alkoxy, cycloalkyl is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Substituted by a cycloalkyl substituent; Alternatively, two R k1 Together with the atoms it is attached to form C 3-6 A carbocyclic ring or a 4- to 7-membered heterocyclic ring, wherein the carbocyclic ring or the heterocyclic ring is optionally further substituted by 0 to 4 rings selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic ring is substituted by an alkoxy substituent, and the heterocyclic ring contains 1 to 4 heteroatoms selected from O, S, and N; R k3 Each independently selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-8 Cycloalkyl or 3-8 membered heterocyclic group, wherein the alkyl, alkoxy, cycloalkyl or heterocyclic group is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S, and N; Or two R k3 and the carbon atoms or ring skeletons directly connected to the two together form a 3-8 membered carbocyclic ring or a 3-8 membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally further substituted by 0 to 4 selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic ring is substituted by an alkoxy substituent, and the heterocyclic ring contains 1 to 4 heteroatoms selected from O, S, and N; R k4 Each independently selected from H, OH, NH2, CN, CONH2, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-8 membered heterocyclic group, wherein the alkyl, cycloalkyl or heterocyclic group is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S, and N; M1 is selected from a bond, -CH2-C(=O)NH- or -C(=O)CH2NH-; M2 is selected from -NHC(=O)-C 1-6 Alkyl, -NHC(=O)-C 3-6 Cycloalkyl or 4-10 membered heterocyclic group, wherein the alkyl, cycloalkyl or heterocyclic group is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, =O, OH, NH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S, and N; M3 is selected from -NH- or -O-; R k10 Selected from C 1-6 Alkyl, wherein the alkyl is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, =O, OH, C 1-6 Alkyl or C 3-6 Substituted by a cycloalkyl substituent; R k11 Each independently selected from H, F, Cl, Br, I, =O, OH, SH, C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Alkylthio or -OC(=O)-C 1-6 The alkyl group, alkoxy group or alkylthio group may be further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent; R k12 , R k13 Each independently selected from H, C 1-6 Alkyl or C 3-6 Cycloalkyl, wherein the alkyl or cycloalkyl is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, =O, OH, NH2, C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent; R k14 is selected from 5-6 membered heteroaryl, wherein the heteroaryl is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, =O, CF3, CN, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 The heteroaryl group is substituted by a substituent of a cycloalkyl group, wherein the heteroaryl group contains 1 to 4 heteroatoms selected from N, O, and S; G is selected from 6-10 membered aryl or 5-10 membered heteroaryl, wherein the aryl or heteroaryl is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, =O, CF3, CN, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, C 1-4 Alkoxy or C 3-6 The heteroaryl group is substituted by a substituent of a cycloalkyl group, wherein the heteroaryl group contains 1 to 4 heteroatoms selected from N, O, and S; n1, n2, n3 are each independently selected from 0, 1, 2 or 3; p1 and p2 are each independently selected from 0, 1, 2, 3, 4 or 5.

2. The compound according to claim 1 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: L is selected from -Cy1-Ak1-Cy2-Ak2-Cy3-Ak3-Cy4-Ak4-Cy5-Ak5-, -Cy1-Cy2-Cy3-Cy4-Ak1-Ak2-Ak3-Ak4-Ak5-, -Cy1-Ak1-Cy2-Ak2-Cy3-Ak3-Cy4-Ak4-Ak5-, -Ak1-Cy1-Ak2-Cy2-Ak3-Cy3-Ak4-Cy4-Ak5-, -Cy1-Ak1-Cy2-Ak2-Cy3-Cy4-Ak3-Ak4-Ak5-, -Cy1-Ak1-Cy2-Ak2-Ak3-Cy3-Cy4-Ak4-Ak5-, -Cy1-Ak1-Ak2-Ak3-Ak4-Ak5-Cy2-Cy3-Cy4-, -Cy1-Cy2-Ak1-Ak2-Ak3-Ak4-Ak5-Cy3-Cy4-, -Cy1-Cy2-Cy3-Ak1-Ak2-Ak3-Ak4-Ak5-Cy4-, -Cy1-Cy2-Cy3-Cy4-Ak1-Ak2-Ak3-Ak4-Ak5-, -Cy1-Ak1-Cy2-Cy3-Cy4-Ak2-Ak3-Ak4-Ak5-, -Cy1-Cy2-Ak1-Cy3-Cy4-Ak2-Ak3-Ak4-Ak5-, -Cy1-Cy2-Cy3-Ak1-Cy4-Ak2-Ak3-Ak4-Ak5-, -Cy1-Ak1-Ak2-Cy2-Cy3-Cy4-Ak3-Ak4-Ak5-, -Cy1-Cy2-Ak1-Ak2-Cy3-Cy4-Ak3-Ak4-Ak5-, -Cy1-Cy2-Cy3-Ak1-Ak2-Cy4-Ak3-Ak4-Ak5-, -Cy1-Ak1-Ak2-Ak3-Cy2-Cy3-Cy4-Ak4-Ak5-, -Cy1-Cy2-Ak1-Ak2-Ak3-Cy3-Cy4-Ak4-Ak5-, -Cy1-Cy2-Cy3-Ak1-Ak2-Ak3-Cy4-Ak4-Ak5-, -Cy1-Ak1-Ak2-Ak3-Ak4-Cy2-Cy3-Cy4-Ak5-, -Cy1-Cy2-Ak1-Ak2-Ak3-Ak4-Cy3-Cy4-Ak5-, -Cy1-Cy2-Cy3-Ak1-Ak2-Ak3-Ak4-Cy4-Ak5-, -Ak1-Ak2-Ak3-Ak4-Ak5-Cy1-Cy2-Cy3-Cy4-, -Ak1-Cy1-Cy2-Cy3-Cy4-Ak2-Ak3-Ak4-Ak5-, -Ak1-Ak2-Cy1-Cy2-Cy3-Cy4-Ak3-Ak4-Ak5-, -Ak1-Ak2-Ak3-Cy1-Cy2-Cy3-Cy4-Ak4-Ak5--Ak1-Ak2-Ak3-Ak4-Cy1-Cy2-Cy3-Cy4-Ak5-、-Ak1-Cy1-Ak2-Ak3-Ak4-Ak5-Cy2-Cy3-Cy4-、-Ak1-Cy1-Cy2-Ak2-Ak3-Ak4-Ak5-Cy3-Cy4-、-Ak1-Cy1-Cy2-Cy3-Ak2-Ak3-Ak4-Ak5-Cy4-、-Ak1-Ak2-Cy1-Ak3-Ak4-Ak5-Cy2-Cy3-Cy4-、-Ak1-Ak2-Cy1-Cy2-Ak3-Ak4-Ak5-Cy3-Cy4-、-Ak1-Ak2-Cy1-Cy2-Cy3-Ak3-Ak4-Ak5-Cy4-、-Ak1-Ak2-Ak3-Cy1-Ak4-Ak5-Cy2-Cy3-Cy4-、-Ak1-Ak2-Ak3-Cy1-Cy2-Ak4-Ak5-Cy3-Cy4-、-Ak1-Ak2-Ak3-Cy1-Cy2-Cy3-Ak4-Ak5-Cy4-、-Ak1-Ak2-Ak3-Ak4-Cy1-Ak5-Cy2-Cy3-Cy4-、-Ak1-Ak2-Ak3-Ak4-Cy1-Cy2-Ak5-Cy3-Cy4-、-Ak1-Ak2-Ak3-Ak4-Cy1-Cy2-Cy3-Ak5-Cy4-;、 Ak1, Ak2, Ak3, Ak4, Ak5 are each independently selected from -(CH2) q -、-(CH2) q -O-, -O-(CH2) q -、-(CH2) q -NR L -、-NR L -(CH2) q -、-(CH2)q-NR L C(=O)-、-(CH2) q -C(=O)NR L -, -C(=O)-, -C(=O)-(CH2) q -NR L -、-(C≡C) q - or a bond, wherein the -CH2- is optionally further replaced by 0 to 2 groups selected from H, halogen, OH, CN, NH2, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl, cyano substituted C 1-4 substituted by an alkyl substituent; Cy1, Cy2, Cy3, Cy4 or Cy5 are each independently selected from a bond, a 4-7 membered heteromonocycle, a 4-10 membered heterocyclic ring, a 5-12 membered heterospirocycle, a 7-10 membered heterobridged ring, a 3-7 membered monocycloalkyl, a 4-10 membered cyclic ring, a 5-12 membered spirocycloalkyl, a 7-10 membered bridged cycloalkyl, a 5-10 membered heteroaryl or a 6-10 membered aryl, wherein the aryl, heteroaryl, cycloalkyl, heteromonocycle, heterocyclic ring, heterospirocycle or heterobridged ring is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 The heteroaryl, heteromonocyclic, heterocyclic, heterospirocyclic or heterobridged ring contains 1 to 4 heteroatoms selected from O, S and N. When the heteroatom is selected from S, it is optionally further substituted by 0, 1 or 2 =0; q is each independently selected from 0, 1, 2, 3 or 4; R L Each independently selected from H or C 1-6 alkyl.

3. The compound according to claim 2 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: Cy1, Cy2, Cy3, Cy4 or Cy5 are each independently selected from a bond, a 4-7 membered nitrogen-containing heteromonocycle, a 4-10 membered nitrogen-containing heterocyclic ring, a 5-12 membered nitrogen-containing heterospirocycle, a 7-10 membered nitrogen-containing heterobridged ring, a 3-7 membered monocycloalkyl, a 4-10 membered cycloalkyl, a 5-12 membered spiroalkyl, a 7-10 membered bridged cycloalkyl, a 5-10 membered heteroaryl or a 6-10 membered aryl, wherein the heteromonocycle, heterocyclic ring, heterobridged ring, heterospirocycle, cycloalkyl, aryl or heteroaryl is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, COOH, CN, NH2, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 The heterocyclic, heterocyclic, heterobridged, heterospirocyclic or heteroaryl group contains 1 to 4 heteroatoms selected from O, S and N. When the heteroatom is selected from S, it is optionally further substituted by 0, 1 or 2 =0; R L Each independently selected from H or C 1-4 alkyl; R b9 is selected from a benzene ring, a naphthalene ring, a 5- to 6-membered heteroaromatic ring, a 9- to 10-membered heteroaromatic ring, R b10 Selected from C 1-4 Alkyl, C 3-6 Cycloalkyl, 4 to 7 membered heterocycloalkyl, said R b9 Optionally further 0 to 4 R b9a Substitute, the R b10 Optionally further 0 to 4 R b10a Substitution, the heterocycloalkyl or heteroaromatic ring contains 1 to 5 heteroatoms selected from O, S, and N; K is selected from indicates that the ring is selected from an aromatic ring or a non-aromatic ring; Q is independently selected from -O-, -S-, -CH2-, -NR q -, -C(=O)-, -NR q C(=O)-, -C(=O)NR q - or a 4-7 membered heterocyclic group, wherein the heterocyclic group is optionally further substituted by 0 to 4 members selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic group is substituted by an alkoxy substituent, wherein the heterocyclic group contains 1 to 4 heteroatoms selected from O, S, and N; R q Select from H or C 1-4 alkyl; R k1 , R k3 Each independently selected from H, F, Cl, Br, I, OH, =O, NH2, CF3, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 Alkoxy, wherein the alkyl or alkoxy is optionally further substituted by 0 to 4 substituents selected from H, F, Cl, Br, I, OH, NH2; Or two R k3 and the carbon atoms or ring skeletons directly connected to the two together form a 3-6-membered carbocyclic ring or a 3-7-membered heterocyclic ring, wherein the carbocyclic ring or heterocyclic ring is optionally further substituted by 0 to 4 atoms selected from H, F, Cl, Br, I, OH, =O, NH2, CN, COOH, CONH2, C 1-4 Alkyl or C 1-4 The heterocyclic ring is substituted by an alkoxy substituent, and the heterocyclic ring contains 1 to 4 heteroatoms selected from O, S, and N; R k4 Each independently selected from H, OH, NH2, CF3, CN, C 1-4 alkyl; R k5 Each independently selected from C(CH3)2, C(=O), CH2, S(=O)2, R k6 Each is independently selected from C(═O), CH, S(═O), S(═O)2, CH2 or N; R k7 Each independently selected from C(CH3)2, C(═O), CH, N, CH2, O, S, N(CH3), N(CH2CH3), N(cyclopropyl) or NH; R k8 are each independently selected from C, N or CH; R k9 are each independently selected from a bond, C(CH3)2, C(=O), CH2, CH2CH2 or S(=O)2; A, H1 or H2 are each independently selected from C 3-8 A carbocyclic ring, a benzene ring, a 4-7 membered heterocyclic ring or a 5-6 membered heteroaryl group, wherein the heterocyclic ring or heteroaryl group contains 1 to 4 heteroatoms selected from O, S, and N; E are each independently selected from C 3-8 A carbocyclic ring, a benzene ring, a 4-7 membered heterocyclic ring, an 8-12 membered heterocyclyl, a 7-12 membered heteroaryl or a 5-6 membered heteroaryl, wherein the heterocyclic ring or heteroaryl contains 1 to 4 heteroatoms selected from O, S and N; F is independently selected from 3-7 membered monocyclic alkyl, 4-10 membered cycloalkyl, 5-12 membered spirocyclic alkyl, 5-10 membered bridged cycloalkyl, 4-7 membered heteromonocyclic, 4-10 membered heterocyclocyclic, 8-15 membered tricyclic heterocyclocyclic, 12-17 membered tetracyclic heterocyclocyclic, 5-12 membered heterospirocyclic, 5-10 membered heterobridged ring, C 6-14 The aryl group or the 5-10 membered heteroaryl group contains 1 to 4 heteroatoms selected from O, S and N, wherein the heteromonocyclic ring, heterocyclic ring, heterospirocyclic ring, heterobridged ring or heteroaryl group contains 1 to 4 heteroatoms selected from O, S and N.

4. The compound according to claim 3 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: R L is selected from H, methyl or ethyl; q is each independently selected from 0, 1 or 2; Cy1, Cy2, Cy3, Cy4 or Cy5 are each independently selected from a bond or one of the following groups which are substituted or unsubstituted: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azetyl, azidine, piperidine, morpholine, piperazine, phenyl, cyclopropyl-cyclopropyl, cyclopropyl-cyclobutyl, cyclopropyl-cyclopentyl, cyclopropyl-cyclohexyl, cyclobutyl-cyclobutyl, cyclobutyl-cyclopentyl, cyclobutyl-cyclohexyl, cyclopentyl-cyclopentyl , cyclopentyl and cyclohexyl, cyclohexyl and cyclohexyl, cyclopropyl spirocyclopropyl, cyclopropyl spirocyclobutyl, cyclopropyl spirocyclopentyl, cyclopropyl spirocyclohexyl, cyclobutyl spirocyclobutyl, cyclobutyl spirocyclopentyl, cyclobutyl spirocyclohexyl, cyclopentyl spirocyclopentyl, cyclopentyl spirocyclohexyl, cyclohexyl spirocyclohexyl, cyclopropyl and azetidinyl, cyclopropyl and azetidinyl, cyclopropyl and azetidinyl, cyclopropyl and azetidinyl, cyclobutyl and azetidinyl, cyclobutyl and azetidinyl, cyclobutyl and azetidinyl, cyclobutyl and azetidinyl Hexyl, cyclopentylazacyclolidinyl, cyclopentylazacyclopentyl, cyclopentylazahexyl, cyclohexylazacyclolidinyl, cyclohexylazacyclopentyl, cyclohexylazacyclohexyl, azetidinazacyclolidinyl, azetidinazacyclopentyl, azetidinazacyclohexyl, azetidinazacyclohexyl, azetidinazacyclolidinyl, azetidinazacyclopentyl, azetidinazacyclohexyl, azetidinazacyclohexyl, azetidinazacyclolidinyl, azetidinazacyclopentyl, azetidinazacyclohexyl, azetidinazacyclohexyl, cyclobutylspiroazacyclo butyl, cyclobutyl spiroazacyclopentyl, cyclobutyl spiroazacyclohexyl, cyclopentyl spiroazetidinyl, cyclopentyl spiroazacyclopentyl, cyclopentyl spiroazacyclohexyl, cyclohexyl spiroazetidinyl, cyclohexyl spiroazacyclopentyl, cyclohexyl spiroazetidinyl, cyclohexyl spiroazetidinyl, azetidinyl spiroazacyclopentyl, azetidinyl spiroazacyclohexyl, azetidinyl spiroazacyclopentyl, azetidinyl spiroazacyclohexyl, azetidinyl spiroazacyclopentyl, azetidinyl spiroazacyclohexyl, azetidinyl spiroazacyclopentyl, azetidinyl spiroazacyclohexyl, azetidinyl spiroazacyclopentyl, azetidinyl spiroazacyclohexyl, When substituted, it is optionally further substituted with 0 to 4 moieties selected from H, F, Cl, Br, I, OH, NH2, COOH, CN, =O, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, hydroxy substituted C 1-4 Alkyl or C 1-4 substituted by an alkoxy substituent; R b9 is selected from benzene ring, benzopyrrole, benzopyrazole, benzimidazole, pyridine, pyrimidine, pyrrole, pyrazole, thiazole, thiophene, oxazole, furan, R b10 is selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, azetyl, azetyl, oxetanyl, oxolyl, oxetanyl, wherein R b9 Optionally further 0 to 4 R b9a Substitute, the R b10 Optionally further 0 to 4 R b10a replace; Ring B4 is selected from a benzene ring, wherein the benzene ring is optionally further substituted by 0 to 4 groups selected from H, F, Cl, Br, I, OH, =O, CN, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, cyano substituted C 1-4 Alkyl, C 3-6 substituted by a cycloalkyl group or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from O, S, and N; K is selected from E is each independently selected from phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, furanyl, thienyl or oxazolyl; A is each independently selected from phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, furanyl, thienyl or oxazolyl; F is independently selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentanyl, 6,7-dihydro-5H-cyclopenta[c]pyridinyl, 2,3-dihydro-1H-indenyl, phenyl, naphthyl, anthracenyl, phenanthrenyl, azetidinyl, azopentyl, piperidinyl, morpholinyl, pyridyl, pyridonyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazine, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, furanyl, thienyl, thiazolyl, benzoxazole, pyridoimidazole, benzimidazolyl, benzopyrazolyl, benzothiazolyl, benzothienyl, benzo furanyl, benzopyrrolyl, benzopyridinyl, benzopyrazinyl, benzopyrimidinyl, benzopyridazinyl, pyrrolopyrrolyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrrolopyridazinyl, pyrrolopyrazinyl, imidazopyrimidinyl, imidazopyridinyl, imidazopyrazinyl, imidazopyridazinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrazolopyridazinyl, pyrimidopyridinyl, pyrimidopyrazinyl, pyrimidopyridazinyl, pyrimidopyrimidinyl, pyridopyridinyl, pyridopyrazinyl, pyridopyridazinyl, pyridazinopyrazinyl, or pyrazinopyrazinyl; or F are each independently selected from R k7 Each independently selected from C(CH3)2, CH2, O, N(CH3), N(CH2CH3), N(cyclopropyl) or NH; p1 and p2 are each independently selected from 0, 1 or 2.

5. The compound according to claim 4 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: Cy1, Cy2, Cy3, Cy4 or Cy5 are each independently selected from a bond or a substituted or unsubstituted one of the following groups: When substituted, it is optionally further substituted with 0 to 4 substituents selected from H, F, CF3, methyl, =O, hydroxymethyl, COOH, CN or NH2; X1 and X2 are each independently selected from O, N(R x ); K is selected from one of the structural fragments shown in Table K-1.

6. The compound according to claim 5 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: L is selected from -Cy1-, -Cy1-Ak1-, -Cy1-Ak1-Ak2-, -Cy1-Ak1-Ak2-Ak3-, -Cy1-Ak1-Ak2-Ak3-Ak4-, -Cy1-Cy2-, -Cy1-Ak1-Cy2-, -Cy1-Cy2-Ak2-, -Cy1-Ak1-Cy2-Ak2-, -Cy1-Ak1-Cy2-Ak2-Ak3-, -Ak1-Cy2-, -Cy1-Ak1-Cy2-Ak2-Ak3-Ak4-, -Cy1-Cy2-Ak2-Ak3-, -Cy1-Cy2-Ak2-Ak3-Ak4-, -Cy1-Ak1-Cy2-Ak2-Ak3-Ak4-, -Cy1-Ak1-Ak2-Cy3-, -Cy1-Ak1-Ak2-Cy3-Ak3-, -Cy1-Cy2-Cy3-, -Cy1-Ak1-Cy2-Cy3-, -Cy1-Cy2-Ak2-Cy3-, -Cy1-Cy2-Cy3-Ak3-, -Cy1-Ak1-Cy2-Cy3-Ak3-, -Cy1-Cy2-Ak2-Cy3-Ak3-, -Cy1-Ak1-Cy2-Ak2-Cy3-, -Cy1-Ak1-Cy2-Ak2-Cy3-Ak3-, -Cy1-Cy2-Cy3-Ak3-Ak4-, -Cy1-Cy2-Cy3-Ak3-Cy4-, -Cy1-Cy2-Cy3-Cy4-, -Cy1-Ak1-Cy2-Cy3-Cy4-, -Cy1-Cy2-Ak2-Cy3-Cy4-, -Cy1-Cy2-Cy3-Ak3-Cy4-, -Cy1-Cy2-Cy3-Cy4-Ak4-, -Cy1-Ak1-Cy2-Ak2-Cy3-Ak3-Cy4-, -Cy1-Ak1-Cy2-Ak2-Cy3-Cy4-, -Ak1-Ak2-Cy3-Cy4-, -Ak1-Cy2-Ak2-Cy3-, -Ak1-Cy2-Cy3-Ak3-Cy4-, -Ak1-Cy2-Cy3-Cy4-Ak4-Cy5-, -Ak1-Cy2-Ak2-, -Ak1-Ak2-Ak3-Ak4-, -Ak1-Ak2-Ak3-, -Ak1-Ak2-, -Ak1-Ak2-Ak3-Ak4-Ak5-, -Cy1-Cy2-Cy3-Ak3-Ak4-Ak5-, -Cy1-Cy2-Ak2-Cy3-Ak3-Ak4-Ak5-, -Cy1-Ak1-Cy2-Ak2-Ak3-Ak4-Ak5-, -Cy1-Cy2-Cy3-Cy4-Ak4-Ak5-, -Cy1-Ak1-Ak2-Ak3-Ak4-Ak5-, -Ak1-Cy2-Ak2-Ak3-Ak4-Ak5--Ak1-Cy2-Ak2-Ak3-Ak4-、-Ak1-Cy2-Ak2-Ak3-;、 Ak1, Ak2, Ak3, Ak4, and Ak5 are each independently selected from -O-, -OCH2-, -CH2O-, -OCH2CH2-, -CH2CH2O-, -C≡C-, -C(CH3)2-, -CH2-, -CH2CH2-, -CH2CH2CH2-, -N(CH3)-, -NH-, -CH2N(CH3)-, -CH2NH-, -NHCH2-, -CH2CH2N(CH3)-, -CH2CH2NH-, -NHCH2CH2-, -C(=O)-, -C(=O)CH2NH-, -CH2C(=O)NH-, -C(=O)NH- or -NHC(=O)-.

7. The compound according to claim 6 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: L is selected from a bond or one of the groups shown in Table L-1 or L-2, wherein the left side of the group is connected to B.

8. The compound according to claim 7 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: B is selected from one of the following structural fragments: R B4 Each is independently selected from H, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, cyclopropyl, pyrrole, pyrazole; rr is selected from 0, 1, 2 or 3; R b9a Each independently selected from H, F, Cl, Br, I, OH, CN, CF3, methyl, methoxy; R b10 Each independently selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, oxacyclopentyl, oxacyclohexyl, said R b10 Optionally further substituted with 0 to 4 substituents selected from H, F, Cl, Br, I, OH, =O, CN, methyl, methoxy; K is selected from one of the structural fragments shown in Table K-2.

9. The compound according to claim 8 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: B is selected from one of the structural fragments shown in Table B-1; K is selected from one of the structural fragments shown in Table K-3.

10. The compound according to claim 1 or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein the compound is selected from one of the structures in Table E-1:.

11. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10 or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, and a pharmaceutically acceptable carrier. Preferably, the pharmaceutical composition contains 1 to 1500 mg of a compound according to any one of claims 1 to 18 or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof.

12. Use of the compound according to any one of claims 1 to 10 or its stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, or the drug and composition according to claim 11 in the preparation of a drug for treating a disease associated with EGFR activity or expression.

13. Use of the compound according to any one of claims 1 to 10 or its stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, or the drug and composition according to claim 11 in the preparation of drugs for treating and inhibiting or degrading EGFR-related diseases.

14. The use according to claim 12 or 13, characterized in that: The disease is selected from cancer.